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SYNOPSIS 
 
THIS THESIS SYSTEMATICALLY REVIEWED THE 
PROGNOSTIC ASSOCIATION AND PREDICTIVE 
ABILITY OF NEONATAL TESTS FOR SHORT AND 
LONG TERM ADVERSE OUTCOMES, AND 
PERFORMED DECISION-ANALYTIC MODELLING TO 
EXPLORE THE IMPACT OF VARYING TEST 
THRESHOLD ON THE COST-EFFECTIVENESS OF 
UMBILICAL CORD PH TESTING AND NEONATAL 
THERAPEUTIC HYPOTHERMIA TO PREVENT 
CEREBRAL PALSY. 
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ABSTRACT 
 
Events in utero have been linked with a variety of diseases throughout life, from the 
neonatal period to adulthood, however there is a lack of consensus regarding the 
ability of neonatal tests to predict these outcomes. Systematic reviews and meta-
analyses were performed, assessing umbilical cord pH and base excess at birth, 
standards of low birth weight, and the Apgar score, including a total of 218 papers 
and 26704980 individuals. The prognostic association and predictive accuracy of 
these tests for adverse outcomes, including neonatal mortality and morbidity, 
childhood morbidity including cerebral palsy, and where possible adult outcomes, 
were determined. A decision-analytic model based analysis assessed the cost-
effectiveness of varying the umbilical cord pH threshold, and treatment with neonatal 
hypothermia. This thesis determined that all of the tests examined had a strong 
association with neonatal mortality, and a significant but smaller association with 
neonatal morbidity and childhood cerebral palsy. In general, where the association 
was strong, tests had a high specificity and positive likelihood ratio for adverse 
outcome, but poor sensitivity and negative likelihood ratio, indicating that negative 
tests do not reduce the risk. The cost effectiveness analysis showed that the 
threshold of pH used in current practice to recommend neonatal hypothermia is more 
effective and less costly than a higher threshold. 
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EXECUTIVE SUMMARY 
 
Background 
 
Events in utero have been linked with a variety of diseases throughout life, from the 
neonatal period to adulthood. Tests performed immediately following delivery of a 
baby not only summarise the condition at that moment, but may reflect events in 
utero and during labour. A variety of tests may be performed, but practice varies 
widely and there is a lack of consensus regarding how the results may be interpreted 
and used to predict adverse outcome or indicate the need for intervention. There is a 
wealth of literature linking neonatal tests with mortality and morbidity throughout the 
life course, but results are inconsistent and there is a lack of clear collated 
information summarising these findings. 
This thesis aimed to evaluate the association and predictive ability of tests performed 
at birth with adverse outcomes during the neonatal period and later life, with a view to 
guiding clinical practice regarding which tests should be performed, and how the 
results may be interpreted. 
Objectives 
The objectives of this thesis were as follows: a) to obtain summary estimates of 
association for neonatal tests and short and long term health outcomes. b) to obtain 
summary estimates of predictive ability of neonatal tests for short and long term 
health outcomes. c) to investigate the impact on the cost effectiveness of neonatal 
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hypothermia, to prevent cerebral palsy, of varying the umbilical cord pH threshold 
used to identify neonates in whom treatment should be given. 
Methods 
Systematic reviews were performed in accordance with current recommended 
methods.  Decision-analytic modelling was used for the cost effectiveness analysis. 
For the systematic reviews, literature was identified from electronic searches, without 
language restrictions, studies were selected by 2 reviewers and data extracted to 
obtain 2 x 2 tables on the index test in question and  mortality, or any measure of 
morbidity, throughout the life course. Methodological quality was assessed using pre-
defined criteria from the STARD and QUADAS checklists. Meta-analysis was 
performed using the bivariate approach, to obtain summary measures of prognostic 
association (odds ratio) and predictive ability (sensitivity, specificity and likelihood 
ratios). A prediction interval was also calculated, which assesses the range in which 
the summary measure of a new study is likely to lie.  
The decision-analytic model employed a decision- tree approach. Inputs to the model 
were systematic review accuracy data derived from this thesis, and effectiveness and 
cost data obtained from the literature. The perspective was that of the NHS with an 
18 month time horizon. Deterministic and probabilistic sensitivity analyses were 
reported. The main outcome was cost per case of cerebral palsy avoided.  
Results  
Main findings of reviews of prognostic association and predictive ability 
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47338 citations were identified as potentially relevant for the included reviews. 218 
papers and 26704980 individuals were finally included. The following tests were 
included: umbilical cord pH and base excess; any standard used to define low birth 
weight (including absolute birth weight at any reported threshold e.g. <2.5kg, 
population and customised centile charts, and ponderal index); and Apgar score.  
51 papers were included in the review of umbilical cord pH and base excess, 92 in 
the birth weight standards review and 87 in the Apgar score review. The total number 
of individuals included per review was 479022 (cord pH), 3690080 (Apgar) and 
23051541 (birth weight standards). Most studies were of a retrospective cohort 
design, and were of high or moderate quality according to predefined criteria. All of 
the neonatal tests assessed had a strong association with neonatal mortality, 
however even where the association was strong, the sensitivity and negative 
likelihood ratios were generally poor, indicating that a negative test does not change 
the odds of an adverse outcome. Most tests and thresholds examined also showed 
an association with neonatal morbidity and childhood cerebral palsy. However the 
magnitude of the association was smaller. It was only possible to assess the 
association between adult outcomes and low birth weight, and in this case there was 
no consistent relationship. 
Findings of decision-analytic modelling 
Decision-analytic modelling demonstrated that, when compared to a higher threshold 
of <7.10, the pH threshold of <7.00 used in current practice as one of the factors to 
indicate a neonate should receive therapeutic hypothermia is more effective and less 
costly and therefore the dominant strategy. Comparison with other thresholds was 
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not possible due to a lack of accuracy and effectiveness data. There were several 
limitations to the model in terms of data inputs and model structure, which restrict 
interpretation of the results of the cost-effectiveness of neonatal cooling overall. 
Conclusions 
The reviews in this thesis have shown that low umbilical cord pH, birth weight and a 
low Apgar score have significant associations with a variety of adverse outcomes and 
are therefore important tests to consider. However, given the fact that in most cases 
a negative test was not found to change the likelihood of an adverse outcome, and 
the inability to fully assess the performance of tests in population subgroups or 
compare multiple tests in the same population, there are many unanswered 
questions regarding their use and interpretation in clinical practice. The main 
recommendations of this thesis are thus for future research, to clarify these issues. 
Such research could take the form of individual patient data meta-analysis, or a large 
cohort or population registry study by which pertinent data on all tests and outcomes 
of interest could be examined, pH and birth weight as a continuous measure be 
assessed, and appropriate subgroups and potential confounding factors accounted 
for. Future studies should adhere strictly to the STARD checklist when reporting to 
facilitate meta-analysis. Decision–analytic modelling, also using individual patient 
data, could then be performed to assess the cost-effectiveness of tests in 
combination with available treatments or management strategies, to inform NHS 
practice. 
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CHAPTER 1: INTRODUCTION 
 
1.1  Aims and objectives of this thesis 
The aim of this thesis was to examine the prognostic association and predictive 
ability of neonatal tests for short and long term health outcomes. 
The objectives were as follows:  
1. To obtain summary estimates of the prognostic association of neonatal tests 
with short and long term health outcomes. 
2. To obtain summary estimates of the predictive ability of neonatal tests for 
short and long term health outcomes. 
3. To investigate the impact on the cost effectiveness of neonatal therapeutic 
hypothermia, to prevent cerebral palsy, of varying the umbilical cord pH 
threshold used to identify neonates in whom treatment should be given. 
 
1.2  Outline of this thesis 
This thesis has been divided into two parts: 
PART A: Systematic reviews of association and predictive ability of neonatal tests for 
short and long term outcomes. 
PART B: Summary of existing literature for neonatal hypothermia to treat hypoxia, 
and decision-analytic modelling 
 
Appendices and References 
 2 
 
1.3 Methods 
This thesis employed systematic reviews and meta-analyses to calculate the 
prognostic association and predictive ability of neonatal tests for a variety of short 
and long term health outcomes. Focusing on the umbilical cord pH, which is a 
measure of neonatal hypoxia, available data regarding neonatal cooling to prevent 
neurodevelopmental problems in these infants was combined with the systematic 
review prediction data in a decision-analytic model, to explore the cost-effectiveness 
of varying the threshold of the test at which treatment is given. 
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CHAPTER 2: BACKGROUND 
2.1 The purpose of neonatal testing and scope of the problem 
There is a growing interest in health across the life course. ‘Living a long and healthy 
life’ has been identified as a priority research theme by the Medical Research Council 
(MRC),1 highlighting the importance of identifying individuals at risk of adverse health 
outcomes, facilitating intervention. Events in utero have been linked with a variety of 
diseases throughout life, from the neonatal period to adulthood. Such conditions may 
be severe and life limiting. However, there is a lack of consensus regarding the ability 
of neonatal tests to predict these outcomes.  
Cerebral palsy, for example, is often linked to adverse events occurring in the 
antenatal or intrapartum period. This is a permanent condition, arising from an insult 
to the developing brain, resulting in non-progressive abnormalities of movement and 
posture. It varies in severity, but an individual with this diagnosis is likely to have 
lifelong needs in terms of health and social care, with the associated costs to the 
health service, and a significant impact on quality of life. The prevalence of cerebral 
palsy within the UK is estimated at 2 to 2.5 per 1000 live births.2 There were 723165 
live births in England and Wales in 2010,3 which would mean a total of 1446 to 1808 
individuals affected with cerebral palsy in that year alone.  
Tests performed immediately following delivery of a baby not only summarise the 
condition at that moment, but also reflect events in utero and during labour, which 
have implications for obstetric practice. Figure 2.1 illustrates the pathway by which 
neonatal tests are related to antenatal and postnatal events. 
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Figure 2.1 The pathway by which neonatal tests are related to antenatal and 
postnatal events  
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This thesis aims to evaluate the association and predictive ability of tests performed 
at birth for adverse outcomes during the neonatal period and later life, with a view to 
guiding clinical practice regarding which tests should be performed, and how the 
results may be interpreted. 
2.2 The relationship between fetal and neonatal wellbeing  
2.2.1 Oxygen transfer and metabolism 
Fetal oxygen levels are maintained through diffusion of oxygen from the maternal 
circulation via the placental interface. Fetal haemoglobin has a higher affinity for 
oxygen than adult haemoglobin, and this allows saturation with oxygen at relatively 
low oxygen tensions. Under normal circumstances, fetal blood is slightly hypercarbic 
and acidotic in comparison to maternal blood.4 Carbon dioxide (CO2) is related to the 
concentration of hydrogen ions, and therefore acidity of the extracellular fluid within 
the body, as follows:5  
CO2 + H2O        H2CO3  H
+ + HCO3
-   
Bicarbonate (HCO3
-) acts as a buffer to maintain the pH balance of the blood. The 
base excess or deficit describes the quantity of bicarbonate within the plasma. Under 
normal circumstances, fetal arterial deoxygenated blood courses through placental 
exchange vessels and gives up hydrogen ions (H+) and CO2 to the maternal 
circulation and acquires oxygen, which returns from the placenta to the fetal 
circulation via the umbilical vein.4 
Any disturbances to this process will result in fetal hypoxaemia, defined as low 
oxygen levels in the fetal blood, and hypercarbia, with a subsequently reduced pH. 
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However, in the early stages of a hypoxic event no metabolic changes occur at the 
tissue level. This would give a low pH in the presence of a normal base excess, a so 
called ‘respiratory’ acidosis. The most common causes of this are a sudden decrease 
in placental or umbilical perfusion. This may result from umbilical cord compression 
or uterine hyperstimulation. Maternal causes include hypotension, for example 
following regional anaesthesia, and also maternal hypoxia or hypoventilation, such as 
in asthma or massive pulmonary embolus.6 Reversal of the underlying cause and a 
restoration of circulation will lead to normalisation of the acid-base balance. 
If the episode of hypoxia is prolonged, the fetal tissues switch to anaerobic 
metabolism, resulting in the accumulation of lactic acid. This leads to a rise in lactate 
levels, a loss of bicarbonate and therefore a larger base deficit, a ‘metabolic’ 
acidosis.7 This situation may arise from a persistence of an acute event, as described 
above, or chronic uteroplacental hypoperfusion. It has been suggested that adverse 
health outcomes are associated with metabolic, rather than respiratory acidosis.8;9 
Should hypoxaemia occur, the fetal cardiovascular system will respond to the insult 
through transient bradycardia, an increase in arterial blood pressure, and a 
redistribution of the combined fetal ventricular output in favour of the adrenal glands, 
heart and brain, at the expense of perfusion to the peripheral circulation.10 
Consequences of hypoxia 
At a tissue level, hypoxic ischaemia initiates energy depletion, the accumulation of 
extracellular glutamate, and activation of receptors, leading to a deleterious cascade 
of events resulting in cell death.11 The effects may be multisystem, resulting in renal 
injury, myocardial dysfunction, and encephalopathy. Death may result if severe, 
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irreversible tissue damage occurs. Peripartum asphyxia affects 3 to 5 per 1000 live 
births in developed countries, with moderate or severe hypoxic ischaemic 
encephalopathy occurring in 0.5-1 per 1000.12 The long term consequences include 
cerebral palsy, neurodevelopmental delay and learning difficulties.13-15 However, 
these outcomes are unpredictable due to the fact that different areas of the 
developing brain are susceptible to damage at different times.16 In infants born at 
term (≥ 37 weeks gestation), neuronal injury predominates, and the hippocampus, 
deeper layers of the cerebral cortex and cerebellar Purkinje cells are the most 
frequently injured.17 In premature infants, the cerebral white matter is the major site 
of injury, resulting in periventricular leukomalacia (PVL), but primary or secondary 
injury to cortical or deep grey matter may also occur.17 However, the clinical 
consequences are unpredictable, resulting from the variation in site and severity of 
lesions and the phenomenon of ‘plasticity’, resulting from an ability of the brain to 
functionally adapt.18  
2.2.2 Labour and delivery events 
Uterine contractions transiently reduce the uterine blood flow and impair gaseous 
exchange. Under normal circumstances, the fetus has a period of recovery in 
between contractions, where circulation is restored, allowing a normal acid-base 
balance to be maintained. A small drop in pH level over the course of labour and 
delivery is expected,19 and the following mean umbilical cord values and standard 
deviations have been quoted as normal post-delivery of a term neonate:20 
Arterial pH 7.27+/- 0.07; Base excess (mEq/L) -2.70+/-2.8 
Venous pH 7.34 +/- 0.06; Base excess (mEq/L) -2.40+/-2.0 
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Immediately following delivery, under normal circumstances the neonate will begin 
breathing within a minute of birth, due partly to the drop in pH occurring due to 
labour, and also the stimulation of neuroreceptors in the suddenly cooled skin.21 This 
response occurs at the brainstem level. Failure to initiate breathing spontaneously 
may result from maternal anaesthesia or opioids, which cause depression of the fetal 
respiratory centre, however asphyxia may also cause apnoea. Animal models have 
demonstrated that following interruption of blood supply to the umbilical cord, a 
cessation of breathing movement occurs (primary apnoea), followed by a period of 
gasping, during which respiratory effort can be restored by sensory stimuli. If the 
hypoxia persists, a secondary phase of apnoea is entered, followed by eventual 
cardiac arrest.22  
Depression of the neonatal heart rate immediately after delivery is most often caused 
by hypoxia; other causes include cardiac arrhythmia, structural developmental 
anomalies and infection.23 If hypoxia is the cause, re-oxygenation stimulates an 
increase in heart rate, unless there has been significant myocardial damage as a 
result of severe or prolonged hypoxaemia.23 Neonatal colour is dependent on both 
circulation and heart rate: compromise of either of these may result in cyanosis or 
pallor.22 Neonatal muscle tone following delivery is reliant on higher cerebral function. 
Passive flexor tone appears between 28 and 34 weeks gestation and matures from 
the legs upwards, therefore normal term babies will lie with their limbs flexed and 
adducted.24 Normal spontaneous movements of the limbs will be varied, and babies 
should open their hands and move their fingers. Normal reflexes that are present, 
controlled at brainstem level, include the Moro reflex, sucking, rooting and stepping.24 
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Hypotonia at birth may result from hypoxic ischaemic encephalopathy, other 
ischaemic or haemorrhagic brain lesions, and in association with chromosomal 
abnormalities or metabolic disorders. Peripheral hypotonia may be caused by 
specific myopathy or neuropathy.25 Drugs administered to the mother may cause 
transient neonatal hypotonia.26 
2.2.3. Intrauterine fetal growth 
Normal growth is characterised by periods of tissue and organ growth, differentiation 
and maturation. The process is dependent on maternal provision of substrates 
(including amino acids, glucose, fats and oxygen), adequate placental transfer, and 
genetic determination of fetal growth potential. In the first 16 weeks of in utero life, 
growth occurs predominantly by hyperplasia and increasing cell numbers, followed 
between 16 and 32 weeks by both cellular hypertrophy and hyperplasia; after 32 
weeks gestation hypertrophy predominates.27 During the first 16 weeks of fetal life, 
there is little variation in growth rate, and this is largely under genomic control.28 
There is a consensus that insulin like growth factor 2 (IGF-2) is an important 
paracrine factor in embryonic growth.28 In later gestation, IGF-1 is the predominant 
growth regulator, produced by the fetal liver and other tissues. The main factor 
stimulating production of IGF-1 is fetal insulin, which in turn is regulated by fetal 
glucose availability.29 The growth velocity in later gestation is much more variable. 
There is a genetic influence, predominantly relating to the genes determining 
maternal habitus, with paternal influence being less significant. However the 
dominant factor is the supply of nutrients and oxygen to the fetus, which is 
determined by a balance of maternal health and homeostasis, uteroplacental 
circulation, placental transfer and metabolism, and umbilical blood flow.28 
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Normal birth weight for a baby born at term (≥ 37 weeks gestation) is considered to 
be 2500 to 4000 grams (g). However, this range should be interpreted with caution, 
as certain babies will be genetically programmed to be smaller and therefore will fall 
outside this range while still achieving their growth potential. Equally, a baby who is 
destined to be larger may undergo a pathological process of growth restriction in 
utero, yet still fall into the normal range at delivery. 
The causes of intra-uterine growth restriction 
The incidence of intrauterine growth restriction varies according to the definition 
used, but is estimated to be 5-7%30 This represents a heterogeneous group of 
aetiologies. The normal growth process may be disturbed by any factors disrupting 
maternal nutrient provision, placental transfer or genetic programming. These are 
summarised in table 2.1:  
Table 2.1 Aetiology of intrauterine growth restriction 
Maternal factors Fetal factors Placental 
Pre-eclampsia/ 
hypertension 
Multiple pregnancy Insufficiency 
Severe chronic disease 
(e.g. 
cardiac/renal/respiratory) 
Infection Abruption/ infarction 
Anaemia Chromosomal disorders 
(e.g. trisomy 21, 18) 
Vascular anomalies 
Smoking Infection (e.g. 
toxoplasmosis, rubella) 
Infection 
Infection Congenital anomaly  
Substance abuse   
Low body mass index/ 
malnutrition 
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Placental insufficiency may occur in association with maternal pre-eclampsia, and 
results from failure of adequate trophoblast invasion into the maternal spiral arteries, 
limiting the potential for nutrient transfer.31 This is thought to occur in approximately 
three percent of pregnancies.32  Maternal ill-health may alter the potential for nutrient 
or oxygen provision within the circulation. This, along with placental insufficiency, will 
extrinsically cause the fetus to fail to reach its growth potential.  Chromosomal 
disorders, congenital anomalies and infections either lead to altered growth potential 
within the fetus, or intrinsic failure to achieve this. The latter tend to cause a pattern 
of symmetrical growth restriction, where both fetal head and abdominal 
circumference are small, and this may be begin in the first or second trimester, 
resulting in decreased cell number and/ or size.30 Placental insufficiency or maternal 
vascular factors tend to cause asymmetric growth restriction, whereby the fetus has a 
smaller abdomen compared to head circumference. This process tends to become 
apparent in the third trimester, and results from impaired cellular hypertrophy. The 
growth asymmetry results from adaptation in the fetus to protect circulation to the 
brain and heart therefore diverting blood away from the peripheries and abdominal 
organs.30  
Consequences of intra-uterine growth restriction 
In severe cases, intra-uterine growth restriction may result in stillbirth or neonatal 
death. 33 In survivors, it has been associated with neonatal morbidity, resulting from 
oxygen and substrate deprivation during intrauterine life, such as hypoxic ischaemic 
encephalopathy, polycythaemia, hypothermia and hypoglycaemia.34 They may also 
be at risk of later life consequences such as cerebral palsy and neurodevelopmental 
delay.35;36 
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In addition, intrauterine growth restriction has been linked with a number of adverse 
health outcomes in adulthood, including cardiovascular disease, diabetes mellitus 
and hypertension.37;38 The ‘fetal origins hypothesis’ was first proposed in 1986 when 
Barker et al demonstrated an inverse relationship between birth weight and adult 
cardiovascular disease.39 The theory suggesting that malnourishment in utero results 
in fetal programming, whereby biological pathways are altered, resulting in increased 
susceptibility to disease in adult life. A number of mechanisms have been proposed, 
including metabolic effects, such as disruption of lipid metabolism in the adipose 
tissue and liver, and β- cell dysfunction leading to altered glucose homeostasis, 
resulting from fetal adaptations to malnutrition.40  Non-metabolic effects such as 
increased apoptosis, leading to altered organ morphology, have also been 
proposed.40 Epigenetic programming, whereby changes in gene transcription occur 
as a result of mechanisms other than changes to the underlying DNA sequence, 
have also been linked to this hypothesis, with suggestions that intrauterine growth 
restriction may alter chromatin associated with important genes, varying their 
expression.40;41 
Since the ‘fetal origins’ or ‘Barker hypothesis’ was first described, numerous studies 
have demonstrated an association between low birth weight and morbidity and 
mortality from a variety of conditions in childhood and  adult life.37;42-48 However, the 
results have not always been consistent.38;49-51 The initial evidence for the Barker 
hypothesis has been criticised for failing to account for important potential 
confounders such as gestational age and socio-economic class, and as such is not 
universally accepted.52 Indeed, should the association be genuine, it may not follow 
that it is also causative. The ‘fetal insulin hypothesis’ suggests that the relationship 
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between low birth weight and non-insulin dependent diabetes mellitus (NIDDM) may 
be attributable to common genetic factors relating to birth weight and NIDDM risk, 
rather than the diabetes as a consequence of intrauterine growth restriction.53  
2.2.4 Prematurity 
Premature infants (born at <37 weeks gestation) may differ significantly from term 
infants, depending on the gestation at delivery. Due to both low birth weight and 
immaturity of organ systems, there are a number of physiological differences from 
term infants, and they are at higher risk of a number of pathological processes; the 
combination of these features leads to differences in the clinical picture at delivery 
and increased risk of adverse outcomes. 
Neurologically, primitive reflexes such as the Moro response and asymmetric tonic 
neck reflex do not fully appear until 33 to 35 weeks gestation, and rooting until 28 
weeks. Premature babies tend to adopt an extended posture at rest.24 They are at 
higher risk of intraventricular haemorrhage (IVH), periventricular white matter injury 
and hydrocephalus.54   
Due to immaturity in central and peripheral chemoreceptors, control of respiration is 
less well developed, and premature infants will frequently display pauses in 
respiration. If they are accompanied by bradycardia, cyanosis or pallor, or last at 
least 20 seconds, this is considered significant. In the majority of infants they improve 
as the infant matures, however they may be related to an underlying neuropathologic 
process such as hypoxic ischaemic encephalopathy (HIE) or IVH.55 As a 
consequence of delay in surfactant production within the immature lungs, premature 
infants are also at higher risk of respiratory distress syndrome.54  
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Other complications arising from preterm delivery include necrotising enterocolitis, 
increased susceptibility to infection, patent ductus arteriosus, fluid and electrolyte 
imbalance, retinopathy of prematurity and hypothermia and hypoglycaemia.54 The 
risks of long term problems including neurodevelopmental delay, cerebral palsy, 
bronchopulmonary dysplasia, hypertension and increased insulin resistance are also 
increased.54 
2.3. Available neonatal tests 
2.3.1 Summary of neonatal tests available in the UK 
The tests, and the context in which they are usually performed, are summarised in 
Table 2.2.  
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Table 2.2 Available tests of neonatal wellbeing according to current UK 
practice 
Test performed 
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Measure of fetal growth: 
Absolute birth weight √    
Birth weight according to population centile chart √    
Birth weight according to customised centile chart    √ 
Ponderal Index (birth weight (kg)/ length (m)
3 
   √ 
Fetal growth ratio (observed weight/ expected for 
population) 
  √  
Head circumference (cm) √    
Skinfold thickness  √   
Weight for length z score   √  
Mid-arm circumference/ head circumference ratio   √ 
 
 
Measurement of fetal hypoxia: 
Umbilical artery cord pH  √   
Umbilical vein cord pH  √   
Umbilical artery base excess  √   
Umbilical vein base excess  √   
Arterial pH within 1 hour of birth  √   
Serum lactate   √   
Overall measure of wellbeing: 
Apgar score √    
Admission to Neonatal Unit required? √    
CRIB (infants admitted to NNU)    √ 
SNAPPE score (infants admitted to NNU)    √ 
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2.3.2 Current service provision: a description of the context in which the tests 
are performed and the results utilised 
Indicators of fetal hypoxia 
Blood sampling from the umbilical cord at delivery, for measurement of pH and base 
excess, gives an indication of whether the neonate has become hypoxic prior to 
delivery. Current UK guidelines for antenatal care recommend that this is not done 
routinely for all deliveries, rather that it should be reserved for infants who are 
suspected to be at higher risk of compromise, including those who have undergone 
an instrumental delivery, or had abnormalities on antenatal fetal heart rate 
monitoring, or any other cause for concern.56 However, in some units in the UK, 
umbilical cord pH testing is performed routinely at delivery.57  
The way in which these results are utilised clinically differs widely. In some units, a 
low pH in an otherwise well baby would prompt admission to the neonatal unit. In 
others, no further action would be taken. The most common course of action is to 
take the pH into consideration along with other tests, or clinical evidence of overall 
neonatal wellbeing,57 to determine the need for further monitoring or treatment 
including neonatal therapeutic hypothermia.58 
 Other tests to determine the acid-base status of a neonate include arterial blood 
sampling within the early neonatal period, and measurement of the serum lactate 
level. These would generally be reserved for babies who required admission to the 
neonatal unit, but the results would be used to guide further monitoring or treatment, 
in the same way as the umbilical cord pH result. 
 
 17 
 
Birth weight 
At present, all infants are weighed routinely and the head circumference is measured 
at birth. Depending on local practice, the length may also be measured. The weight 
for gestational age is then plotted on a centile chart, which is based on a range 
around normal values for the general population.59 Depending on local practice, the 
ponderal index (birth weight (kg)/ length (m3)) may be calculated, or a customised 
centile chart (normal range defined according to the mother’s height, weight, parity 
and fetal sex) used.60 If an infant is deemed to be of low birth weight, for example 
less than 2.5kg at a gestation of 37 weeks or greater, this may be used to indicate 
the need for further intervention and monitoring such as blood sugar testing and 
admission to the neonatal unit.  
Overall measures of wellbeing 
The Apgar score is routinely recorded for all infants at delivery by the attending 
midwife or doctor. Neonatal characteristics are evaluated as described in Table 2.3, 
including heart rate, respiratory effort, reflex responsiveness, muscle tone, and 
colour, and a total score assigned, in a range from zero to ten. The score is usually 
recorded at one, five and ten minutes following delivery.61 The initial purpose of the 
score, when first introduced by Virginia Apgar in 1953, was to focus attention on the 
newborn infant and identify those in need of resuscitation.62 The Apgar score may be 
reduced by any factor that causes compromise to the neonate, for example 
prematurity, hypoxia, and maternal opioids prior to delivery.63 The change in Apgar 
score over time documents neonatal recovery and response to resuscitation. Again, 
the action taken for a low Apgar score at delivery, besides immediate resuscitation, 
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varies according to local practice and how long from delivery the low score persists 
for.  Some would admit all babies with a ten minute Apgar score less than seven to 
the neonatal unit, whereas the majority would perform an additional review of the 
baby at a later time, and a minority would take no further action. 57 
Table 2.3 The Apgar score 64 
Sign Score 0 Score 1 Score 2 
Heart rate Absent <100/min >100/min 
Respiration Absent Weak Good cry 
Muscle tone Flaccid Some flexion Well flexed 
Reflex response 
(to skin 
stimulation of 
skin of feet) 
No response Grimace Cry or active 
withdrawal 
Colour Pale/ blue Blue extremities Pink 
 
Other measures that may be considered an overall indicator of neonatal wellbeing 
include whether the baby is admitted to the neonatal unit or not. On admission, an 
additional scoring system such as the Clinical Risk Index for Babies (CRIB), or 
SNAPPE score, may be applied to assign a risk of adverse outcome depending on a 
combination of factors such as temperature, pH, blood pressure or base excess.65;66 
Use of these scores varies according to local practice. 
2.3.3 Selection of tests to include in this thesis 
Three tests were selected from those available to be the focus of systematic reviews 
performed in this thesis. Umbilical cord pH or base excess, birth weight and Apgar 
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score are tests that are performed immediately following delivery, and are not only 
used to inform the future care of the neonate, but also as bench marks for obstetric 
care, both within clinical practice and frequently as outcome measures in obstetric 
clinical trials.67;68 69;70 In this context they are considered a surrogate for neonatal and 
long term morbidity, however due to the uncertainty surrounding this assumption 
observed effects are often viewed with suspicion.  
2.3.4 Summary of the current evidence for the association of neonatal tests 
with short and long term outcomes 
Umbilical cord pH 
The occurrence of perinatal asphyxia can be measured by the presence of fetal 
acidosis, determined by umbilical cord pH at birth.7 Cerebral palsy is thought to occur 
more frequently at an arterial cord pH of <7.00 and a base deficit ≥ 12mmol/l.71 
However, such criteria have been derived through consensus, not through evaluation 
of collated evidence summaries in the field,71 leading to some uncertainty about their 
use.72 This is because existing studies of the association between pH levels and 
outcomes have drawn inconsistent inferences, in part due to the different parameters 
measured, including arterial or venous pH and base excess, the variety of outcomes 
evaluated and the different thresholds used to define abnormality.73-76  
Previous reviewers have examined the relationship between fetal acidosis and the 
outcomes neonatal death and cerebral palsy, and found a significant association for 
both.77 However, this review was performed a decade ago, during which time new 
studies on the subject have been published and guidelines produced regarding the 
methodology and reporting of systematic reviews, including quality assessment of 
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included studies, which were not in widespread use at the time of its publication.78 
Substantial uncertainty remains about the value clinicians may attach to acidosis in 
the clinical management of neonates, and the long term implications of the umbilical 
cord pH result. 
Birth weight standards 
As described in Table 2.2, there are a variety of different definitions of low birth 
weight, which attempt to capture cases of intrauterine growth restriction, and identify 
infants most at risk of adverse outcome. These include population based centile 
charts, the most commonly used threshold being the tenth centile;21 customised 
charts where the mother’s BMI and ethnicity are used to calculate individualised 
growth centiles;22 and ponderal index which takes into account the neonatal weight 
and length.23 The published associations between each standard for defining growth 
restriction and adverse outcome vary, and there is no current consensus regarding 
the best method.24  
A number of systematic reviews have been performed to assess the relationship 
between low birth weight and a variety of health outcomes in childhood and adult life. 
However, the definitions of low birth weight have varied and results have been mixed, 
with pre-term infants included in the analysis, which may confound the results. 37;79;80 
No existing systematic reviews comparing definitions of low birth weight have been 
identified. 
Apgar score 
A group of neonates with a low Apgar score defined by a conventional cut-off will 
include neonates with asphyxia, but also a low score due to maternal medication, 
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delivery method or anaesthesia, and therefore the interpretation of these results has 
been questioned.81 Also, there is a lack of consensus regarding the threshold that 
defines a ‘low’ score, and the timing of measurement to which the greatest 
importance can be attached.82 A systematic review of the association of Apgar score 
with adverse outcome demonstrated a significant association between a low score 
and both neonatal mortality and later cerebral palsy.77  However, this review was 
published a decade ago, and does not differentiate between pre-term and term born 
infants, between whom the Apgar score and adverse outcomes may vary widely.83 
 
A comprehensive systematic review of the literature surrounding these tests will 
clarify the existence and strength of a relationship between an abnormal test and 
adverse outcomes throughout the life course, and guide clinical practice regarding 
the use of different tests and thresholds to predict these. 
2.4 Development of this thesis 
The Mary Crosse Fellowship (Birmingham Women’s Hospital NHS trust) funded an 
evidence synthesis project to examine the association between neonatal tests and 
health outcomes. The author worked on this project performing systematic reviews 
and health economic evaluation, and also received formal training at the University of 
Birmingham in Health Technology Assessment, Health Economic Evaluation, 
Advanced Statistics and Decision Modelling; and the Oxford Centre for Evidence 
Based Medicine in Evidence Based Diagnostics. 
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CHAPTER 3: RESEARCH QUESTIONS 
ADDRESSED IN THIS THESIS 
 
3.1 Research questions addressed in this thesis by systematic review 
 
1. What is the association of umbilical cord pH or base excess with neonatal and 
long term adverse outcomes? 
2. What is the predictive ability of umbilical cord pH or base excess for neonatal 
and long term adverse outcomes? 
3. What is the association of different standards for defining low birth weight with 
neonatal and long term adverse outcomes? 
4. What is the predictive ability of low birth weight standards for adverse 
outcome? 
5. What is the association of the Apgar score at birth with neonatal and adverse 
outcomes? 
6. What is the predictive ability of the Apgar score for adverse outcomes? 
 
3.2 Research questions addressed in this thesis by decision- analytic 
modelling 
1. Which threshold of umbilical cord pH is the most cost-effective in combination 
with treatment with neonatal hypothermia to reduce the risk of cerebral palsy 
following intrapartum hypoxia? 
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CHAPTER 4: METHODS FOR SYSTEMATIC 
REVIEWS OF ASSOCIATION AND 
PREDICTIVE ABILITY 
 
4.1 Introduction 
The systematic reviews performed in this thesis evaluate the association and 
predictive ability of tests performed at birth for neonatal and long term adverse 
outcomes. The neonates on whom the tests were performed were from different 
population spectrums and, where possible, pre-term (<37 weeks gestation) and term 
born (≥ 37 weeks) were analysed separately to reflect the different risk of adverse 
outcomes between these populations. The systematic reviews used a common 
methodology which is detailed in this chapter. Where specific methodology differed, 
this is given in the chapter relevant to each test.  
All systematic reviews were performed using a prospective protocol and widely 
recommended methods.84-88 The following steps were taken in all cases: 
i) Framing the question 
ii) Study identification 
iii) Quality assessment 
iv) Data extraction 
v) Analysis and interpretation of data 
This work has been published by Malin GL, Morris RK, and Khan KS. Mary Crosse 
project: Systematic reviews and grading the value of neonatal tests in predicting long 
term outcomes. BMC Pregnancy and Childbirth 2009; 9:49. 
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4.2 Framing the question 
Each review should set a clear question in order to ensure that the objectives of the 
review are achieved. The question can be framed according to the ‘PICOS’ criteria, 
ensuring that all elements of the review question are clearly defined.84 This includes 
the population, index test (or intervention), comparator (not used in these reviews), 
outcome measure and study design of interest; a well-structured question will 
determine components of the search strategy and therefore aid identification of 
relevant studies for inclusion. The common components of the question used in each 
of the reviews in this thesis are given below. 
1. Population Live-born infants who have had the index test of interest 
performed at birth. 
2. Index test Any measure of weight or growth at birth including: absolute birth 
weight (thresholds <2.5kg, <2.0kg, <1.5 kg); population or customised centile 
charts (thresholds < 10th centile, < 5th centile, <3rd centile); ponderal index or 
other growth ratios; Umbilical cord blood examination for arterial or venous pH 
or base excess; Apgar score at 1, 5 or 10 minutes of age.  
3. Outcome Any measure of compromise of neonatal, childhood or adult 
wellbeing such as: mortality, neonatal morbidity including hypoxic ischemic 
encephalopathy; childhood or adult motor disability; childhood or adult disease 
including diabetes mellitus, cardiovascular disease and hypertension.  
4. Study design Randomised controlled trials or observational studies (including 
cohort and case control design) that allowed generation of a 2x2 table (true 
positives, false positives, false negative and true negatives) to compute an 
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estimate of the association and predictive ability between test result and 
outcomes. Studies with ≤ 5 individuals in total were excluded on account of 
unreliability. 
4.2.1 Population 
In all cases the population for inclusion was live born infants. In the birth weight 
standards review, this was further limited to infants born at term (≥ 37 weeks 
gestation) to avoid the confounding effect of prematurity on this group of tests. No 
other restrictions in terms of study setting or other risk factors for adverse outcome 
were applied, although these were considered in subgroup analyses where possible. 
4.2.2 Index tests 
The reasons for selection of the included tests are described in Section 2.3.3. 
Scoping searches were performed to confirm the availability of primary evidence for 
these tests and the outcomes of interest. To ensure that the assessment of each test 
was as comprehensive as possible all methods and thresholds described by authors 
in primary studies were included. 
4.2.3 Outcome measures 
In order to optimise the assessment of the tests, the outcome measures selected for 
inclusion were not limited to specific conditions a priori, rather the search strategies 
used a combination of specific adverse outcomes (including neonatal, childhood and 
adult mortality, learning difficulties, cerebral palsy, hypertension, diabetes mellitus) 
and open terms (e.g. morbidity) and any papers with the appropriate index test and 
 27 
 
population and any measure of adverse outcome throughout the life course were 
included. 
4.2.4 Study design 
Randomised controlled trials (RCT) or observational studies (including prospective 
and retrospective cohort and case control design) that allowed generation of a 2x2 
table (true positives, false positives, false negative and true negatives) to compute an 
estimate of the association and predictive ability between test result and outcomes. 
Studies with ≤ 5 individuals in total were excluded on account of unreliability. Case- 
control studies, whereby individuals are selected for inclusion on the basis of their 
disease status, are thought to be prone to spectrum bias.89 This was accounted for in 
the quality assessment of included studies.   
4.3 Study identification 
The search strategies for each study were designed to capture primary studies with 
data regarding the association or predictive ability of each neonatal test with adverse 
outcomes throughout the life course, using elements of the question outlined in 
section 4.2.  
The initial scoping search, outlined in Appendix 1, was performed by Dr R K Morris 
(see acknowledgments) in preparation for the application for fellowship funding for 
this project. The search was run in 2006 in three electronic databases (Medline, 
EMBASE, Cinahl) at which time 3698 potentially relevant citations were retrieved. 
The final searches, outlined in chapters 5 to 7, were performed by the author 
following appointment to the fellowship and decision of the final tests for inclusion in 
this thesis.   
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In all cases, a combination of MeSH headings, keywords and word variants for the 
index test in question were combined using the Boolean operator ‘OR’ for capturing 
citations of the relevant text. These were combined using ‘AND’ with a combination of 
MeSH headings, keywords and word variants to capture relevant outcomes. The 
search was restricted to human studies, but no language or methodological 
restrictions were applied. Pilot searches were performed in Medline before the final 
search strategy was applied to maximise capture of relevant studies. 
Searches were performed from database inception until the search date. The 
following sources were used to search for relevant literature: 
1. Medline and EMBASE (general bibliographic databases) 
2. Specialised electronic databases: The Cochrane Library (including systematic 
reviews and clinical trials databases), DARE (Database of reviews of 
effectiveness), Medion, British Nursing Index (EBSCO) 
3. Sources of ‘grey’ literature: Web of Science, OpenGrey, contact with experts in 
the field. 
4. Hand searching of specialist journals 
5. Reference checking of review articles and included studies 
6. Contact with authors for clarification where 2 x 2 tables could not be obtained 
from published studies. 
7. SCISEARCH and Web of Science to identify frequently cited articles and 
conference proceedings 
 A comprehensive database collating all citations was constructed using Reference 
Manager 11.0/12.0. The list of citations was initially scrutinised by the author, and full 
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articles of all citations that were felt on examination of title and abstract to be likely to 
meet the predefined selection criteria were obtained. Translations of articles in 
languages other than English were obtained (see acknowledgements). Final 
inclusion or exclusion decisions were made through their examination by the author, 
depending on their adherence to a pre-defined checklist based on population, index 
test, outcome measure, study design and ability to obtain data to populate 2 x 2 
tables. The study selection and data extraction process was also repeated, in a 
random sample of 10% of the papers, by a second reviewer (see acknowledgments). 
Where any disagreements occurred, these were resolved by consensus or the input 
of a third reviewer (Professor K S Khan). A random sample rather than dual review of 
all papers was performed for pragmatic reasons, due to the large number of articles 
reviewed at each stage of the process. There was a high level of inter-reviewer 
agreement (98%) which was felt to justify deviating from the recommendation of 
reviewing in duplicate throughout. 
All manuscripts were carefully examined to identify duplications in population. Where 
this was identified, the most recent and complete versions were selected.  
4.4 Quality assessment 
All articles meeting the selection criteria were assessed for methodological quality, 
defined as the confidence that the study design, conduct and analysis minimised bias 
in estimation of the association. Quality was assessed (by the author and in duplicate 
by a second reviewer where possible) using the complete Standards for Reporting of 
Diagnostic Accuracy (STARD) (Appendix 2) and Quality Assessment of Diagnostic 
Accuracy (QUADAS) (Appendix 3) checklists, which are validated for the reporting 
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and methodological quality of diagnostic test accuracy studies. The quality elements 
from these checklists which were felt to be most relevant for these reviews on 
prognostic tests, associations and predictive ability were selected.90;91 A quality score 
was not assigned as this been shown to give flawed results.92 Cohort study design 
was considered to be superior to case- control. A study was rated high quality if it 
had at least four of the following items: adequate description of population; adequate 
description of the index test and outcome measure; consecutive recruitment; 
prospective recruitment; > 90% completions of follow up; appropriate outcome 
measurement; blinding of the investigators performing the outcome measure and a 
statement regarding the use of intervention between the index test and outcome. A 
study was deemed to be of medium quality when only three criteria were met and low 
if two or less were adhered to. Description of the population was considered 
adequate if the gestational age at delivery and the setting from which the population 
was recruited were reported, and information regarding risk factors or co-morbidities 
for adverse outcome given. An ‘unclear’ grading was given if some of this information 
was missing, for example the gestational age of the population was reported but not 
the study setting. Consecutive or random recruitment were considered ideal, and a 
prospective study design was thought to introduce less bias than retrospective 
methods. The index test was considered to be described in full if the timing, method 
and personnel taking the test were specified. Adequate description of the outcome 
measure required specification of the exact nature of the condition in question, the 
threshold used to determine whether an individual had the condition of interest or not, 
and who performed the test to determine disease status. Blinding of that individual to 
the index test result, and a description of any treatment the individual had received in 
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the intervening time which may have affected the outcome was also considered 
important. Completions of follow up of greater than 90% were thought to minimise 
verification bias. This was calculated from a flow chart on the data collection sheet 
detailing the number of eligible infants for each study, those that received the index 
test and outcome measure, and any reported exclusions or withdrawals from the 
study at each stage. The number or infants receiving the outcome measure/ number 
receiving the index test x 100 was used to calculate the completeness of follow up 
percentage.  
The overall quality of a study was not used to define inclusion/ exclusion into a 
review, but, where possible, either meta-regression or subgroup analysis according 
to study quality was performed, and the overall quality of the included studies and 
adherence to each of the criteria described above are presented in table form in each 
review. 
4.5 Data extraction  
Information was extracted from the selected articles, in duplicate (by the author and a 
second reviewer as described in section 4.3) using a pre-designed data collection 
sheet. This was piloted for each review to ensure all relevant items were included. 
The data collection sheets for each review were similar and are given in Appendices 
4 to 6. Data were extracted on study characteristics including population and setting, 
index test (including threshold values used), outcome measure (including blinding, 
definition and threshold), study quality and results, and were entered onto an Excel 
spreadsheet. Data were used to construct 2x2 tables of the association between the 
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index test of interest using the threshold reported in the paper and the postnatal 
outcome for each individual, as described in Table 4.1. 
Table 4.1 2 x 2 table 
 Outcome 
measure positive 
Outcome 
measure 
negative 
Total 
Index Test 
positive 
True positive (TP) False positive 
(FP) 
TP + FP 
Index Test 
negative   
False negative 
(FN) 
True negative 
(TN) 
FN + TN 
Total TP + FN FP + TN TP +FP+ 
FN+ TN 
 
If results for multiple thresholds were reported, a separate 2x2 table for each 
threshold was constructed. In studies where data were felt to be relevant but 2x2 
tables could not be completed, or the outcome or population reported in the paper did 
not meet the specific inclusion criteria, the authors were contacted. The study was 
not included unless the data could be provided and the population, and outcome, 
considered satisfactory. Difficulties in data extraction were resolved by seeking input 
from a third reviewer (Professor KS Khan).  
4.6 Analysis and interpretation of data 
In this thesis, the term ‘prognostic’ refers to strength of association between a test at 
birth and the odds of an adverse outcome, as measured by an odds ratio. The term 
‘predictive’ refers to the ability of a test to discriminate between those babies who will 
and those who will not experience an adverse outcome, as measured by sensitivity, 
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specificity, and positive and negative likelihood ratios. A test may have strong 
prognostic ability, but not necessarily good predictive ability, and so it is important to 
consider both.93  
4.6.1 Data synthesis for prognostic association  
The 2 x 2 tables were used to compute odds ratios (OR) and 95 % confidence 
intervals (CI) for each index test-outcome pair. OR were calculated using the formula 
(TP x TN)/ (FP x FN). The CI were calculated using the formula logOR +/- 
1.96SE(logOR). ORs were selected as the summary statistic as they represent the 
effect of the exposure on the odds of having the condition in an unbiased fashion and 
enable the results of case- control and cohort studies to both be included.94 It is 
frequently used to demonstrate an epidemiologic association,94 and here it provides a 
measure of a test’s prognostic ability. Where possible the results for each index test 
and outcome measure were pooled using meta-analysis.  
4.6.2 Data synthesis for predictive ability 
Where there was a strong and statistically significant prognostic association between 
a test and an outcome measure (defined by an OR >5 ,with 95% confidence interval 
that did not cross 1) sensitivity, specificity and likelihood ratios (LR) were calculated, 
again using data from the 2 x 2 tables as follows: sensitivity TP / (TP+ FN); specificity 
TN/ (FP + TN); positive likelihood ratio sensitivity/ (1-specificity); negative likelihood 
ratio (1-sensitivity)/ specificity. This allowed the predictive ability of the test to be 
determined;95 that is, whether the test can accurately discriminate between those 
who do and those who do not have a poor outcome (as measured by sensitivity and 
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specificity), and how much a positive or negative test result modifies the odds of a 
poor outcome (as measured by the positive and negative likelihood ratios). 
4.6.3 Assessment of heterogeneity 
OR data was plotted in forest plots and the between-study heterogeneity in the 
prognostic association for each test was assessed visually and by estimating I2 (the 
amount of variability in prognostic effects due to between-study heterogeneity)96  and 
tau-squared (an estimate of between study variance).97  
Where significant heterogeneity (defined as I2 >50%) was present, the reason for 
heterogeneity was explored using meta-regression (where the number of studies 
included in a particular meta-analysis was ≥ 10), planned a priori in keeping with 
published recommendations.96  Where meta-regression was significant, or if meta-
regression was not possible, subgroup analyses were performed to explore the effect 
on results and heterogeneity. Pre-defined categories included: 
1. Study quality (high quality versus low or medium quality) 
2. Population characteristics (including gestational age, year of birth of study 
population, risk factors for adverse outcomes) 
3. Study setting (including country of origin where standards of care thought to 
be similar: USA/ Europe/ Australia and New Zealand versus others) 
Factors thought to be relevant to particular index tests and their relationship with the 
outcome measures in question are reported in the relevant chapter. 
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4.6.4 Meta-analysis 
Meta-analysis was performed where two or more studies used the same index test 
and outcome measure. In each study when a table contained cells with a value of 0, 
0.5 was added to all cells to allow the calculation of log ORs and their variances for 
meta-analysis.98 The primary outcomes were considered to be neonatal mortality, 
and composite measures of neonatal, childhood and adult morbidity. A composite 
outcome measure for morbidity was employed to maximise the number of events that 
could be included in the analysis and avoid the need to select a single morbidity as a 
primary outcome measure. However, a hazard of composite outcome measures is 
the assumption that the significance of the result applies to all components.99 To 
address this issue, the component outcomes were analysed as subgroups where 
possible. When the composite outcome measure was used, care was taken to 
ensure that each individual was only counted once in each analysis, particularly 
where studies reported multiple outcomes for a single population. Where multiple 
outcomes were reported, attempts were made to select the outcome most consistent 
with other studies within the meta-analysis. 
Due to the expected presence of clinical and statistical heterogeneity between 
studies, a random effects model was used throughout, which dichotomises the log 
OR estimates for each test and weights each study by the inverse of the study’s 
variance plus between-study variance. When this method is used to calculate odds 
ratios, it provides a summary estimate of the average prognostic effect of a test.100 
As a test’s prognostic ability may vary from this average from setting to setting, after 
each random-effects meta-analysis ,if I2 was greater than 0%, a prediction interval 
(EPI) was calculated to reveal the potential prognostic association if the test is 
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applied in a single setting similar to one of the studies from the analysis.101 This was 
calculated where three or more studies were included in the meta-analysis.  
Pooled sensitivity, specificity and likelihood ratios were also calculated using a 
bivariate random-effects meta-analysis model. Bivariate meta-analysis accounts for 
the possible negative correlation between the sensitivity and specificity of a test, 
thought to be due to the fact that varying test threshold affects these parameters, and 
that different studies may have explicit or implicit differences in the threshold used to 
define a positive test. Explicit differences arise from studies using different thresholds 
to define a positive test, whereas implicit threshold variations may result from 
differences in observers or equipment.102 Bivariate meta-analysis assumes that the 
sensitivities from different studies (after logit transformation) within a meta-analysis 
are normally distributed around a mean value, with variability around this, and the 
same considerations are applied to the specificities of the study. The combination of 
the two normally distributed outcomes, acknowledging the potential correlation 
between them, results in the bivariate normal distribution.102 
All bivariate meta-analyses were performed in Stata version 10.0 (StataCorp, Texas, 
USA) using the metan and metandi commands.103;104 Plots were generated using 
StatsDirect (StatsDirect, Cheshire, UK). Meta-Disc was used for calculations and 
non-bivariate meta-analyses.105 
4.6.5 Publication bias 
Publication bias arises when the studies included in a review differ systematically 
from those that are missed. Funnel plots assess sample size effects by plotting the 
log odds ratio (ln OR) against the sample size of precision (estimated by the 
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reciprocal of the standard error (SE). Where no sample size effect exists, the points 
will form a symmetrical funnel plot.106 Sources of asymmetry include publication bias 
and location bias (e.g. language bias), poor methodological quality leading to 
spuriously inflated effects in smaller studies,107 and true heterogeneity.108 Certain 
tests of funnel plot asymmetry have been found to be more prone to type I error rates 
within meta-analyses of diagnostic accuracy, due to correlation between lnOR and its 
SE, and  therefore these were avoided.106 To explore for the presence of funnel plot 
asymmetry (small study effects) and thus potential publication bias, the Peters test 
was performed in each meta-analysis containing at least 10 studies.108 This uses a 
weighted linear regression which has been shown to be more accurate.109 The 
analysis was performed in Stata 10 using the metabias command.110 
4.7 Description of data 
For each neonatal test, data on individual studies are presented as follows: 
1. Table of the characteristics of included studies including population, test and 
outcome measure. 
2. Table of the methodological quality of the included studies according to the 
pre-specified criteria. 
3. Forest plots of odds ratios of individual studies and summary OR from meta-
analysis according to the index test, threshold and outcome of interest. 
4. Sensitivity, specificity and likelihood ratios are presented in tabular form along 
with their 95% confidence intervals. 
5. Forest plots or tables with subgroup analyses (where possible). 
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6. Results of the Peters test for publication bias (asymmetry) according to p 
value. 
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CHAPTER 5: SYSTEMATIC REVIEW AND 
META – ANALYSIS OF THE PROGNOSTIC 
AND PREDICTIVE ABILITY OF UMBILICAL 
CORD PH OR BASE EXCESS AT BIRTH 
FOR SHORT AND LONG TERM 
OUTCOMES 
 
5.1 ABSTRACT 
5.1.1 Background 
The purpose of this systematic review was to evaluate the association between 
umbilical cord pH or base excess at birth and outcomes. 
5.1.2 Methods 
A systematic review of the literature with random effects meta-analysis and meta-
regression, using standard techniques was performed. Odds ratios with their 95% 
confidence intervals were computed, and summary sensitivity, specificity and 
likelihood ratios, to assess predictive ability. Electronic searches were performed 
from database inception until August 2008 without language restrictions. The 
 40 
 
reference lists of selected articles were screened and authors contacted. Studies 
were selected by two reviewers if umbilical cord pH at birth, and/or base excess, by 
any threshold, were related to neonatal or long term outcomes. 
5.1.3 Results 
51 articles including 481753 individuals met the selection criteria. Studies varied in 
design, quality, outcome definition and results. Meta-analysis performed within pre-
defined groups showed that low arterial cord pH had significant associations with 
neonatal mortality (OR 16.4, 95% CI 8.9-30.4, I2 0%), hypoxic ischemic 
encephalopathy (OR 15.2, 95% CI 7.0-33.0, I2 0%), intraventricular hemorrhage or 
periventricular leukomalacia (OR 2.7, 95% CI 2.0-3.7, I2 0%) and cerebral palsy (OR 
2.1, 95% CI 1.3-3.4, I2 0%). Umbilical arterial pH showed a high specificity but poor 
sensitivity for neonatal mortality and morbidity. 
5.1.4 Conclusion 
Low arterial cord pH showed strong, consistent and temporal associations with 
clinically important neonatal outcomes that are biologically plausible. These data can 
be used to inform clinical management and justify the use of arterial cord pH as an 
important outcome measure alongside neonatal morbidity and mortality in obstetric 
trials. 
5.1.5 Publications arising from this work 
Malin GL, Morris RK, Khan KS. Umbilical cord pH in the prediction of neonatal and 
long term morbidity: a systematic review of the literature and meta-analysis. Archives 
of Disease in Childhood: Fetal and Neonatal Edition 2009; 94 (supplement 1): Fa 26 
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Malin GL, Morris RK, Khan KS. What is the relationship between umbilical cord pH 
and perinatal and long term outcome? A systematic review and meta-analysis to 
evaluate strength of association. BMJ 2010; 340: c1471. 
5.2 Introduction 
Perinatal asphyxia is a major cause of neonatal and childhood morbidity and 
mortality.111 It is predicated by fetal acidosis, determined by umbilical cord pH at 
birth.112 Cerebral palsy is thought to occur more frequently at an arterial cord pH of 
<7.00 and a base deficit ≥ 12mmol/l.71 However, these criteria have been derived 
through consensus, not through evaluation of collated evidence summaries in the 
field,71 leading to clinical uncertainty.72 As described in section 2.3.4, this is because 
existing observational studies of the association between cord pH and outcomes 
have drawn inconsistent inferences, and the only other systematic review in this area 
did not provide robust results.77 Substantial uncertainty therefore remains about the 
value clinicians may attach to acidosis in the management of neonates, and the long 
term implications of a low arterial cord pH. A documented low umbilical cord pH is a 
factor which may be used to support medico-legal claims of harm during intra-partum 
events resulting in long term disability.113 It is therefore imperative that the validity of 
this association is supported with high quality evidence. 
The aim of this systematic review of the literature was to quantitatively establish the 
prognostic association and predictive ability of acidosis at birth with neonatal 
mortality, morbidity and long term outcomes, and assess if causal criteria were 
met.114 
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5.3 Methods  
The methods employed are those outlined in Chapter 4, with those specific to this 
review detailed below.  
5.3.1 Data sources and searches 
Electronic searches were performed with the aim of capturing data regarding 
neonates with umbilical cord pH performed at birth, and adverse outcomes 
throughout the life course. Searches were performed by the author from database 
inception until August 2008. The search strategy employed in Medline is given in 
Appendix 7. This was adapted for use in other electronic databases.  
5.3.2 Study selection 
Studies were selected if they contained data on neonates who had an umbilical cord 
blood tested for arterial, venous pH or base excess at birth, and the association with 
neonatal or long term outcomes 
5.3.3 Data extraction and quality assessment 
The data extraction tool employed in this review is given in Appendix 4. Any 
threshold of arterial or venous pH, or base excess, taken from the umbilical cord after 
delivery was included. All live born neonates were included. All studies were 
assessed fully using the STARD and QUADAS checklists(Appendix 2 and 3).90;91 The 
elements felt to be most relevant to systematic reviews assessing prognostic 
association and predictive ability, as described in Section 4.4, were used to assess 
the overall quality of the included studies. A study meeting four or more of the criteria 
was considered to be of high quality, three moderate, and two or less of low quality.  
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5.3.4 Data synthesis 
The 2 x 2 tables were used to compute odds ratios (OR) and 95 % confidence 
intervals (CI) for each index test-outcome pair, and pooled the results for each index 
test (considering each definition and threshold of growth as a separate test) using 
meta-analysis. 
Analyses were performed for groups defined a priori according to index test (arterial 
cord pH, venous cord pH and base excess). The main outcome measures 
considered included neonatal mortality, a composite measure of neonatal morbidity, 
and cerebral palsy. The component neonatal outcomes of hypoxic ischemic 
encephalopathy, seizures, intraventricular hemorrhage or periventricular 
leukomalacia were analysed separately. Within the composite analysis of neonatal 
morbidity, HIE was the most commonly reported across the included studies, and 
therefore this outcome was selected if studies reported more than one measure of 
morbidity. 
Within the largest groups, (arterial cord pH paired with neonatal mortality and 
neonatal morbidity), meta-regression was performed to explore the reasons for 
heterogeneity. Study design (cohort versus case-control), study quality (high versus 
medium/ low quality) and population risk (high versus low/ unselected or unreported) 
were considered potential sources of heterogeneity. Population at high risk for 
complications was defined based on reported characteristics including CTG 
abnormalities, meconium liquor, low Apgar score at birth, gestation < 37 weeks, and 
birth weight < 2500g. Comparison of a low risk population to others was not possible 
as only one included study met the criteria for this definition. Exploration of other 
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potential sources of heterogeneity was not possible given the reporting quality of the 
primary studies. Multivariable and univariate meta-regression were performed, in 
accordance with published guidance, which recommends allowing at least 10 studies 
per covariate explored.38 Where a source of heterogeneity was identified, subgroup 
analyses were performed. As complications such as cerebral palsy and intra-
ventricular haemorrhage have been shown to be increased in pre-term and low birth 
weight infants, studies with these populations were analysed separately, and 
compared the results to that of a term population (≥ 37 weeks gestation). 
In order to assess causal association for each outcome Hill’s criteria were 
considered.115;116 To explore the prognostic association and predictive accuracy of 
umbilical arterial cord pH at different thresholds, the summary odds ratios and 
sensitivity and specificity were calculated for subgroups of studies using different 
thresholds to predict neonatal mortality and morbidity. 
5.4 Results 
5.4.1 Literature identification and study characteristics 
As shown in Figure 5.1, after an initial search of 5690 citations, 51 primary articles 
were included, two following provision of further information from authors. 481753 
individuals were included in the overall review. Some of the studies reported multiple 
umbilical cord parameters or outcomes; these are counted in each relevant category 
but only once in the overall total. 43 of the studies were eligible for inclusion in meta-
analyses according to pre-defined outcome measures, including 479383 individuals 
in total and 70 2x2 tables. The characteristics of included studies are given in 
Appendix 8, and the references in Appendix 9. 
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5.4.2 Data extraction and quality assessment 
The majority of papers reported arterial cord pH (n=46), with thresholds ranging from 
7.00-7.24. Arterial base excess was reported in five studies, with thresholds of 12 to 
16mmol/l. Four studies reported venous cord pH; three using a threshold of 7.20 and 
one 7.10. Only one study utilised venous base excess. The umbilical cord pH level 
was always obtained prior to the occurrence of the adverse outcome. A wide variety 
of outcome measures were reported, ranging from neonatal mortality and morbidity 
to long term outcomes including cerebral palsy, unspecified neurological abnormality, 
intelligence quotients and developmental assessments including the Bayley and 
Griffiths scores. Where the same outcome was reported the thresholds and ages at 
assessment varied between studies. 36 studies reported only on outcomes within the 
neonatal period. 15 studies performed long term follow up, one did not report the age 
of ascertainment of the outcome. The range reported in other studies was 1 to 8 
years; the median across studies was 5 years.  
Overall study quality was variable (Table 5.1). The majority of studies were 
retrospective but with a cohort design, allowing inferences concerning temporality of 
association. Over 80% of studies met the following quality items: appropriate 
outcome measure, > 90% verification with outcome measure, and cohort design. 
Studies scored poorly on the following items: adequate description of index test and 
outcome measure, and consecutive recruitment. All included studies were unclear 
regarding the use of medical intervention between the index test and outcome 
measure. Overall 45% of studies were high quality, 39% medium and 16% low. Study 
design and quality did not appear to influence results on meta-regression (Table 5.2).  
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5.4.3 Relationship between cord blood assessment at birth and outcomes  
Association between cord blood assessment at birth and neonatal mortality 
There were 15 studies (13 cohort design and 2 case control design) with a total of 
469395 infants, which reported the association between arterial cord pH and 
mortality. All studies had an OR point estimate > 1.0. There was significant 
heterogeneity (I2 61.0%) overall. Meta-regression (Table 5.2) identified population 
risk as a significant explanatory factor. Within sub-groups (Figure 5.2) the association 
was consistent across studies. The association of low umbilical artery pH with 
neonatal mortality was stronger in the unselected population (OR 16.9, 95% CI 9.7 to 
29.5, I2 0%) than in the high risk population (OR 4.3, 95% CI 2.2 to 8.5, I2 29.5%).  
The analysis for the unselected population was dominated by one very large study, 
which was based on data from a regional perinatal register where umbilical cord pH 
was performed at the majority of births (Heller et al 2003). A sensitivity analysis was 
performed excluding this study. This did not significantly alter the point estimate (OR 
17.0, 95% CI 4.4 to 65.5), however the estimated prediction interval became very 
wide (0.0 to 106299.0) 
Examination of the high risk population further showed that studies reporting on a 
population of infants born at less than 32 weeks gestation, or with a birth weight 
<2,000g, when analysed separately (7 studies), had a significant association 
between cord pH and mortality (OR 3.5, 95% CI 2.3 to 5.4, I2 0%). When limited to a 
term (>37 weeks gestation) population (4 studies), the association was also strong 
(OR 9.3, 95% 1.4 to 63.2, I2 84%). Grouping the studies according to quality did not 
affect the significance or direction of association of the pooled result (Figure 5.2). 
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Exploration for a threshold effect (Table 5.3) showed that the results for a cut off of 
pH 7.00 the association did not reach significance overall (OR 6.1, 95% CI 0.9 to 
41.6) and the prediction interval was very broad (0.0 to 20406.6). The results for a 
threshold of 7.10 gave a similar point estimate but achieved significance (OR 7.1, 
95% CI 3.3 to 15.3); however the predictive interval remained broad (0.8 to 64.3) and 
crossed the line of no effect. For a threshold of 7.20, the OR was lower (4.3, 95% CI 
2.2 to 8.7) with a broad predictive interval (0.5 to 40.6). Only one study (Heller et al 
2003) examined all 3 thresholds, which demonstrated the strongest association at 
threshold 7.00 (OR 16.9, 95% CI 9.2 to 31.1) and the weakest at 7.20 (OR 3.1, 95% 
CI 2.3 to 4.1).  
Association between cord blood assessment at birth and neonatal morbidity 
There were 31 studies comparing umbilical artery pH with a variety of neonatal 
outcomes (Figure 5.3). One of these was excluded from meta-analysis of composite 
neonatal morbidity because it contained a duplicate population to another included 
study, therefore the dataset to assess the association of arterial pH with a composite 
measure of morbidity included 30 studies with 10904 individuals. Only two studies 
had an OR point estimate < 1.0, the rest showed an association. However, significant 
heterogeneity was present (I2 58.2%). Meta-regression showed population to be an 
explanatory variable (Table 5.2). Subgroup meta-analysis for a high risk population 
(Figure 5.3) showed a weaker association (OR 3.4, 95% CI 2.3 to 4.9) than in an 
unselected/ undefined population (OR 10.6, 95% CI 4.7 to 24.1, I2 66.4%). When 
analysed in subgroups according to quality, the direction of effect remained 
consistent and significant between the group of 12 high quality studies (OR 6.6, 95% 
CI 3.7 to 11.8, I2 51.2%) and 18 low/medium quality studies (OR 4.6, 95% CI 2.5 to 
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8.4, I2 61.5%). Exploration by subgroup analysis for a threshold effect (Table 5.3) 
showed the most substantial association exists at a threshold of 7.00 (OR 12.5, 95% 
CI 6.1 to 25.6). The EPI was broad but did not cross the line of no effect (1.7 to 89.9) 
The results for a threshold of 7.10 (OR 2.4, 95% CI 1.3 to 4.3) and 7.20 (OR 2.2, 
95% CI 1.3 to 3.7) were similar. 
When components of the composite outcome were analysed (Figure 5.3), the 
association between umbilical artery pH and HIE had an OR of 13.8 (95% CI 6.6 to 
28.9, I2 0%). That between arterial pH and seizures had an OR of 8.1 (95% CI 3.0 to 
21.9, I2 66.3%). A low arterial pH was associated with IVH or PVL (Figure 5.3) with 
an OR of 2.9 (95% CI 2.1 to 4.1, I2 0%). Only 2 of 9 studies reporting this outcome 
were not limited to a pre-term (<32 weeks) or low birth (<2000g) population. 
Excluding these 2 studies did not affect the strength or significance of the 
association. 
The association between venous pH and neonatal morbidity was reported in 5 
studies. Meta-analysis demonstrated a significant association (OR 2.9, 95% CI 1.9 to 
4.4, I2 44.5%). Four studies examined the association between arterial base excess 
and neonatal morbidity, which was similar to venous pH (OR 2.6, 95% CI 1.4 to 4.9, 
I2 0%). Due to the small number of studies reporting this variable, it was not possible 
to combine the cord pH and base excess to compare the difference between 
respiratory and metabolic acidosis. 
Association between umbilical cord pH at birth and cerebral palsy 
Seven studies examined the association between umbilical artery pH and cerebral 
palsy, including 1117 individuals. Of those, two had an OR point estimate <1.0, but 
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the rest showed an association of low pH with cerebral palsy (Figure 5.4).  The 
criteria used to diagnose cerebral palsy were given in only two studies. The overall 
association was OR 2.3 (95%CI 1.3 to 4.2, I2 0%). It was not possible to explore the 
threshold effect by subgroup analysis due to the small number of studies reporting 
this outcome. 
Predictive ability of umbilical cord pH at birth for neonatal morbidity and 
mortality 
As reported in Table 5.3, at the lowest threshold of umbilical arterial pH reported (pH 
<7.00), specificity was high for neonatal mortality and morbidity (1.0, 95% CI 0.99 to 
1.0 and 0.92, 95% CI 0.91 to 0.93 respectively) but sensitivity low, indicating that 
neonates with a positive test (i.e. a low cord pH) are at high risk of adverse outcome, 
but that a negative test does not change the odds of a poor outcome significantly. 
Increasing the threshold to 7.20 reduced the specificity and slightly increased the 
sensitivity, but not to a level where it would be considered a good discriminator for 
‘test negative’ infants. 
5.4.4 Publication Bias 
Within the group of studies considering the association between arterial pH and 
neonatal mortality (n=15), Peters test was not significant (p=0.318). For neonatal 
morbidity (n=31), the result was also not significant (p=0.847) indicating no small 
study effects. 
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Figure 5.1: Study selection process for systematic review of umbilical cord pH  
or base excess and neonatal and long term morbidity and mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total studies identified from electronic searches  
(Database inception to August 2008)  n=5690 
Potentially relevant articles obtained in full manuscripts n= 443 
Identified from electronic searches n= 375                                                                                                                                    
Identified from manual reference list checking n= 69 
 Articles excluded from review with reasons: 
Not umbilical cord pH                                        n= 146  
Inappropriate outcome measure                           n= 79        
Lack of original data (review articles/letters)       n = 60                             
Duplicate publications                                   n= 6                                                                     
Incorrect population     n=1                                                                        
Data not extractable                                             n= 82                                                                                                                                   
Case series ≤ 5                                                       n= 16                                                                                      
Papers unavailable                                                     n=3    
Total excluded                                                     n= 393                                                                                                                                                
Total primary articles included evaluating arterial cord pH                     n=46  (479022 patients) 
 Outcome measure                                              No. of studies     No. of patients 
Neonatal mortality*       15           469365 
Composite neonatal morbidity*     30  10904 
 Hypoxic ischaemic encephalopathy*    7  827 
 Seizures*       9  5191 
 Intraventricular haemorrhage/periventricular leukomalacia* 12  284 
Cerebral palsy*        7  1117 
Comprehension and reading ability     1  116 
Intelligence        2  41 
Speech/language       3  423 
Global development        3  359 
Movement disorder       1  44 
*pooled in meta-analyses 
 
Citations excluded n= 5315 
Selected for inclusion in systematic review        n= 51       (481753 patients) 
Test                                                                                                     No. of studies        No. of patients 
Arterial cord pH                  46              479022 
Venous cord pH         6  2531 
Arterial base excess       4  549 
Venous base excess       1  25 
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Figure 5.2 Forest plot of odds ratios for the association of umbilical arterial cord pH with neonatal mortality. Single studies 
are represented by a filled circle, and pooled studies (and 95% confidence intervals) by a diamond 
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Figure 5.3 Forest plot of odds ratios for the association of umbilical arterial 
cord pH with neonatal morbidity. Single studies are represented by a filled 
circle, and pooled studies (and 95% confidence intervals) by a diamond 
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Figure 5.4 Forest plot of odds ratios for the association of umbilical arterial cord pH with cerebral palsy. Single studies are 
represented by a filled circle, and pooled studies (and 95% confidence intervals) by a diamond 
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Table 5.1 Methodological quality of studies included in systematic review of 
umbilical cord pH and neonatal and long term outcomes 
 
 
 
 Number (%) of studies n= 51 
Quality Item Yes No Unclear 
Cohort study design 42 (82) 9 (18) 0 
Population adequately described 40 (78) 2 (4) 9 (18) 
Consecutive recruitment 2 (4) 1 (2) 48 (94) 
Prospective recruitment 15 (29) 29 (57) 7 (14) 
Appropriate outcome measure 51 (100) 0 0 
Outcome measure blinded 7 (14) 0  44 (86) 
>90% of individuals had outcome measure 41 (80) 10(20) 0 
Index test and outcome measure described 8 (16) 12 (24) 31 (61) 
Intervention between index test and outcome 0 0 51 (100) 
Quality Classification    
High 23 (45) - - 
Medium 20 (39) - - 
Low 8  (16) - - 
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Table 5.2 Exploration of heterogeneity in the estimation of association of low arterial cord pH with neonatal mortality and 
morbidity 
 
Multivariable analysis including quality grade, study design, and population risk as explanatory variables. See sections 4.6.3 and 
5.3.4 for details. 
Univariable analysis using dummy variables to set the reference category as medium/low quality, case- control design and 
unselected/ low risk population. 
 Univariable analysis Multivariable analysis 
Factor Odds ratio (95% CI) p value Odds ratio (95% CI) p value 
Outcome: Neonatal mortality     
Study design: cohort v. case control 0.4 (0.03-6.5) 0.52 0.8 (0.1-13.1) 0.87 
Study quality: high v. medium or low quality 0.8 (0.3-2.4) 0.63 0.7 (0.3-2.1) 0.52 
Population: high risk v. unselected 0.3 (0.1-1.0) 0.048 0.3 (0.1-1.1) 0.06 
 
Outcome: Composite neonatal morbidity     
Study design: cohort v. case control 1.1 (0.2-5.3) 0.90 1.0 (0.3-3.2) 0.98 
Study quality: high v. medium or low quality 1.4 (0.5-3.7) 0.51 1.6 (0.6-3.8) 0.32 
Population: high risk v. unselected or low 
risk 
0.4 (0.2-0.9) 0.03 0.4 (0.2-0.9) 0.02 
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Table 5.3 The effect of the use of varying thresholds of umbilical artery pH on the association and predictive ability of 
arterial cord pH for neonatal morbidity and mortality 
 
Outcome measure Number of Studies Umbilical cord pH 
threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Odds Ratio 
(95% CI) 
Neonatal mortality 4 7.00 0.13 (0.09-0.18) 1.0 (0.99-1.0) 6.1 (0.89-41.61) 
 6 7.10 0.19 (0.15-0.23) 0.98 (0.98-0.98) 7.09 (3.3-15.26) 
 5 7.20 0.39 (0.33-0.45) 0.85 (0.85-0.85) 4.31 (2.15-8.67) 
Neonatal 
morbidity 
15 7.00 0.51 (0.43-0.59) 0.92 (0.91-0.93) 12.47 (6.08-25.59) 
 10 7.10 0.24 (0.20-0.29) 0.92 (0.91-0.92) 2.38 (1.22-4.65) 
 6 7.20 0.55 (0.48-0.63) 0.62 (0.60-0.64) 2.41 (1.42-4.08) 
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5.5 Discussion 
Low arterial cord pH had a strong, consistent and temporal association with neonatal 
mortality and morbidity (composite of hypoxic ischemic encephalopathy, seizures and 
intraventricular hemorrhage / periventricular leukomalacia) and long term outcome 
(cerebral palsy). In all of the associations between arterial pH and outcome explored, 
with the exception of composite morbidity in a low risk population and seizures, the 
estimated prediction interval suggested that a future study would have the same 
direction and significance of effect observed. The associations observed are 
biologically plausible.76, 117-119 
Strengths and limitations of this review 
The strength of this review and the validity of the inferences lie in the methodology 
used. It complies with existing guidelines for the reporting of systematic reviews of 
diagnostic  and observational studies evaluating causal association.78;116 The most up 
to date techniques for performing and interpreting meta-analysis were used.84;85 An 
extensive literature search was performed in relevant databases with no language 
restrictions applied. The pooled studies had heterogeneity in terms of quality, 
population risk, threshold of umbilical cord pH used, and ascertainment of neonatal 
outcome. Recommended analyses were performed to address this issue, including 
bivariate and subgroup meta-analysis to take into account the threshold effect,102 
meta-regression analysis to explore for reasons for heterogeneity,120 and component 
outcome analysis to examine the suitability of the composite morbidity outcome. This 
did not significantly affect the results. The observed associations were qualitatively in 
the same direction and statistical heterogeneity, where present, arose from variation 
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in strength of associations from study to study rather than opposition in direction of 
association. The inferences concerning a causal association between low arterial 
cord pH at birth and neonatal death and a variety of neonatal morbidities therefore 
merit consideration. 
There are several limitations to this review. The quality of the primary studies was 
variable. Meta-regression and subgroup analysis were employed to explore for the 
effect of this issue, which demonstrated that limiting to high quality studies did not 
affect the results. The poor reporting of population characteristics limited the 
subgroup analysis according to risk factors: a large number of the papers with an 
‘unselected’ population did not fully report characteristics such as birth weight or 
gestational age, which means that it is difficult to extrapolate the findings to the 
general obstetric population. Only one paper included in the meta-analysis specified 
that it was limited to a low-risk term population. With regard to the index test 
examined, only a small number of papers reported base excess, which meant that no 
comparison of metabolic and respiratory acidosis was possible. The results 
demonstrated that a high base excess is associated with neonatal morbidity, but in 
clinical practice the pH and base excess level would be considered together in any 
individual, and this could not be commented upon. Additionally, the analysis could 
only be based on the thresholds reported in the primary studies, which limited 
exploration of the effect of varying pH levels. Some of these issues may be dealt with 
using individual patient data meta-analysis.121 
Venous cord pH and arterial base excess showed weaker associations with neonatal 
morbidity than that of arterial cord pH, with estimated predictive intervals that crossed 
the line of no effect. This analysis was however based on a small number of studies 
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and no other subgroup analysis could be performed, therefore a direct comparison 
with arterial cord pH was not possible. It seems likely from the results that arterial pH 
shows a stronger association with outcome. 
Evidence to support the causality of association of a low umbilical artery pH 
with adverse outcomes 
Hypoxia-ischemia initiates energy depletion, accumulation of extracellular glutamate 
and activation of receptors, leading to a deleterious cascade of events resulting in 
neuronal death.11 However, different areas of the brain are susceptible to injury at 
different stages in development and the consequences of injury are unpredictable.16 
This would support the findings of a strong association with hypoxic ischemic 
encephalopathy but a weaker association with cerebral palsy. Only 10% of infants 
with evidence of hypoxic ischemic encephalopathy develop cerebral palsy and the 
reasons for this are not yet fully understood.122 This issue is further highlighted by the 
findings of the term breech trial, where long term follow up did not reveal any 
difference in neurodevelopmental delay, despite an apparent increase in neonatal 
morbidity in the vaginal breech group.123 
It is difficult to comment on the specificity with which umbilical cord pH is associated 
with the outcomes examined within the review. All of the outcomes examined may 
arise from a variety of causes, for example neonatal seizures may be caused by 
congenital brain anomaly, infection and metabolic disorders in addition to hypoxia. 
Although some of the included studies excluded cases of congenital anomaly, others 
did not specify that they had excluded individuals with an adverse outcome related to 
another cause from their analysis. The strength of association of a low arterial cord 
 60 
 
pH with neonatal mortality and morbidity was stronger in the unselected than high 
risk group. This may be explained by the fact that individuals in the high risk group 
are more likely to suffer an adverse outcome from a cause other than asphyxia (e.g. 
prematurity, low birth weight), therefore although there is a proportionally higher 
number of deaths in the high risk group, there is a higher specificity for low arterial 
cord pH and death in the unselected population. Due to the fact that the primary 
studies did not report the cause of death within the study population, it is not possible 
to compare the odds ratios for death related to asphyxia, or subdivide the high risk 
population further. 
The strength of association and predictive ability was calculated for different pH 
thresholds, between arterial cord pH and neonatal mortality and morbidity. Although 
the meta-analysis did not show a clear dose- response relationship, and the 
estimated predictive intervals were broad, the association for both neonatal mortality 
and morbidity were weakest at the highest threshold. Only one study (Heller et al 
2003) explored the association of arterial pH and neonatal mortality at all three 
thresholds examined. Within this study, a clear dose- response relationship with the 
strongest association at a threshold of 7.00 and the weakest association at 7.20 was 
apparent. The within study comparison may be more valid as it avoids confounding 
by other study level factors which may affect between-study comparisons.  
Implications for clinical practice 
Umbilical cord pH is currently performed in infants believed to be at high risk for 
neonatal asphyxia. However, the results suggest that the strength of association with 
cord pH and outcome is not limited to this population group. Therefore future 
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research should assess the use of cord pH across neonatal populations, particularly 
exploring the cost effectiveness of performing the test on all neonates. 
Based on the review findings, increased initial surveillance of neonates born with a 
low arterial pH, regardless of their clinical condition, is warranted as the odds of 
complications have been shown to be higher in this group. The avoidance of a low 
pH at birth should continue to be a target for day to day obstetric practice. The results 
justify the use of arterial cord pH as an important outcome measure alongside 
neonatal morbidity and mortality in obstetric clinical trials. It is difficult to draw strong 
conclusions regarding the necessity of long term follow up for babies with low arterial 
cord pH, as the observed association with cerebral palsy was in a limited number of 
primary studies and the association, though statistically significant, was only 
moderately strong, and based on studies with varying quality.  
Recommendations 
Further research is required to clarify the optimum threshold and population in which 
umbilical cord pH should be performed to predict adverse outcome. A recent review 
highlighted the current deficits in prognosis research, and suggested that individual 
patient data (IPD) meta-analysis, where high quality primary studies exist, enables 
the prognostic value of a test to be assessed at an individual level.124 However, there 
were a lack of high quality primary studies within this field which would impair IPD 
analysis. A large prospective cohort study with long term follow up, accounting for 
potential confounding factors, is therefore required. Such a study must include 
evaluation of outcomes relevant to the individual and society, such as developmental 
impairment and use of health care and educational resources, before the use of cord 
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pH as a prognostic test and predictive test, and its cost effectiveness, may be 
clarified. This will enable further exploration of the threshold effect and the use of the 
combination of pH and base excess to predict outcome. Future smaller studies 
should adhere to the STARD reporting criteria to facilitate meta-analysis. 
5.6 Conclusion 
A low umbilical arterial pH at birth is significantly associated with neonatal mortality, 
morbidity and cerebral palsy. Test positive (low pH) babies are at a substantially 
increased risk of neonatal mortality and morbidity, especially at a pH of <7.00. 
However, babies who test negative do not have a decreased risk of a neonatal 
mortality or morbidity. Further research is required to define the population in which 
umbilical cord pH testing should be performed and the threshold which should be 
used in clinical practice.
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CHAPTER 6: SYSTEMATIC REVIEW AND 
META – ANALYSIS OF THE PROGNOSTIC 
AND PREDICTIVE ABILITY OF CURRENT 
BIRTH WEIGHT STANDARDS FOR SHORT 
AND LONG TERM OUTCOMES 
 
6.1 Abstract 
6.1.1 Background 
The purpose of this systematic review was to evaluate whether different birth weight 
standards are associated with subsequent outcome in infants born at term (≥ 37 
weeks gestation). 
6.1.2 Methods 
Systematic review of the literature, with random effects meta-analysis, to compute 
summary odds ratios (OR) to assess prognostic association, and summary 
sensitivity, specificity and likelihood ratios, to assess predictive ability.  
Electronic searches were performed from database inception until January 2011 
without language restrictions. The reference lists of selected articles were screened 
and authors contacted. Studies were selected by 2 reviewers if growth restriction at 
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birth, by any method and threshold, was related to neonatal or long term outcomes. 
The population was limited to infants born at term (≥ 37 weeks gestation) to avoid the 
confounding effects of prematurity. 
6.1.3 Results  
92 articles including 23051341 individuals were selected. Meta-analysis performed 
according to definition of growth restriction showed that absolute birth weight was 
strongly associated with neonatal mortality, with a birth weight <1.5kg giving the 
largest prognostic effect (summary OR 48.6, 95% CI 28.62 to 82.53) and increasing 
thresholds (2.0kg, 2.5kg, and 2.9kg) reducing this association but remaining high 
(2.5kg: summary OR 8.46, 95% CI 6.25 to 11.46). When using centile charts to 
define low birth weight, regardless of the threshold chosen, the summary ORs were 
also highly significant for neonatal mortality, but were closer to 1 than when using an 
absolute birth weight of 1.5kg or 2.0kg (<10th centile summary OR 4.11, 95% CI 3.70 
to 4.56). The association between birth weight standards and childhood and adult 
morbidity varied; there was no significant relationship between birth weight <2.5kg 
(summary OR 1.33, 95% CI 1.00 to 1.78) or population chart <10th centile (summary 
OR 1.17, 95% CI 0.93 to 1.48) with a composite measure of morbidity in either age 
group. For all tests, summary predictive ability was generally a high specificity and a 
high positive likelihood ratio for neonatal death, but a low sensitivity, and a negative 
likelihood ratio close to 1, indicating that being test positive substantially increases 
the risk of neonatal mortality, but being test negative does not reduce the risk.  
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6.1.4 Conclusion 
Absolute birth weight is a prognostic factor for neonatal mortality as it is strongly 
associated with this outcome, with the strongest associations at the lowest 
thresholds. Centile charts or other definitions of low birth weight at a variety of 
thresholds are also prognostic, but the indirect evidence suggests they are not as 
strongly associated as absolute birth weight. The association between low birth 
weight and childhood and adult morbidity was inconsistent. In terms of predictive 
ability at the individual-level, test positive babies are at substantially increased risk of 
neonatal mortality, but being test negative generally does not reduce the risk of death 
in the neonatal period. 
6.1.5 Publications arising from this work 
Malin GL, Morris RK, Riley RD, Teune M, Khan KS. Should we forget about centile 
charts? Comparing definitions of fetal growth restriction to predict adverse outcome. 
Archives of Disease in Childhood: Fetal and Neonatal Edition 2012; Suppl 1). A111. 
6.2 Introduction 
The ‘Fetal origins’ hypothesis suggests that malnourishment in utero changes fetal 
programming, whereby biological pathways are altered, resulting in increased 
susceptibility to disease. In 1986 Barker et al demonstrated an inverse relationship 
between birth weight and adult cardiovascular disease.39 Since then, numerous 
studies have evaluated the association between low birth weight and morbidity and 
mortality from the neonatal period through to late adulthood.36;37;42-48;125 However, the 
results have not always been consistent.38;49-51 
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A number of methods have been used to identify babies at risk of adverse outcome, 
including population based centile charts, the most commonly used threshold being 
the tenth centile;126 customised charts where the mother’s BMI and ethnicity are used 
to calculate individualised growth centiles;127 and ponderal index which takes into 
account the neonatal weight and length.128 The published associations between each 
standard for defining being small for gestational age and adverse outcome vary, and 
there is no current consensus regarding the best method.129 
The aim of this systematic review was to re-examine the association between low 
birth weight and adverse outcomes, avoiding the confounding influence of 
prematurity, and to determine which definition of small for gestational age has the 
strongest prognostic and predictive association with subsequent morbidity and 
mortality from the neonatal period through to adulthood.  
6.3 Methods 
The methods employed are those outlined in Chapter 4, with those specific to this 
review detailed below.  
6.3.1 Data sources and searches 
Electronic searches were performed with the aim of capturing neonates with any birth 
weight standard, used to define being small for gestational age, and adverse 
outcomes throughout the life course. Searches were performed by the author from 
database inception until January 2011. The search strategy employed in Medline is 
given in Appendix 10. This was adapted for use in other electronic databases.  
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6.3.2 Study selection 
Studies were selected if they examined the association between a measure of low 
birth weight and an adverse outcome in neonates born alive at ≥ 37 weeks gestation.  
6.3.3 Data extraction and quality assessment 
The data extraction tool employed in this review is given in Appendix 5. Any birth 
weight standard considered to be a measure of small for gestational age at any 
threshold was included (e.g. absolute birth weight 1.5, 2.0 and 2.5kg; population birth 
weight chart <10th centile).  For population, studies had to clearly state that the 
neonates included were born at term (≥ 37 weeks gestation). If this was unclear, or if 
a mixed population was reported, authors were contacted to ask for clarification or to 
provide data relating to term born infants only.  
All studies were assessed fully using the STARD and QUADAS checklists (Appendix 
2 and 3).90;91 The elements felt to be most relevant to systematic reviews assessing 
prognostic association and predictive ability, as described in Section 4.4, were used 
to assess the overall quality of the included studies. A study meeting four or more of 
the criteria was considered to be of high quality, three of moderate quality, and two or 
less of low quality.  
6.3.4 Data synthesis 
The 2 x 2 tables were used to compute odds ratios (OR) and 95 % confidence 
intervals (CI) for each index test-outcome pair, and the results pooled for each index 
test (considering each definition and threshold of growth as a separate test) using 
meta-analysis. 
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Summary OR data is presented in forest plots. Meta-analyses were performed where 
2 or more studies reported the same index test and outcome measure. The outcome 
measures were grouped according to neonatal (up to 28 days), infant (up to 1 year), 
child and adolescent (up to 18 years) and adult (over 18 years). The primary 
outcomes were considered to be neonatal neonatal mortality (up to 28 days), and a 
composite measure of morbidity in infancy (up to 12 months), childhood and 
adolescence (12 months to 18 years) and adulthood (>18 years). 
 When the composite outcome measure was used, attempts were made to select the 
most consistent threshold and outcome across the analysis, for example in the 
childhood morbidity analysis hypertension was the most commonly reported outcome 
therefore this was selected primarily, followed by other components of the metabolic 
syndrome.  
Within the largest meta-analyses, subgroup analysis was performed where possible 
to examine the effect of potential confounding factors. Singleton or multiple birth 
status, ethnicity, exclusion of congenital anomalies and birth of the study population 
during or after 1990 (due to recent advances in antenatal and neonatal care), and 
study quality were considered to be important factors which may influence the 
strength of the association between low birth weight and adverse outcome.  
For the purposes of the meta-analyses, data where birth weight had been 
dichotomised around a threshold specified in the primary studies was used. In order 
to compare the effect of birth weight as a continuous variable, all of the included 
studies where logistic regression analysis had been performed were examined and 
the findings qualitatively summarised. 
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6.4 Results 
6.4.1 Literature identification and study characteristics 
As shown in Figure 6.1, after an initial search of 36956 citations, 92 primary articles 
were included, 25 after contact with authors who provided data or information. 
23051341 individuals were included in the review in total. Some of the studies 
reported multiple birth weight parameters; these are counted in each relevant 
category but only once in the overall total. Characteristics of the included studies are 
given in Appendix 11, and the references of studies included in this review are 
presented in Appendix 12. 
A total of 145 further articles were felt to contain potentially relevant data, but either 
the authors could not be contacted, could not supply data to create 2 x 2 tables, or on 
clarification regarding the population the study was excluded. If a study included 
infants of less than 37 weeks gestation, it was only included if separate data 
regarding term infants was given or the authors provided this. A number of studies 
contained duplicate populations with each other: where there was duplication of the 
test and outcome measure the least complete study was excluded from the review. If 
the population was the same but the measure of birth weight or adverse outcome 
differed both studies were included, but care was taken not to count any individual 
twice within a single meta-analysis, or within the overall numbers. 
The majority of studies used population growth chart <10th percentile (n=34) or birth 
weight <2.5kg (n=31) as the index test. A wide variety of outcome measures 
including mortality and morbidity (e.g. hypertension, diabetes mellitus, learning 
difficulties, cerebral palsy) were reported.  
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6.4.2 Study quality assessment 
The results for the quality assessment are presented in Table 6.1. The majority of 
included studies were of cohort design (95%), most were retrospective studies (58%). 
Most studies were of high or moderate quality according to the pre-specified criteria. 
Studies often failed to adequately describe the test or outcome in a way that would 
make them reproducible, and very few studies described any interventions that were 
performed between the time of the birth weight measurement and the outcome test. 
Where possible a subgroup analysis using only high quality studies was performed 
and the results are presented in Table 6.2. No subgroup analysis for study quality 
was performed for population <10th centile and adult outcomes, as only one of the 
studies was considered to be of high quality.   
6.4.3 Data analysis 
Neonatal outcomes 
A forest plot of the summary meta-analysis odds ratios and 95% confidence intervals 
for each measure of being small for gestational age and neonatal mortality is given in 
Figure 6.2. Birth weight <1.5kg showed the strongest association with neonatal 
mortality (OR 48.6, 95% CI 28.62 to 82.53), with no between-study heterogeneity in 
this effect. Raising the birth weight threshold to 2.0kg, 2.5kg or 2.9kg gradually 
reduced the association and increased the heterogeneity, but the summary effect 
remained highly significant at each threshold. Population centile charts were also 
strongly associated with neonatal mortality, but generally showed a weaker 
association at all thresholds than absolute birth weight, because the summary ORs 
were closer to 1, especially compared to an absolute birth weight < 1.5kg or 
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2.0kg.The results for other measures, including ponderal index, birth weight < 2 
standard deviations below the population mean, and fetal growth ratio (defined in the 
primary study as the observed birth weight over the population mean) varied (Figure 
6.2). 
The association between measures of being small for gestational age and neonatal 
morbidity are given in Figure 6.3. The analysis was subdivided into reported 
neurological morbidity (including seizures, HIE, IVH) and non-neurological morbidity 
(including hypoglycaemia, respiratory distress syndrome, cardiac failure) according to 
the definitions given in the primary studies.  Birth weight <2.0kg was the most 
strongly associated with neurological morbidity, (OR 17.34, 95% CI 5.63 to 53.70) 
however this was based on a single study of 770 neonates. There was a significant 
association between weight below the 3rd, 5th and 10th centiles and neurological 
morbidity. Birth weight <10th centile according to customised growth chart and 
ponderal index ≤2.25 did not show a significant association with this outcome. For 
non-neurological morbidity, birth weight <3rd, 5th or 10th centiles on population chart 
and birth weight > 2 standard deviations (SD) below the population mean showed 
significant association with this outcome with odds ratios of a similar magnitude. 
Infant outcomes 
Figure 6.4 gives the association between measures of being small for gestational age 
and infant outcomes. Birth weight <1.5kg was strongly associated with infant 
morbidity on average (OR 21.57, 95% CI 6.31 to 73.70), however significant 
heterogeneity was present in the analysis. Birth weight <2.0kg and <2.5kg were also 
significantly associated with this outcome but the odds ratios were smaller. For 
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neurodevelopmental delay, birth weight <10th centile according to population chart 
was significantly associated with this outcome (OR 2.03, 95% CI 1.01 to 4.08) 
Childhood and adolescent outcomes 
A forest plot for the association of definitions of being small for gestational age with 
childhood and adolescent outcomes is given in Figure 6.5. Meta-analysis was 
performed to assess the association of birth weight <2.5kg with a composite group of 
adverse outcomes reported in primary studies (including obesity, hypertension, type 
1 diabetes mellitus, asthma, hypercholesterolaemia, learning difficulties and 
strabismus). There was no significant association present (OR 0.98, 95% CI 0.87 to 
1.10). A meta-analysis for birth weight <10th centile on population chart showed a 
small association that was just significant (OR 1.49, 95% CI 1.02 to 2.19) however 
there was significant heterogeneity present. When the analysis was restricted to 
learning difficulties or mental handicap, birth weight <3rd centile on population chart 
and <10th centile both showed a weak but significant association. There was no 
significant association between any birth weight standard and childhood obesity, 
hypertension, asthma, visual impairment or psychiatric diagnosis. 
Adult outcomes 
A forest plot of odds ratios for the association of measures of being small for 
gestational age and adult outcomes is given in Figure 6.6. A meta-analysis was 
performed for the association of birth weight <2.5 kg with a composite measure of 
adult morbidity (including obesity, hypertension, hypercholesterolaemia, type 2 
diabetes mellitus, coronary heart disease, and polycystic ovarian syndrome). There 
was no significant association between birth weight <2.5kg, or birth weight <10th 
 73 
 
centile on population chart, with this outcome. When individual morbidities were 
considered, birth weight <10th centile according to population chart was significantly 
associated with obesity according to a single study (OR 1.86, 95% CI 1.20 to 2.88). 
Birth weight <2.5kg showed a weak association with hypertension, diabetes mellitus 
or impaired glucose tolerance and cardiovascular mortality. Ponderal index (kg/m3) 
<24 was also weakly associated with mortality from cardiovascular disease. 
Childhood or adulthood end stage renal disease showed a significant association 
with birth weight <10th centile on population chart. 
Subgroup analyses 
The results for subgroup analyses within the meta-analysis groups for each age 
group and birth weight standard are presented in Table 6.2. Few studies reported 
ethnicity in enough detail to permit subgroup analysis. For neonatal death, none of 
the subgroup analyses affected the magnitude or significance of the association 
between population chart <10th centile and this outcome. Limiting to a singleton 
population slightly weakened the association between birth weight <1.5kg and 
neonatal death, but did not affect birth weight <2.5kg for the same outcome. For 
childhood morbidity, singleton population, Caucasian population or year of birth ≥ 
1990 did not significantly influence the results.  
Birth weight as a continuous variable 
There were seven papers that reported regression analysis using birth weight as a 
continuous outcome. These studies looked at adult hypertension (age 50 and 60 
years) and hypercholesterolaemia, childhood obesity and hypertension, composite 
childhood metabolic risk index. Only one found a significant association (Anderrson 
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et al 2000): logistic regression analysis to examine the association between birth 
weight and hypertension (defined as treatment for hypertension and /or systolic BP ≥ 
160mmHg and/or diastolic BP >95mmHg) found that at age 60, the OR was 0.96 
(95% CI 0.92 to 0.99, p= 0.028 for change in risk of hypertension per 100g birth 
weight). 
Direct comparison of absolute versus population centiles 
Only two studies directly compared absolute birth weight and centile on population 
chart in the same population.  For type 1 diabetes in childhood, birth weight <2.5kg 
had an OR of 0.68 (95% CI 0.22 to 2.12), and population chart <10th centile had an 
OR of 0.46 (95% CI 0.26 to 0.82) (Algert et al 2009). For neonatal mortality, birth 
weight <2.9kg had an OR of 2.64 (95% CI 1.45 to 4.82) and population chart <10th 
centile had an OR of 5.51 (95% CI 2.95 to 10.31) for the same outcome (Balcazar 
1990). 
Predictive ability of birth weight standards for neonatal death 
The outcome that had the strongest prognostic association overall with fetal growth 
restriction was neonatal death. For those birth weight tests with a large (OR>5) and 
statistically significant prognostic association for this outcome, their predictive ability 
for individual babies was summarised by using meta-analysis to calculate summary 
sensitivity, specificity and likelihood ratios (Table 6.3). These measures reveal the 
discriminative ability of each test and how test results modify a baby’s odds of having 
a neonatal death. For each test the specificities and positive likelihood ratios were 
high, but the sensitivity and negative likelihood ratios were generally poor (Table 6.3). 
This can be explained by the fact that although a higher proportion of deaths 
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occurred within the low birth weight group, because this group represents a small 
fraction of the overall population, a large absolute number of deaths still occurred 
within the normal weight groups, and therefore sensitivity is low and the ‘false 
negative’ numbers are high, giving a poor negative likelihood ratio (close to 1). For 
example, the highest positive likelihood ratio was for 1.5kg, indicating that any baby 
under this weight multiplied their pre-test odds of neonatal death by 49.1 (95% CI: 
27.3 to 88.5). However the negative likelihood ratio was only 1.01 (1.00 to 1.01), 
indicating that the odds of death barely change after a negative test result. Thus 
although being < 1.5kg substantially increases the odds of a poor outcome, being > 
1.5kg does not increase the odds of a good outcome.  
6.4.4 Publication bias for prognostic association 
The Peters test was performed on all groups where there were 10 or more studies 
included in the meta-analysis (population <10th centile and neonatal mortality, birth 
weight <2.5kg and population <10th centile and childhood morbidity). There was no 
significant evidence of small study effects in any of the groups analysed (funnel plots 
not shown) (p values ranged from 0.326 to 0.996). 
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Figure 6.1 Study selection process for systematic review of the prognostic and 
predictive ability of current birth weight standards for short and long term 
outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total studies identified from electronic searches  
(Database inception to January 2011)  n=36956 
Potentially relevant articles obtained in full manuscripts  
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Identified from electronic searches n= 1419                                                                                                                                  
Identified from manual reference list checking n= 187 
 
Articles excluded from review with reasons: 
Not a measure of low birth weight     n=  166 
Inappropriate outcome measure                   n=    37      
Lack of original data (review articles/letters)     n=  384                            
Gestational age unreported   n=  229 
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Figure 6.2 Forest plot of odds ratios for the association between birth weight standards and neonatal mortality.  
Single studies are represented by a filled box, and pooled studies (and 95% confidence intervals) by a filled diamond 
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Figure 6.3 Forest plot of odds ratios for the association between birth weight standards and neonatal morbidity. Single 
studies are represented by a filled box, and pooled studies (and 95% confidence intervals) by a filled diamond 
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Figure 6.4 Forest plot of odds ratios for the association between birth weight standards and infant outcomes. Single 
studies are represented by a filled box, and pooled studies (and 95% confidence intervals) by a filled diamond 
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Figure 6.5 Forest plot of odds ratios for the association between birth 
weight standards and childhood outcomes. Single studies are 
represented by a filled box, and pooled studies (and 95% confidence 
intervals) by a filled diamond 
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Population chart <5th centile 3.57 (0.36, 35.24)
Population chart <3rd percentile 1.15 (0.05, 28.79)
Birth weight <2.5kg 0.85 (0.21, 3.55)
Birth weight <2.0kg 2.56 (1.44, 4.57)
Motor disability (including cerebral palsy)
Birth weight(g)/head circumference(cm) 
<25th centile
1.27 (0.82, 1.99)
Ponderal index (kg/m3) <2.30 2.02 (1.63, 2.49)
Ponderal index (kg/m3)<25th percentile 0.76 (0.46, 1.25)
Population chart <15th percentile 1.39 (0.52, 3.70)
Population chart <10th percentile 2.03 (1.65, 2.50)
I2 29, Tau2 0.02,EPIa 1.29,3.21
Population chart <5th percentile 5.56 (0.13, 248.7)
I2 94, Tau2 7.04
Population chart <3rd centile 1.80 (1.31, 2.49)
I2 41, Tau2 0.03, EPIa 0.08,40.8
Learning difficulties or mental handicap
Population chart <10th centile 1.49 (1.02, 2.19)
I2 86, Tau2 0.26,EPIa 0.44,5.14
Birth weight <2.5kg 0.98 (0.87, 1.10)
I2 0, Tau2 0
Morbidity (composite measure )
Definition
No. of 
Individuals Year of birth Odds ratio (95% CI)
0.1 0.5 1 2 5 10 1000.01 0.2 1000
odds ratio (95% confidence interval)
No. of
Studies 
13 528539 1959-2005
11 1984-2005509676
3 1970-19847226
2 1970-19823158
6 1970-200429283
1 1986-1988625
1 1981-1984400
1 1959-196524371
1 1981-1984511
1 >19891555
1 1959-196529551
1 1960-1966132
1 1978-1982131
1 1986-1988141
1 1983-1990654
1 1983-1990654
1 1983-1990654
1 1975-1982613
1 1975-1982613
3 1982-19991336
1 810 1992-1997
1991-19923 4790
1982-19851 995
1996-19971 339
1959-19996 31318
1986-19881 110
1984-19862 159
1994-20001 4989
1 5770 1991-1992
1 131 1986-1988
1 140 1986-1988
Birth weight <2.5kg
2.16 (0.90, 5.21)
Death from neuroblastoma
1 303 1964-1978
a= estimated prediction 
interval
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Figure 6.6 Forest plot of odds ratios for the association between birth 
weight standards and adult outcomes Single studies are represented by a 
filled box, and pooled studies (and 95% confidence intervals) by a filled 
diamond
Population chart <10th centile 1.95 (1.46, 2.61)
End stage renal disease (childhood/adulthood)
Population chart <10th centile 1.12 (0.92, 1.37)
Birth weight <2.9kg 1.25 (0.76, 2.07)
Anxiety +/- Depression
Ponderal Index (kg/m3) <24 1.31 (1.06, 1.62)
Birth weight <2.5kg 1.53 (1.03, 2.29)
Cardiovascular mortality
Birth weight <2.5kg 1.20 (0.51, 2.85)
Diabetic retinopathy
Population chart <10th centile 3.02 (0.30, 30.98)
I2 =65, Tau2=2.05
Birth weight <2.5kg 1.93 (1.06, 3.53)
Type II diabetes mellitus
/ impaired glucose tolerance
Birth weight < mean -2SD 0.83 (0.25, 2.77)
Ponderal Index <24.5 1.20 (0.89, 1.63)
Birth weight <2.5kg 0.97 (0.58, 1.63)
I2 =50, Tau2=0.11, EPIa 0, 200
Hypercholesterolaemia
(Total cholesterol >5mmol/L)
Birth weight < mean -2SD 0.13 (0.01, 2.63)
Ponderal Index (kg/m3)<24.5 1.15 (0.74, 1.79)
Population chart <10th centile 1.44 (0.48, 4.35)
Birth weight <2.5kg 1.38 (1.14, 1.69)
I2 =0, Tau2=0
Birth weight <3.1kg 1.73 (1.08, 2.78)
Hypertension
Birth weight < mean -2SD 1.00 (0.19, 5.33)
Ponderal Index (kg/m3) <24.5 0.67 (0.32, 1.40)
Population chart <10th centile 1.98 (1.23, 3.20)
Birth weight <2.5kg 0.94 (0.76, 1.56)
I2 =0, Tau2=0
Obesity (BMI >30)
Population chart<10th centile 1.17 (0.93, 1.48)
I2=18, Tau2=0.01, EPIa 0.59,2.34
Birth weight <2.5kg 1.33 (1.00, 1.78)
I2 =58, Tau2=0.06,EPIa 0.61,2.94
Morbidity (composite measure)
0.01 0.10.2 0.5 1 2 5 10 100
odds ratio (95% confidence interval)
Definition
No. of 
Individuals Odds ratio (95% CI)
No. of
Studies 
Year of 
birth
6 80029 1921-1980
4 16638 1967-1985
3 12198 1948-1979
1 851 1971-1985
1 932 1948-1954
1 70 1984-1986
1 438 1918-1930
2 9451 1948-1958
1 113 1975-1976
1 932 1948-1954
1 70 1984-1986
3 4770 1948-1979
1 932 1948-1954
1 4770 1948-1979
1 931 1948-1954
2 1421 1971-1985
1 609 1923-1944
1 13830 1924-1944
1 13728 1924-1944
1 810 1920-1930
1 7415 >1967
1 1937768 >1967
a= estimated prediction 
interval
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Table 6.1 Methodological quality of studies included in systematic review 
of birth weight standards for short and long term outcomes 
 
 
 
 
 
 
 
 
 
 
 Number (%) of studies n= 92 
Quality Item Yes No Unclear 
Cohort study design 84 (91) 7 (8) 1 (1) 
Population adequately described 90 (98) 0 2 (2) 
Consecutive recruitment 42 (46) 12 (13) 38 (41) 
Prospective recruitment 33 (36) 53 (58) 6 (6) 
Appropriate outcome measure 92 (100) 0 0 
Outcome measure blinded 10 (11.0) 1 (1) 81 (88) 
>90% of individuals had outcome measure 42 (46) 41(44) 9 (10) 
Index test and outcome measure described 36 (39) 5 (5) 51 (56) 
Intervention between index test and outcome 5 (5) 0 87 (95) 
Quality Classification    
High 56 (61) - - 
Medium 27 (29) - - 
Low 9  (10) - - 
  
 
8
3 
Table 6.2 Subgroup analyses according to birth weight standard and outcome, where possible, for study quality, ethnicity, 
year of birth of study population and singleton population 
 
 Birth weight 
standard 
Number 
of 
studies 
Subgroup Odds ratio 
(95% CI) 
Estimated 
prediction 
interval (EPI) 
I2 
Tau2 
Neonatal death 
Birth weight 
<1.5kg 
3 High quality studies 53.29 (30.08 to 
94.39) 
- I2=0, Tau2=0 
Birth weight 
<1.5kg 
2 Singletons 41.85 (16.53 to 
105.94) 
- I2=0, Tau2=0 
Birth weight 
<2.5kg 
4 
 
Singletons 8.39 
(4.90 to 14.36) 
0.86 to 81.36 I2=81, Tau2=0.20 
Birth weight 
<2.5kg 
5 High quality studies 8.15 
(5.76 to 11.54) 
2.40 to 27.66  I2=80, Tau2=0.12 
Birth weight 
<2.5kg 
2 Year of birth ≥ 1990 9.74 (5.31 to 
17.86) 
- I2=91, Tau2=0.17 
Population chart 
<10th centile 
6 Singletons 4.03 (3.88 to 
4.18) 
- I2=0, Tau2=0 
Population chart 
<10th centile 
8 Year of birth ≥ 1990 4.23 (3.73 to 
4.81) 
3.23 to 5.55 I2=31, Tau2=0.01 
Population chart 
<10th centile 
4 Congenital anomalies 
excluded 
4.01 (3.86 to 
4.16) 
- I2=0, Tau2=0 
Population chart 
<10th centile 
6 Studies in USA/ Europe 4.04 
(3.89 to 4.19) 
- I2=0, Tau2=0 
Childhood morbidity 
Birth weight 
<2.5kg 
5 Singleton 0.95 
(0.63 to 1.44) 
- I2=0, Tau2=0 
Birth weight 
<2.5kg 
5 High quality studies  0.82 (0.63 to 
1.07) 
- I2=0, Tau2=0 
  
 
8
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Birth weight 
<2.5kg 
7 Ethnicity >90% Caucasian 0.99 (0.68 to 
1.44) 
- I2=0, Tau2=0 
Population chart 
<10th centile 
4 Singleton 1.35 (0.82 to 
2.24) 
0.15 to 12.24 I2=90, Tau2=0.20 
Population chart 
<10th centile 
8 High quality studies 1.65 (0.96 to 
2.83) 
0.31 to 8.86 I2=89, Tau2=0.40 
Population chart 
<10th centile 
2 Year of birth ≥ 1990 0.67 (0.35 to 
1.31) 
- I2=76, Tau2=0.19 
Population chart 
<10th centile 
2 Ethnicity Caucasian 3.70 
(0.75 to 18.28) 
- I2=91, Tau2=1.22 
Adult morbidity 
Birth weight 
<2.5kg 
4 Singleton 1.41 (0.80 to 
2.47)  
0.14, 13.82 I2=70, Tau2=0.20 
Birth weight 
<2.5kg 
2 High quality studies 1.39 (1.14 to 
1.69) 
- I2=0, Tau2=0 
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Table 6.3 Results for the predictive ability (sensitivity, specificity and 
likelihood ratios) of different birth weight standards for neonatal mortality 
Birth weight 
standard 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
likelihood 
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
Birth weight 
<1.5kg (4 
studies) 
0.008 (0.004 
to 0.146) 
0.99 (0.99 to 
1.00) 
49.1 (27.3 to 
88.5) 
1.01 (1.00 to 
1.01) 
Birth weight 
<2.0kg (3 
studies) 
0.05 (0.03 to 
0.07) 
0.99 (0.99 to 
1.00) 
13.3 (2.27 to 
78.28) 
0.94 (0.85 to 
1.02) 
Birth weight 
<2.5kg (8 
studies) 
0.31 (0.19 to 
0.47) 
0.94 (0.88 to 
0.97) 
5.27 (3.57 to 
7.76) 
1.37 (1.15 to 
1.62) 
Population 
chart <3rd 
centile (1 
study) 
0.24 (0.12 to 
0.41) 
0.96 (0.96 to 
0.96) 
6.31 (3.57 to 
11.14) 
0.79 (0.66 to 
0.94) 
Fetal growth 
ratio <0.80 (1 
study) 
0.67 (0.09 to 
0.99) 
0.94 (0.93 to 
0.95) 
11.9 (3.87 to 
32.52) 
0.36 (0.07 to 
1.75) 
Birth weight < 
mean -2SD (1 
study) 
0.13 (0.09 to 
0.19) 
0.99 (0.99 to 
0.99) 
10.53 (7.25 to 
15.28) 
0.88 (0.83 to 
0.92) 
 
6.5 Discussion 
Low birth weight showed a strong, consistent association with neonatal 
mortality. The relationship was highest at lower thresholds and gradually 
decreased (but remained strong) as the threshold increased. The absolute birth 
weight seemed to be more strongly related to this outcome than centiles on 
population weight charts, especially for thresholds of 1.5kg and 2.0kg. 
Restricting the analysis to singletons, year of birth since 1990, or by country of 
origin did not change the magnitude of the association. Other definitions of 
being small for gestational age were based on single studies and showed mixed 
results, but none appeared to be more strongly associated with neonatal 
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mortality than the absolute birth weight. A limitation, however, is that different 
numbers of studies contributed to each analysis, and there were few direct 
comparisons. Indeed, in the only study that compared absolute birth weight and 
centile chart in the same population, the association for birth weight below 10th 
centile was observed stronger than absolute birth weight <2.9kg for neonatal 
mortality. There was a lack of data in some analyses, e.g. customised centile 
charts and ponderal index in relation to adverse outcome, but as every effort 
was made to acquire both published and unpublished data nothing further could 
be done to address this. The results for neonatal morbidity were mixed, but no 
single definition of being small for gestational age appeared to be consistently 
more strongly associated with adverse outcomes than others. All of the birth 
weight and population chart thresholds assessed for predictive ability showed a 
high specificity and positive likelihood ratio for neonatal death, and thus babies 
who test positive are at a substantially higher risk of neonatal mortality. 
However, each test generally had a low sensitivity and negative likelihood ratio 
close to 1, and thus a negative test result does not improve the odds that a 
baby will not have a neonatal death.  
For outcomes in childhood, there was a significant association between birth 
weight <10th centile according to population chart and a composite measure of 
morbidity. However when this analysis was restricted to a singleton population, 
this became non-significant. There was no significant association between any 
measure of low birth weight and childhood obesity, hypertension or asthma. 
Learning difficulties and motor disability were significantly associated with some 
reported definitions of being small for gestational age, but the associations 
overall were weak and no one measure showed a significantly stronger 
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relationship, including customised growth chart centiles. For adult outcomes, 
there was no consistent association seen between birth weight standards and 
adult health, although individual studies showed a weak association between 
birth weight <2.5kg and hypertension, cardiovascular mortality and diabetes. 
The strength of this review lies in the methodology used. It complies with 
existing guidelines for the reporting of systematic reviews of diagnostic and 
observational studies78;84-88 and uses the most up to date techniques for 
performing and interpreting meta-analysis. 102;130;131 An extensive literature 
search was performed in relevant databases with no language restrictions 
applied. Every effort was made to obtain the most complete dataset possible 
through contact with authors and experts in the field. Peters test showed that 
there was no evidence of small study bias. 
There are several limitations to this review. Although every effort was made to 
control for potential confounding factors through subgroup analysis, due to the 
quality and reporting of the primary studies this was not always possible. The 
inclusion criteria were strictly limited to infants born at 37 weeks gestation or 
more, however the method of estimating gestation in the primary studies was 
often inaccurate. Very few studies used ultrasound measurement of crown-
rump length at 10-13 weeks gestation, which is the most accurate method;132 
the majority used the mother’s last menstrual period, some clinical examination 
of the newborn, which are less reliable and may have resulted in pre-term 
infants being included inadvertently.  
Another limitation is that gestation may still influence outcome within the 
population of infants born at 37 weeks gestation or greater. It is known that 
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outcomes for babies at 37 weeks are worse than at 39 weeks. It is likely that the 
absolute birth weight thresholds captured more infants who were close to 37 
weeks than the centiles did, and therefore this may account for the stronger 
association with adverse association seen in this group. The decision to restrict 
the review to infants born at term gestation meant that definitions for growth 
restriction at earlier gestations could not be assessed. This is clearly of 
importance due to the fact that if growth restriction is suspected antenatally 
these infants are often delivered prematurely, however it was felt that the 
potential for confounding in this group was also higher and that the objective 
should focus initially on tern born infants. Due to poor reporting in the primary 
studies, the potential to perform subgroup analysis according to ethnicity was 
limited. Although the results did not differ much when limited to a Caucasian 
population, it is known that Afro-Caribbean and Asian populations have smaller 
babies, and therefore it is likely that the same thresholds would not give the 
same results in all ethnic backgrounds.133 Social class was not analysed as a 
subgroup, however previous epidemiological studies that have accounted for 
this have found that association between birth weight and cardiovascular risk 
factors persisted across social groups, suggesting that known and unknown 
confounding variables do not affect this relationship.134  
Differences may exist between the birth weight standards that were combined 
within the analysis, particularly regarding the variety of different population 
charts used. It was not possible to compare different charts, however if each 
study used the appropriate chart for their population then this should not 
influence the results. Comparing different standards of birth weight through 
analyses using different populations may not give a true result. However, no 
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studies reported more than two standards in the same population, and only two 
studies compared absolute birth weight and population centile charts, limiting 
the ability to address this issue. 
There is a vast literature exploring the relationship between low birth weight and 
adverse outcomes, using different methodologies to do so. The aim of this 
review was to consider the association and prediction of different thresholds of 
birth weight or centile charts, and therefore studies were excluded where 2 x 2 
tables could not be obtained from the original paper or authors could not 
provide this. A complete assessment of the association of birth weight as a 
continuous variable with adverse health outcomes could not be made. In order 
to address this, a qualitative analysis of all the studies included in the review 
where regression analyses for the association of continuous birth weight with 
the health outcomes in question were reported. Only one study found a 
significant relationship between birth weight and adult blood pressure on 
regression analysis. Other systematic reviews performed in this field using birth 
weight as a continuous variable have shown mixed results. Owen et al 
examined the association between birth weight and blood cholesterol level, and 
found a weak association, however this analysis did not exclude pre-term 
infants. Huxley et al found an inverse association between birth weight and 
systolic blood pressure in children, adolescents, and adults, but again did not 
exclude pre-term infants from the analysis. Whincup et al found mixed results in 
the relationship between type II diabetes mellitus and birth weight. Nine out of 
31 studies included in their systematic review showed a significant inverse 
relationship between birth weight and this outcome, again prematurity was not 
excluded.  
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Arcangeli et al recently conducted a systematic review examining the influence 
of small for gestational age (birth weight <10th centile or <2.5kg) and fetal 
growth restriction (birth weight <10th centile plus abnormal antenatal umbilical 
Doppler or placentation) on neurodevelopmental outcome in term infants. They 
found that small for gestational age infants had significantly lower 
neurodevelopmental indices than normally grown controls, but did not have 
sufficient data for precise results in the fetal growth restriction group. They 
acknowledge that some of the infants classified as small for gestational age 
may have had abnormal Dopplers, that were not reported in the primary 
studies.135 This finding highlights the importance for improved reporting and 
individual patient data meta-analysis in this field.    
The original literature published in support of the Barker hypothesis has been 
criticised for failing to control for potential confounding factors within their 
analysis.52 Every effort was made to consider these within this analysis, and the 
findings with regard to childhood and adult health outcomes linked with the 
metabolic syndrome have been inconsistent. Where a composite outcome was 
used, no significant association for childhood or adult morbidity was seen. No 
significant association was present for childhood diabetes, hypertension or 
obesity. Weak associations were seen between birth weight and adult 
hypertension, diabetes and cardiovascular mortality, however meta-analysis 
was not possible for every outcome and therefore the results are based on the 
results of one or two studies.  
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Implications for clinical practice 
Meta-analysis confirms that birth weight has a strong prognostic association 
with neonatal mortality, with low birth weight substantially increasing the risk of 
a poor outcome. However, although specificity and positive likelihood ratios 
were excellent, sensitivity was usually less than 0.5 and negative likelihood 
ratios were close to 1. This means that, compared to the pre-test risk of 
neonatal death (prevalence), babies with a low birth weight (test positive) are at 
a substantially increased risk, but the risk for those with a normal birth weight 
(test negative) does not change.  
For example using the results for a threshold of 1.5kg (Table 6.3), for a 
population with a prevalence (risk) of neonatal death of 0.003 (3 in 1000), then 
following a positive test result a baby’s risk of neonatal death becomes 0.13 
(130 in 1000), but following a negative test result the risk remains at 0.003. The 
same pattern was seen for the other birth weight standards, and therefore being 
test negative does not reduce the odds of a poor outcome. None of the other 
health outcomes in the neonatal period or later life showed a strong enough 
prognostic association with measures of fetal growth restriction to warrant 
calculation of sensitivity, specificity and likelihood ratios. 
Recommendations 
Future research is necessary to identify a birth weight standard which can 
predict adverse health outcomes. Initially, it is important to compare the different 
standards across the same population to enable an unbiased comparison, and 
to further explore the standards which were less frequently reported and 
therefore could not be included in meta-analysis within this review, such as 
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ponderal index and customised centile charts.  This could be performed through 
an individual patient data meta-analysis, where multiple definitions of fetal 
growth restriction could be compared across the same population, and factors 
such as ethnicity more adequately assessed.121 An alternative option would be 
to perform further analysis on the large Scandinavian birth registries, which 
record a variety of birth anthropometry that can be linked to health outcomes.136  
Finally, it is likely that more accurate predictions could be made using birth 
weight as a continuous variable, rather than dichotomising it using a threshold 
as is currently the general practice.137 Using the raw birth weight, and potentially 
considering non-linear associations between weight and outcome risk, would 
allow outcome risk to be estimated for each individual accordingly to their 
specific weight value. This would increase the power and is likely to improve 
predictive accuracy. At the meta-analysis level, individual patient data are 
required to undertake such an analysis approach, which was beyond the scope 
of our review. 138 Even when analysed on its continuous scale, birth weight on 
its own may not have sufficiently accurate  predictive ability, and so then birth 
weight in combination with other factors should be explored to predict adverse 
outcome in clinical practice. This could be achieved using a prognostic 
model.139 
6.6 Conclusion 
Birth weight tests are strongly associated with neonatal mortality and morbidity, 
especially at lower absolute birth weight thresholds, and test positive babies 
(small for gestational age) are at a substantially increased risk of neonatal 
mortality. However, babies who test negative do not have a decreased risk of a 
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neonatal mortality. The association between low birth weight and childhood and 
adult morbidity was inconsistent.  Further research is required to identify the 
optimum definition of being small for gestational age that helps best predict the 
risk of adverse outcomes, and this may require using birth weight as a 
continuous variable, developing prognostic models also containing other 
factors, and using individual patient data meta-analysis. 
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CHAPTER 7: SYSTEMATIC REVIEW AND 
META – ANALYSIS OF THE PROGNOSTIC 
AND PREDICTIVE ABILITY OF APGAR 
SCORE AT BIRTH FOR SHORT AND LONG 
TERM OUTCOMES 
7.1 Abstract 
7.1.1 Background 
The purpose of this systematic review was to evaluate the relationship between 
Apgar score and subsequent adverse outcome and to explore the predictive ability of 
this test, including the optimal threshold to define a low score.  
7.1.2 Methods 
Systematic review of the literature, with random effects meta-analysis, to compute 
summary odds ratios (OR) to assess prognostic association, and summary 
sensitivity, specificity and likelihood ratios, to assess predictive ability.  
Electronic searches were performed from database inception until June 2011 without 
language restrictions. The reference lists of selected articles were screened and 
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authors contacted. Studies were selected by 2 reviewers if a low Apgar score, by any 
threshold, was related to neonatal or long term outcomes.  
7.1.3 Results  
87 manuscripts were selected for final inclusion, with a total of 3690080 neonates. 
Meta-analysis performed according to threshold of Apgar score, showed that a low 
Apgar score was strongly associated with neonatal mortality, particularly in a 
population born at term (≥ 37 weeks gestation) or with normal birth weight (≥ 2.5kg) 
The largest associations in this population were seen with a 5 minute Apgar score ≤ 1 
(single study, OR 2209.16, 95% CI 425.88 to 11000) and a 10 minute Apgar score ≤ 
3 (single study, OR 1417.75, 95% CI 915.99 to 2194.36). Raising the Apgar score at 
a particular time reduced the strength of association, which for the 1 minute Apgar 
score became non-significant at a threshold of ≤9.  In a pre-term population, the 
magnitude of the association with neonatal mortality was smaller, with the strongest 
association being at a 10 minute score ≤ 3 (single study, OR 66.49, 95% CI 45.00 to 
98.22). For neonatal morbidity, significant association was seen at a number of 
thresholds across all of the populations examined, but the magnitude of the 
association was smaller and the prediction intervals crossed 1. In a term population, 
there was a significant association between a low Apgar score and cerebral palsy at 
all thresholds examined, with the largest association seen at a 5 minute Apgar score 
≤ 3 (3 studies, OR 46.35, 95% CI 11.21 to 191.59).  When the predictive ability of the 
Apgar score was considered, the specificity and positive likelihood ratios were 
generally large at low scores, however, the corresponding sensitivity and negative 
likelihood ratios were poor.  
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7.1.4 Conclusion 
A low Apgar score at birth is strongly associated with neonatal mortality, morbidity 
and childhood cerebral palsy, particularly in a population born at term, or with normal 
birth weight. Further research is required to identify the subgroups in which Apgar 
score may best predict adverse outcome. This may be done through individual 
patient data meta-analysis.  Prognostic models also containing other factors may 
optimise the prediction of adverse outcome on an individual level. 
7.2 Introduction 
Virginia Apgar score initially introduced her score in 1953 with the aim of focusing 
attention on the newborn infant and to identify those in need of resuscitation.62 It is 
described in Table 2.3. The score is usually recorded at 1, 5 and 10 minutes 
following delivery.61The total score may be reduced by any factor that causes 
compromise to the neonate, and the validity of using the results to predict adverse 
outcomes has been questioned.81 Conventional thresholds defined on the basis of 
the original cohort used to define the Apgar score, and subsequent biochemical 
studies, grouped a score of 0 to 3 at 1 minute as ‘poor’, 4 to 6 ‘fair’ and 7 to 10 as 
‘good’.140 This classification was ascribed 50 years ago, since which time there have 
been significant changes in neonatal care and a large body of work examining the 
relationship between a low Apgar score and adverse outcome. However, there 
remains a lack of consensus regarding the threshold that defines a ‘low’ score, and 
the timing of measurement to which the greatest importance can be attached.82 The 
American Academy of Pediatrics recommends that it is inappropriate to use a low 
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Apgar score alone to diagnose asphyxia, or predict neurological adverse outcomes in 
the neonate.61 
The aim of this review was to examine the association between a low Apgar score 
and adverse outcomes, considering subgroups according to gestational age, and to 
assess the predictive ability and optimum threshold of Apgar score for adverse 
outcome. 
7.3 Methods 
The methods employed are those outlined in Chapter 4, with those specific to this 
review detailed below.  
7.3.1 Data sources and searches 
Electronic searches were performed with the aim of capturing neonates with Apgar 
score recorded at birth (at either 1, 5 or 10 minutes of age). Searches were 
performed by the author from database inception until June 2011. The search 
strategy employed in Medline is given in Appendix 13. This was adapted for use in 
other electronic databases.  
7.3.2 Study selection 
Studies were selected if they examined the association between Apgar score at birth 
weight and an adverse outcome in live born neonates.  
7.3.3 Data extraction and quality assessment 
The data extraction tool employed in this review is given in Appendix 6. A low Apgar 
score recorded at 1, 5 and 10 minutes, defined by any threshold was included (e.g.5 
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minute Apgar score ≤ 6). Where multiple thresholds or outcome measures were 
reported, 2 x 2 tables were created for each individual threshold and outcome. Care 
was taken not to include each individual more than once in any given meta- analysis. 
Where possible, if a study reported data for pre-term (born at <37 weeks gestation) 
or low birth weight (< 2.5kg) infants separately to that of term born infants, a 2 x 2 
table was created for each subgroup to enable further analysis. Data were extracted 
by the author, and partly in duplicate by a second reviewer (see acknowledgements). 
All studies were assessed fully using the STARD and QUADAS checklists90;91 
(Appendix 2 and 3). The elements felt to be most relevant to systematic reviews 
assessing prognostic association and predictive ability, as described in section 4.4, 
were used to assess the overall quality of the included studies. A study meeting four 
or more of the criteria was considered to be of high quality, three moderate quality, 
and 2 or less of low quality.  
7.3.4 Data synthesis 
The 2 x 2 tables were used to compute odds ratios (OR) and 95 % confidence 
intervals (CI) for each index test-outcome pair, and pooled the results for each index 
test (considering each definition and threshold of growth as a separate test) using 
meta-analysis. 
Summary OR data is presented in forest plots. Meta-analyses were performed where 
2 or more studies reported the same index test and outcome measure. The primary 
outcomes were considered to be neonatal mortality and a composite measure of 
morbidity (up to 28 days), infant mortality (up to 1 year), cerebral palsy and a 
composite measure of other childhood morbidity. For each outcome group, separate 
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analysis was performed for a preterm (<37 weeks gestation) or low birth weight 
(<2.5kg) population; term born (≥ 37 weeks gestation) or normal birth weight (≥ 
2.5kg) neonates; and an unrestricted population in terms of gestational age or birth 
weight. Predictive ability was assessed by calculating specificity, sensitivity and 
likelihood ratios, for the outcomes of neonatal mortality and cerebral palsy (i.e. non-
composite measures) where the OR was greater than 5. 
 When a composite outcome measure was used, attempts were made to select the 
most consistent threshold and outcome across the analysis: for a 1 minute Apgar 
score ≤ 3 and neonatal morbidity in a pre-term population, IVH and other cerebral 
abnormalities were the most commonly reported outcomes therefore were selected 
preferentially to non-neurological morbidity. Subgroup analysis according to 
individual conditions within the morbidity groups was also performed where possible. 
Within the largest meta-analyses subgroup analysis was performed to examine the 
effect of potential confounding factors. Study quality, exclusion of congenital 
anomalies, birth of the study population during or after 1990 (due to recent advances 
in antenatal and neonatal care), and location of study (USA, Europe, Australia and 
New Zealand versus elsewhere) were considered to be important factors which may 
influence the strength of the association between Apgar score and adverse outcome.  
7.4 Results 
7.4.1 Literature identification and study characteristics 
As described in Figure 7.1, after an initial review of 4692 citations derived from 
electronic searches, 275 studies were selected for full review, with a further 73 
identified from manual reference checking of included studies and review articles, or 
 100 
 
hand searching of major journals. 87 manuscripts were selected for final inclusion, 
with a total of 3690080 neonates. Four of these studies were included following 
provision of further data from the authors.  
The characteristics of the included studies are given in Appendix 14. The reference 
list of included studies is given in Appendix 15. A number of studies contained 
duplicate populations with each other. If there was no difference in the population, 
index test threshold or outcome measure then the least complete study was 
excluded, but where different index test thresholds, subgroups or outcome measures 
were reported care was taken to include each individual only once in any meta-
analysis and in the overall numbers included in the review. The majority of studies 
reported the 1 and/or 5 minute Apgar scores and the most commonly used 
thresholds to define a low Apgar score were ≤ 3 and ≤ 6. For neonatal mortality, data 
were available for all thresholds of the 1 minute Apgar score in all three populations, 
and for the 5 minute Apgar score in a term population. The thresholds reported for 
other outcomes varied. 
7.4.2 Study quality assessment 
The results for the quality assessment of included studies are given in Table 7.1. The 
majority of studies were of cohort design (80%). 56% of included studies were 
classified as being high quality according to the pre-specified criteria given in section 
4.4. Most studies described the population adequately, and all had an appropriate 
outcome measure. However, descriptions of the index test and outcome measures 
were poor, with only 10% of included studies reporting these in a reproducible 
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fashion. This particularly applied to the Apgar score, with very few studies describing 
the personnel or technique employed.  
Where possible, subgroup analysis was performed using high quality studies only, 
and the results are presented in Table 7.2.  
7.4.3 Data analysis 
Prognostic association between a low Apgar score and neonatal mortality 
A forest plot of the prognostic association of the 1, 5 and 10 minute Apgar score, at a 
variety of thresholds, for an unrestricted population, is given in Figure 7.2. There was 
a significant association between a low Apgar score and mortality at all thresholds 
examined, with the strongest being a 10 minute Apgar score ≤ 3 (OR 616.72, 95% CI 
461.52 to 824.10). This was based on a single study.  A 10 minute Apgar score ≤ 6 
(single study, OR 392.08, 95% CI 304.70 to 504.52) and a 5 minute score of ≤ 3 (4 
studies, OR 290.88, 95% CI 183.91 to 460.07) also showed a very strong association 
with neonatal mortality in this population. In general, the higher the 1 minute Apgar 
score the weaker the association with neonatal mortality, and a low 5 and 10 minute 
Apgar score were more strongly associated with mortality than a low 1 minute score. 
The data for most thresholds at 1 minute were based on a single study (Apgar and 
James 1962). At thresholds where meta-analysis was possible there was significant 
heterogeneity present. 
As reported in Figure 7.3, when limited to a population defined as either born at term 
(≥ 37 weeks) or with a birth weight ≥ 2.5 kg, the association was again significant at 
all thresholds, and appeared stronger than in an unrestricted population. The largest 
associations were seen with a 5 minute Apgar score ≤ 1 (single study, OR 2209.16, 
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95% CI 425.88 to 11000) and a 10 minute Apgar score ≤ 3 (single study, OR 
1417.75, 95% CI 915.99 to 2194.36). Again there was significant heterogeneity 
present in the majority of meta-analysis groups. 
When the population was limited to infants either born pre-term (< 37 weeks 
gestation) or low birth weight (<2.5kg), a low Apgar score by any threshold was still 
significantly associated with neonatal mortality (Figure 7.4), and the association was 
strong at most thresholds. However, the odds ratios were smaller than in the term/ 
normal birth weight population. 
Prognostic association between a low Apgar score and neonatal morbidity 
The association of the Apgar score with a composite measure of neonatal morbidity 
is presented in Figure 7.5. In an unrestricted population, there was a significant 
association between a low Apgar score by any threshold and neonatal morbidity. The 
strongest association was seen at a 5 minute Apgar score of ≤ 4 (single study, OR 
25.26, 95% CI 10.14 to 62.91). At the thresholds where meta-analysis was possible, 
the strength of association was similar: 1 minute ≤ 3 had OR 3.32 (95% CI 1.80 to 
6.17), 1 minute ≤ 6 OR 2.44 (95% CI 1.37 to 4.33) and 5 minute ≤ 6 OR 3.08 (95% CI 
1.55 to 6.12). However, in all of these the EPI had a lower threshold below 1, giving 
uncertainty whether the association would be significant if tested in a new study.  
When limited to a term/ normal birth weight population (Figure 7.5), the association 
between a low Apgar score and neonatal morbidity was again significant at all 
thresholds, with the strongest association at a 10 minute Apgar score ≤ 4, however 
this was based on a single study and the confidence interval was very large (OR 
64.22, 95% CI 3.98 to 1037.39). It was only possible to calculate a prediction interval 
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for a 1 minute Apgar score ≤ 3 and neonatal morbidity in this population, and this had 
a lower threshold below 1 and was very broad (OR 11.83, 95% CI 3.36 to 41.65, EPI 
0.06 to 2409). 
For the pre-term/ low birth weight population, a low 10 minute Apgar score was not 
significantly associated with neonatal morbidity.  A 1 minute Apgar score ≤ 3 and 5 
minute Apgar score ≤6 both showed a significant association with morbidity through 
meta-analysis. It was only possible to calculate a prediction interval for 1 minute 
Apgar score ≤ 3 in this population and this had a lower threshold below 1 (5 studies, 
OR 2.36, 95% CI 1.32 to 4.22, EPI 0.31 to 17.73).  
Subgroup analysis was performed where possible to investigate the association of 
Apgar score with individual morbidities rather than the composite outcome. This was 
only possible in a the pre-term population, where the association of a low Apgar 
score, defined as ≤ 3 at 1 minute, and neonatal IVH was calculated. This showed a 
significant association (OR 3.22, 95% CI 2.50 to 4.14, I2= 12.4%, Tau2 = 0.01; EPI 
1.55 to 6.68) based on 4 studies.  
Prognostic association between a low Apgar score and infant mortality 
The association between a low Apgar score and infant mortality (defined as death up 
to 12 months of age) is given in Figure 7.6. The prognostic association for this 
outcome was significant at all thresholds of the Apgar score in both a pre-term/ low 
birth weight and term/ normal birth weight populations, with the largest association 
seen in the term population at a 5 minute Apgar score of ≤ 3 (OR 36.40, 95% CI 5.84 
to 226.80). However, there was significant heterogeneity present in all of the meta-
analyses possible, and the prediction intervals all crossed 1.  
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Prognostic association between a low Apgar score and cerebral palsy 
As presented in Figure 7.7, when an unrestricted population was considered, a low 
Apgar score by any threshold showed a significant prognostic association with 
childhood cerebral palsy. The largest association was seen at a 5 minute Apgar 
score ≤ 3 (2 studies, OR 39.31, 95% CI 8.64 to 178.75). A strong association was 
also present at a 5 minute Apgar score ≤ 6 (2 studies OR 17.38, 95% CI 5.01 to 
60.29), however these were the only thresholds where meta-analysis was performed 
and significant heterogeneity was present in both cases.  
When limited to studies reporting neonates born at term or with normal birth weight, 
the association was significant at all thresholds, with the strongest association again 
seen at a 5 minute Apgar score ≤ 3 (3 studies, OR 46.35, 95% CI 11.21 to 191.59).  
However, there was significant heterogeneity present in the analysis and the 
prediction interval was very large, indicating substantial uncertainty regarding the true 
magnitude of association. 
In the pre-term/ low birth weight population, the association between low Apgar score 
and cerebral palsy was significant at all thresholds of the 1 minute Apgar score, and 
was largest at a 5 minute Apgar score of ≤ 3 (3 studies, OR 8.18, 95% CI 4.83 to 
13.84). There was no significant heterogeneity within the analysis but the prediction 
interval crossed 1.  A 5 minute Apgar score ≤ 4 or 5, and a 10 minute Apgar score ≤ 
3 were not significantly associated with cerebral palsy, although these results were 
based on relatively small numbers of individuals. 
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Prognostic association between a low Apgar score and other childhood 
morbidity 
The association between a low Apgar score and childhood morbidity (other than 
cerebral palsy) is presented in Figure 7.8. In an unrestricted population, there was a 
small but significant association between a low 1 minute Apgar score and the 
composite measure of childhood morbidity (≤3 3 studies, OR 2.14, 95% CI 1.46 to 
3.15; ≤ 6 3 studies, OR 2.92, 95% CI 1.51 to 5.67). The prediction intervals crossed 1 
in both cases. At a threshold of ≤ 7, the association was non-significant. A 10 minute 
score ≤9 had the largest association with morbidity in this population, however this 
was based on a single study (OR 9.95, 95% CI 3.68 to 35.65). When limited to a 
term/ normal birth weight population, the association was significant at a 1 minute 
Apgar score ≤ 3, but this was based on a single study and meta-analysis of other 
thresholds of the 1 minute Apgar score were non- significant. A 5 minute Apgar score 
of ≤3 and ≤6 both showed a significant association of a similar magnitude (5 studies, 
OR 3.11, 95% CI 1.40 to 6.92 and 6 studies, OR 3.53, 95% CI 1.74 to 7.13 
respectively). However significant heterogeneity was present in both groups.  
For a preterm/ low birth weight population, the 1 minute Apgar score was not 
associated with morbidity at any threshold, but the 5 minute Apgar score showed a 
significant association at both thresholds examined (≤3 5 studies, OR 4.11, 95% CI 
1.25 to 13.54 and ≤ 6 4 studies, OR 2.01, 95% CI 1.03 to 3.91). Again, the prediction 
intervals crossed 1 in both cases. 
Subgroup analysis according to individual conditions was possible in three groups. 
For a pre-term population, where a 5 minute Apgar score ≤ 3 was considered, there 
 106 
 
was no significant prognostic association for neurologic disability (other than cerebral 
palsy, by definitions used in the primary studies) (3 studies OR 2.23, 95% CI 0.73 to 
6.82, I2=50%, Tau2=0.49, EPI 0 to 221765). In a term population for the same 
outcome and Apgar score, the association was significant (3 studies, OR 2.12, 95% 
CI 1.15 to 3.92, I2= 55%, Tau2= 0.165, EPI 0 to 1438.9). At a 5 minute Apgar 
threshold of ≤ 6, there was a significant association with childhood epilepsy in a term/ 
normal birth weight population, as determined by meta-analysis of 2 studies (OR 
3.84, 95% CI 2.47 to 5.96, I2=0, Tau2=0).  
Subgroup analyses 
The results for subgroup analyses for factors considered to be potential sources of 
heterogeneity are presented in Table 7.2. In a pre-term/ low birth weight population, 
limiting the analysis to 2 studies with populations born in 1990, or later, made the 
association between 1 minute Apgar score ≤ 3 and neonatal mortality non-significant. 
None of the other factors considered, including where possible high quality studies, 
exclusion of neonates with congenital anomalies, and location of study changed the 
significance of the association for this population and outcome. 
In a term/ normal birth weight population, none of the subgroup analyses changed 
the significance of the association with mortality at any threshold, but limiting to high 
quality studies did eliminate heterogeneity from the analysis at 1 minute Apgar score 
thresholds of ≤ 3 and ≤ 6, and increased the magnitude of the association in both 
cases (OR 104.35, 95% CI 59.73 to 102.31 and OR 61.86, 95% CI 36.11 to 105.96 
respectively). 
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In an unrestricted population, again subgroup analysis did not change the 
significance of the association of a low Apgar score at any threshold with neonatal 
mortality, or eliminate significant heterogeneity, with the exception of limiting to high 
quality studies in the analysis for a 1 minute Apgar score ≤ 3. In this case the 
heterogeneity was eliminated but the strength of the association was reduced and 
the prediction interval crossed 1 (3 studies OR 16.91, 95% CI 9.52 to 30.06).  
For childhood morbidity, limiting the analysis to studies performed in Europe, the 
USA or Australia or New Zealand made the association between a 5 minute Apgar 
score ≤ 3 and this outcome non-significant in a pre-term population.  For a 
term/normal birth weight population, limiting the analysis to studies where neonates 
with congenital anomalies were excluded eliminated heterogeneity in the analysis at 
a 5 minute Apgar score of ≤ 6, and the prediction interval also became significant (5 
studies, OR 4.38, 95% CI 3.19 to 6.01, EPI 2.62, 7.33). However, the same subgroup 
analysis at the same threshold in an unrestricted population made the association 
non-significant.  
For neonatal morbidity, limiting the analysis to high quality studies, year of birth ≥ 
1990, or those excluding congenital anomalies eliminated heterogeneity within the 
analysis for 1 minute Apgar score ≥ 3 in a pre-term/ low birth weight population, 
without affecting the magnitude of the association. No subgroup analysis was 
possible for this outcome in a term or unrestricted population. 
Subgroup analysis for the outcome of infant mortality was only possible in a pre-term 
population, and none of the analyses performed significantly affected the results or 
the magnitude of heterogeneity present. 
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Predictive ability of the Apgar score for adverse outcomes 
The sensitivity, specificity and likelihood ratios of the Apgar score for neonatal 
mortality are presented in Table 7.3, and for cerebral palsy in Table 7.4. In general, 
the Apgar score at low thresholds had a high specificity and positive likelihood ratio 
for both outcomes. However, the associated sensitivity and negative likelihood ratios 
were low. For example, the highest positive likelihood ratio was for a 10 min score ≤ 
3, indicating that any baby with a score less than this threshold multiplied their pre-
test odds of neonatal death by 958.99 (95% CI: 698.99 to 1315.9). Assuming a pre-
test probability of 0.003 of neonatal death,3 having a score below this threshold 
increases the probability of death to 0.74. However the negative likelihood ratio was 
only 0.68 (0.59 to 0.77), giving a post-test probability of 0.002, therefore having an 
Apgar score of ≥ 3 at 10 minutes does not substantially change the risk of neonatal 
death. The formulae for these calculations are given in Appendix 16.  
Publication bias for prognostic association 
There was only one meta-analysis group large enough to perform the Peters test. For 
a pre-term/low birth weight population, 10 studies were included in the analysis for an 
Apgar score of 5 minutes ≤ 6, and neonatal mortality. The Peters test suggested a 
significant small study effect (p= 0.016
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Figure 7.1. Study selection process for systematic review of the prognostic 
and predictive ability of Apgar score for short and long term outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total studies identified from electronic searches  
(Database inception to June 2011)  n=4692 
Potentially relevant articles obtained in full manuscripts  
n= 348 
Identified from electronic searches n= 275                                                                                                                               
Identified from manual reference list checking n= 73 
 
Articles excluded from review with reasons: 
Not Apgar score       n=  34 
Inappropriate outcome measure                   n=  21      
Lack of original data (review articles/letters)     n=  43                            
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Figure 7.2 Forest plot of odds ratios for the association between Apgar score and neonatal mortality in an 
unrestricted population. Single studies are represented by a filled box, and pooled studies (and 95% confidence 
intervals) by a diamond 
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Figure 7.3. Forest plot of odds ratios for the association between Apgar score 
and neonatal mortality in a term/ normal birth weight population. Single studies 
are represented by a filled box, and pooled studies (and 95% confidence 
intervals) by a diamond 
10 min ≤ 6 770.83 (550.58, 1141.36)
10 min ≤ 3 1417.75 (915.99, 2194.36)
5 min ≤ 9 5.02 (0.31, 82.68)
5 min ≤ 8 53.89 (15.99, 181.64)
5 min ≤ 7 137.89 (50.80, 374.28)
5 min ≤ 6 68.76 (26.74, 176.79)
5 min ≤ 5 290.51 (121.12, 696.80)
5 min ≤ 4 332.98 (129.16, 807.67)
5 min ≤ 3 215.84 (51.58, 903.21)
5 min ≤ 2 551.96 (178.89, 1703.04)
5 min ≤ 1 2209.16 (425.88, 11000.00)
1 min ≤ 9 0.94 (0.02, 59.15)
1 min ≤ 8 8.16 (1.70, 39.26)
1 min ≤ 7 11.79 (6.56, 21.19)
1 min ≤ 6 39.62 (12.86, 122.12)
1 min ≤ 5 22.54 (4.82, 105.40)
1 min ≤ 4 25.71 (6.86, 96.39)
1 min ≤ 3 44.39 (13.79, 142.88)
1 min ≤ 2 41.48 (15.36, 112.01)
1 min ≤ 1 63.95 (20.41, 235.66)
1 min = 0 82.98 (41.96, 164.11)
0.01 0.1 0.2 0.5 1 2 5 10 100 1000 1.00E+05
odds ratio (95% confidence interval)
Odds ratios (95% CI)Apgar score No. of Infants
Affected/Total
No. of Studies
1 113/25293
2 136/35417
I2=85, Tau2=0.665
2 136/35417
I2=79, Tau2=0.413
7 425/549489
I2=97, Tau2=2.38, EPI= 0.63, 3109
2 136/35417
I2=88, Tau2=0.804
2 136/35417
I2=90, Tau2=1.122
6
I2=96, Tau2=1.857, EPI= 0.65, 2404.34
425/543708
3 166/41198
I2=46, Tau2=1.254, EPI= 0.03, 4257.9
2 136/35417
I2=42, Tau2=0.760
2 136/35417
I2=87, Tau2=7.80
1 23/10124
1 23/10124
1 23/10124
1 23/10124
1 23/10124
1 23/10124
1 23/10124
1 90/479882
1 90/479882
5 444/873243
I2=97, Tau2 2.424, EPI= 0.91, 51420
6 464/873468
I2=95, Tau2 1.386, EPI= 2.42, 1955.8
EPI= Estimated prediction interval
 
 
 
 
 
 
 
 
 
 
 
 112 
 
Figure 7.4 Forest plot of odds ratios for the association between Apgar score 
and neonatal mortality in a preterm/low birth weight population. Single studies 
are represented by a filled box, and pooled studies (and 95% confidence 
intervals) by a diamond 
2 5 10 100 1000
10 min ≤ 6 49.83 (35.75, 69.47)
10 min ≤ 3 66.49 (45.00, 98.22)
5 min ≤ 6 16.00 (6.27, 40.84)
5 min ≤ 5 6.64 (4.09, 10.78)
5 min ≤ 4 24.12 (4.12, 141.31)
5 min ≤ 3 29.21 (8.96, 95.20)
1 min ≤ 9 8.26 (3.05, 22.37)
1 min ≤ 8 7.55 (4.80, 11.86)
1 min ≤ 7 8.18 (6.18, 10.83)
1 min ≤ 6 11.54 (8.33, 16.00)
1 min ≤ 5 12.19 (9.21, 16.16)
1 min ≤ 4 12.66 (9.69, 16.52)
1 min ≤ 3 8.50 (5.06, 14.38)
1 min ≤ 2 14.43 (10.95, 19.02)
1 min ≤ 1 13.75 (10.00, 18.92)
1 min = 0 34.27 (11.58, 101.45)
odds ratio (95% confidence interval)
Odds ratios (95% CI)Apgar score No. of Infants
Affected/Total
No. of Studies
1 311/2422
1 
1 
1 
1 
1 
1 
1 
1 
1 
311/2422
311/2422
311/2422
311/2422
311/2422
1179/396989
2 317/2650
I2=92, Tau2=0.564, EPI 1.29,55.91
I2=0, Tau2=0
6 964/38308
2 383/3124
I2=67, Tau2=0.104, EPI 4.21,31.68
I2=0, Tau2=0
7 8986/738539
I2=99, Tau2=2.51, EPI 0.37, 2279
6/228
123/852
10 14,21/743609 
159/32165 
159/32165 
I2=99, Tau2=2.24, EPI 0.43, 599.4
 113 
 
Figure 7.5 Forest plot of odds ratios for the association between Apgar score 
and neonatal morbidity. Single studies are represented by a filled box, and 
pooled studies (and 95% confidence intervals) by a diamond 
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Figure 7.6 Forest plot of odds ratios for the association between Apgar score and infant mortality. Single studies are 
represented by a filled box, and pooled studies (and 95% confidence intervals) by a diamond 
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Figure 7.7 Forest plot of odds ratios for the association between Apgar score 
and cerebral palsy. Single studies are represented by a filled box, and pooled 
studies (and 95% confidence intervals) by a diamond 
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Figure 7.8 Forest plot of odds ratios for the association between Apgar score and childhood morbidity. Single studies are 
represented by a filled box, and pooled studies (and 95% confidence intervals) by a diamond 
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Table 7.1 Methodological quality of studies included in systematic review 
of Apgar score and adverse outcomes 
 
 
  
 Number (%) of studies n=87 
Quality Item Yes No Unclear 
Cohort study design 70 (80) 16 (19)  1   (1) 
Population adequately described 80 (92) 3   (3) 4   (5) 
Consecutive recruitment 47 (54) 10 (12) 30 (34) 
Prospective recruitment 28  (33) 53 (60) 6   (7) 
Appropriate outcome measure 87 (100) 0 0 
Outcome measure blinded 3   (3) 1   (1) 83 (96) 
>90% of individuals had outcome measure 62 (72) 22 (25) 3   (3) 
Index test and outcome measure described 8   (10) 71 (80) 8 (10) 
Intervention between index test and outcome 2   (2) 0 85 (98) 
Quality Classification    
High 48 (56) - - 
Medium 34 (38) - - 
Low 5   (6) - - 
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Table 7.2 Subgroup analysis according to Apgar score and outcome, 
where possible, for study quality, year of birth of study population, place 
of study and exclusion of congenital anomalies 
Apgar 
score 
Population Number 
of 
studies 
Subgroup Odds 
ratio 
(95% 
CI) 
Estimated 
prediction 
interval 
(EPI) 
I2 
Tau2 
Neonatal death 
1 min ≤ 
3 
Preterm 4 High quality 
studies 
6.23 
(3.31, 
11.74) 
0.38,103.5
7 
I2=79, 
Tau2=0.3
2 
1 min ≤ 
3 
Preterm 4  Congenital 
anomalies 
excluded 
11.79(4.
63, 
30.05) 
0.14, 
1010.75 
I2=96, 
Tau2=0.8
4 
1 min ≤ 
3 
Preterm 2  Year of birth ≥ 
1990 
7.75 
(0.54, 
111.16) 
- I2=98, 
Tau2=3.6
3 
1 min ≤ 
6 
Preterm 2 High quality 
studies 
7.72 
(5.35, 
11.14) 
- I2=0, 
Tau2=0 
1 min ≤ 
6 
Preterm 3  Congenital 
anomalies 
excluded 
16.01 
(11.37, 
22.55) 
0.72, 
357.11 
I2=31, 
Tau2=0.0
3 
5 min ≤ 
3 
Preterm 4  High quality 
studies 
35.55 
(8.11, 
155.89) 
0.03,48460 I2=99, 
Tau2=2.2
4 
5 min ≤ 
3 
Preterm 4  Congenital 
anomalies 
excluded 
33.52 
(6.66, 
168.79) 
0.01, 
90443 
I2=99, 
Tau2=2.6
9 
5 min ≤ 
3 
Preterm 3  Year of birth ≥ 
1990 
32.74 
(4.19, 
255.63) 
Too large I2=99, 
Tau2=3.2
8 
5 min ≤ 
6 
Preterm 6  High quality 
studies 
16.00 
(4.51, 
56.80) 
0.14, 
1787.33 
I2=99, 
Tau2=2.4
7 
5 min ≤ 
6 
Preterm 7  Congenital 
anomalies 
excluded 
14.58 
(4.95, 
14.92) 
0.28, 
765.08 
I2=99, 
Tau2=2.0
7 
5 min ≤ 
6 
Preterm 4  Year of birth ≥ 
1990 
16.63 
(3.81, 
72.62) 
0.01, 
22252 
I2=99, 
Tau2=2.2
3 
5 min ≤ 
6 
Preterm 9  USA/Europe/ 
Australia/NZ  
studies 
17.18 
(6.41, 
46.01) 
0.41, 
713.13 
I2=99, 
Tau2=2.2
3 
1 min ≤ 
3 
Term 2 High quality 
studies 
104.35 
(59.73, 
102.31) 
- I2=0, 
Tau2=0 
1 min ≤ Term 2  Congenital 44.39 - I2=99, 
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3 anomalies 
excluded 
(1.10, 
1791.77
) 
Tau2=7.0
7 
1 min ≤ 
6 
Term  2 High quality 
studies 
61.86 
(36.11, 
105.96) 
- I2=0, 
Tau2=0 
1 min ≤ 
6 
Term 2  Congenital 
anomalies 
excluded 
21.36 
(2.03, 
225.2) 
- I2=98, 
Tau2=2.8
4 
5 min ≤ 
3 
Term 2  High quality 
studies 
179.42 
(38.17, 
843.5) 
- I2=62, 
Tau2=0.8
9 
5 min ≤ 
3 
Term  3 Congenital 
anomalies 
excluded 
247.30 
(36.18, 
1644.78
) 
Too large I2=98, 
Tau2=2.7
6 
5 min ≤ 
6 
Term 2  High quality 
studies 
87.86 
(57.23, 
134.87) 
- I2=24, 
Tau2=0.0
4 
5 min ≤ 
6 
Term  3 Congenital 
anomalies 
excluded 
83.44 
(22.65, 
307.3) 
Too large I2=97, 
Tau2=1.2
9 
5 min ≤ 
6 
Term  5 USA/Europe/ 
Australia/NZ  
studies 
88.96 
(34.58, 
228.85) 
2.7,3332.7 I2=95, 
Tau2=1.0
6 
1 min ≤ 
3  
Unrestricted 3  High quality 
studies 
16.91 
(9.52, 
30.06) 
0.41, 
703.14 
I2=0, 
Tau2=0 
1 min ≤ 
3  
Unrestricted 2  Year of birth ≥ 
1990 
59.36 
(6.04, 
583.58) 
- I2=89, 
Tau2=2.4
5 
1 min ≤ 
3  
Unrestricted 7  USA/Europe/ 
Australia/NZ  
studies 
27.91 
(11.32, 
68.85) 
1.05, 
739.44 
I2=98, 
Tau2=1.4
1 
1 min ≤ 
6 
Unrestricted 4  High quality 
studies 
19.71 
(10.66, 
36.44) 
1.74, 222.6 I2=63, 
Tau2=0.2
2 
1 min ≤ 
6 
Unrestricted 3  Year of birth ≥ 
1990 
46.33 
(19.22, 
111.64) 
Too large I2=96, 
Tau2=0.4
5 
1 min ≤ 
6 
Unrestricted 6 USA/Europe/ 
Australia/NZ  
studies 
22.99 
(10.35, 
51.03) 
1.27, 
416.06 
I2=97, 
Tau2=0.9
2 
5 min ≤ 
6 
Unrestricted 5  High quality 
studies 
109.68 
(77.16, 
155.88) 
34.26, 
351.05 
I2=90, 
Tau2=0.1
0 
5 min ≤ 
6 
Unrestricted 3  Year of birth ≥ 
1990 
115.25 
(66.20, 
204.17) 
0.19, 
70822 
I2=90, 
Tau2=0.1
7 
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5 min ≤ 
6 
Unrestricted 5 USA/Europe/ 
Australia/NZ  
studies 
97.74 
(58.30, 
163.85) 
13.99, 
682.84 
I2=95, 
Tau2=0.3
0 
Neonatal morbidity 
1 min ≤ 
3 
Preterm 3  High quality 
studies 
3.50 
(2.87, 
4.28) 
0.96, 12.77 I2=0, 
Tau2=0 
1 min ≤ 
3 
Preterm 2  Congenital 
anomalies 
excluded 
2.45 
(1.52, 
3.87) 
- I2=2, 
Tau2=0.0
01 
1 min ≤ 
3 
Preterm 2  Year of birth ≥ 
1990 
3.53 
(2.87, 
4.34) 
- I2=0, 
Tau2=0 
1 min ≤ 
3 
Preterm 2  USA/Europe/ 
Australia/NZ  
studies 
2.13 
(1.12, 
4.05 
0.12, 38.53 I2=84, 
Tau2=0.3
5 
Infant mortality 
1 min ≤ 
3 
Preterm 3  Year of birth ≥ 
1990 
4.28 
(2.78, 
6.58) 
0.02, 
1038.43 
I2=96, 
Tau2=0.1
4 
1 min ≤ 
3 
Preterm 3  Congenital 
anomalies 
excluded 
9.34 
(3.14, 
27.73) 
Too large I2=98, 
Tau2=0.8
4 
5 min ≤ 
3 
Preterm 2 Congenital 
anomalies 
excluded 
12.97 
(1.39, 
121.3) 
- I2=95, 
Tau2=2.4
7 
5 min ≤ 
3 
Preterm 4 Year of birth ≥ 
1990 
7.90 
(4.24, 
14.73) 
0.52,119.5
5 
I2=90, 
Tau2=0.3
0 
5 min ≤ 
3 
Preterm 4 USA/Europe/ 
Australia/NZ  
studies 
12.68 
(5.52, 
29.10) 
0.25, 
639.57 
I2=97, 
Tau2=0.6
5 
Childhood morbidity 
5 min ≤ 
3 
Preterm 3  High quality 
studies 
5.98 
(1.61, 
22.27) 
Too large I2=48, 
Tau2=0.6
7 
5 min ≤ 
3 
Preterm 3  Congenital 
anomalies 
excluded 
3.98 
(1.80, 
8.80) 
0.02, 683.7 I2=0, 
Tau2=0 
5 min ≤ 
3 
Preterm 3  USA/Europe/ 
Australia/NZ  
studies 
2.64 
(0.66, 
10.63) 
Too large I2=41, 
Tau2=0.6
6 
5 min ≤ 
3 
Term 4  Congenital 
anomalies 
excluded 
4.14 
(1.97, 
8.69) 
0.49,35.07 I2=17, 
Tau2=0.1
0 
5 min ≤ 
3 
Term 4  USA/Europe/ 
Australia/NZ  
studies 
2.44 
(1.22, 
4.85) 
0.17, 34.02 I2=57, 
Tau2=0.2
5 
5 min ≤ Term 2  High quality 4.36 - I2=29, 
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Table 7.3 The predictive ability of the Apgar score for neonatal mortality 
Apgar 
score 
No. of 
studies 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
likelihood 
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
Unrestricted population 
1 min =0 1 0.07 (0.05-
0.1) 
0.99 
(0.998-
0.999) 
49.88 
(31.52-
78.95) 
0.93 (0.90-
0.95) 
1 min ≤ 1 1 0.36 (0.32-
0.41) 
0.98 
(0.982-
0.985) 
21.93 
(18.77-
25.63) 
0.65 (0.60-
0.70) 
1 min ≤ 2 1 0.52 (0.47 
to 0.57) 
0.96 (0.962 
to 0.966) 
14.43 
(12.93-
16.10) 
0.50 (0.45 
to 0.55) 
1 min ≤ 3 8 0.45 (0.36 
to 0.53) 
0.97 (0.95 
to 0.98) 
16.17 
(15.22 to 
52.87) 
0.57 (0.49 
to 0.66) 
1 min ≤ 4 1 0.67 (0.61 
to 0.70) 
0.90 (0.90 
to 0.91) 
6.85 (6.34 
to 7.41) 
0.38 (0.33 
to 0.43) 
1 min ≤ 5 1 0.72 (0.68 
to 0.77) 
0.86 (0.86 
to 0.87) 
5.31 (4.97 
to 5.67) 
0.32 (0.27 
to 0.37) 
1 min ≤ 6 8 0.71 (0.67 
to 0.75) 
0.90 (0.87 
to 0.93) 
7.75 (5.77 
to 10.42) 
0.31 (0.28 
to 0.36) 
6 studies (2.89, 
6.56) 
Tau2=0.0
3 
5 min ≤ 
6 
Term 5  Congenital 
anomalies 
excluded 
4.38 
(3.19, 
6.01) 
2.62, 7.33 I2=0, 
Tau2=0 
5 min ≤ 
6 
Term 5  USA/Europe/ 
Australia/NZ  
studies 
3.29 
(1.59, 
6.78) 
0.24, 44.49 I2=89, 
Tau2=0.5
3 
5 min ≤ 
6 
Unrestricted 3 High quality 
studies 
3.05 
(1.35, 
6.90) 
0, 35355 I2=78, 
Tau2=0.3
7 
5 min ≤ 
6 
Unrestricted 2 Congenital 
anomalies 
excluded 
3.20 
(0.95, 
10.80) 
- I2=86, 
Tau2=0.6
7 
5 min ≤ 
6 
Unrestricted 2 Year of birth ≥ 
1990 
2.20 
(1.22, 
3.95) 
- I2=0, 
Tau2=0 
5 min ≤ 
6 
Unrestricted 4  USA/Europe/ 
Australia/NZ  
studies 
3.70 
(2.03, 
6.74) 
0.28,48.88 I2=78, 
Tau2=0.2
7 
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1 min ≤ 7 2 0.79 (0.68 
to 0.86) 
0.77 (0.66 
to 0.85) 
3.34 (2.21 
to 5.23)* 
0.28 (0.19 
to 0.43)* 
1 min ≤ 8 1 0.91 (0.88 
to 0.94) 
0.46 (0.46 
to 0.47) 
1.69 (1.64 
to 1.75) 
0.19 (0.14 
to 0.26) 
1 min ≤ 9 1 0.98 (0.97 
to 0.99) 
0.14 (0.13 
to 0.14) 
1.14 (1.12 
to 1.15) 
0.12 (0.06 
to 0.15) 
5 min ≤ 3 4 0.29 (0.16 
to 0.46) 
0.999 
(0.997 
to0.999) 
212.9 
(141.02 to 
321.27) 
0.71 (0.58 
to 0.88) 
5 min ≤ 6 7 0.53 (0.42 
to 0.63) 
0.99 (0.98 
to 0.99) 
48.43 
(28.91 to 
81.13) 
0.48 (0.38 
to 0.59) 
5 min ≤ 7 1 0.07 (0.05 
to 0.10) 
0.994 
(0.992 to 
0.995) 
11.50 (7.65 
to 17.28) 
0.93 (0.91 
to 0.95) 
10 min ≤ 3 1 0.28 (0.23 
to 0.34) 
0.999 
(0.999 to 
0.999) 
444.13 
(355.74 to 
554.48) 
0.72 (0.67 
to 0.78) 
10 min ≤ 6 1 0.42 (0.36 
to 0.49) 
0.998 
(0.998 to 
0.998) 
226.17 
(193.87 to 
263.84) 
0.58 (0.52 
to 0.64) 
Term/ normal birth weight population 
1 min =0 1 0.11 (0.06 
to 0.18) 
0.999 
(0.998 to 
0.999) 
74.28 
(39.69 to 
139.0) 
0.90 (0.84 
to 0.95) 
1 min ≤ 1 2 0.37 (0.30 
to 0.46) 
0.99 (0.98 
to 0.99) 
44.86 
(13.70 to 
146.94)* 
0.63 (0.56 
to 0.72)* 
1 min ≤ 2 2 0.47 (0.39 
to 0.55) 
0.98 (0.96 
to 0.99) 
24.13 (8.43 
to 69.11)* 
0.55 (0.47 
to 0.64)* 
1 min ≤ 3 7 0.47 (0.38 
to 0.56) 
0.98 (0.96 
to 0.99) 
23.33 
(10.75 to 
50.65) 
0.54 (0.46 
to 0.64) 
1 min ≤ 4 2 0.59 (0.50 
to 0.67) 
0.95 (0.89 
to 0.98) 
11.54 (3.46 
to 38.48)* 
0.45 (0.37 
to 0.55)* 
1 min ≤ 5 2 0.63 (0.55 
to 0.71) 
0.92 (0.84 
to 0.97) 
8.81 (2.51 
to 30.93) 
0.42 (0.34 
to 0.52) 
1 min ≤ 6 6 0.66 (0.61 
to 0.70) 
0.95 (0.91 
to 0.97) 
12.73 (7.26 
to 22.31) 
0.36 (0.31 
to 0.42) 
1 min ≤ 7 3 0.78 (0.71 
to 0.83) 
0.80 (0.72 
to 0.86) 
3.82 (2.41 
to 6.05)* 
0.31 (0.22 
to 0.44)* 
1 min ≤ 8 2 0.95 (0.45 
to 1.00) 
0.44 (0.41 
to 0.48) 
1.65 (1.58 
to 1.73)* 
0.20 (0.04 
to 0.95)* 
5 min ≤ 1 1 0.30 (0.13 
to 0.53) 
1.00 (0.99 
to 1.00) 
1537.1 
(337.1 to 
7008.9) 
0.70 (0.53 
to 0.91) 
5 min ≤ 2 1 0.30 (0.13 
to 0.53) 
0.999 
(0.998 to 
1.00) 
384.28 
(151.89 to 
972.21) 
0.70 (0.53 
to 0.91) 
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5 min ≤ 3 5 0.26 (0.16 
to 0.38) 
0.999 
(0.997 to 
0.999) 
188.41 
(75.73 to 
468.77) 
0.74 (0.64 
to 0.86) 
5 min ≤ 4 1 0.44 (0.23 
to 0.66) 
0.998 
(0.996 to 
0.998) 
182.99 
(99.05 to 
388.08) 
0.57 (0.40 
to 0.81) 
5 min ≤ 5 1 0.57 (0.35 
to 0.77) 
0.996 
(0.994 to 
0.997) 
126.87 
(79.93 to 
201.38) 
0.44 (0.27 
to 0.70) 
5 min ≤ 6 6 0.50 (0.36 
to 0.64) 
0.98 (0.95 
to 1.00) 
30.97 
(10.86 to 
88.36) 
0.51 (0.38 
to 0.67) 
5 min ≤ 7 1 0.78 (0.56 
to 0.93) 
0.98 (0.97 
to 0.98) 
30.76 
(24.03 to 
39.37) 
0.22 (0.10 
to 0.48) 
5 min ≤ 8 1 0.87 (0.66 
to 0.97) 
0.89 (0.88 
to 0.90) 
7.90 (6.68 
to 9.34) 
0.15 (0.05 
to 0.42) 
10 min ≤ 3 1 0.32 (0.24 
to 0.42) 
1.00 (1.00 
to 1.00) 
958.99 
(698.89 to 
1315.9) 
0.68 (0.59 
to 0.77) 
10 min ≤ 6 1 0.47 (0.37 
to 0.47) 
0.999 
(0.999 to 
0.999) 
411.57 
(329.95 to 
513.39) 
0.53 (0.45 
to 0.64) 
Preterm/ low birth weight population 
1 min =0 1 0.06 (0.04 
to 0.09) 
0.998 
(0.995 to 
0.999) 
32.24 
(11.04 to 
94.15) 
0.94 (0.91 
to 0.97) 
1 min ≤ 1 1 0.36 (0.31 
to 0.42) 
0.96 (0.95 
to 0.97) 
9.16 (7.08 
to 11.85) 
0.67 (0.61 
to 0.72) 
1 min ≤ 2 1 0.54 (0.48 
to 0.59) 
0.93 (0.91 
to 0.94) 
7.22 (6.02 
to 8.67) 
0.50 (0.44 
to 0.56) 
1 min ≤ 3 9 0.54 (0.43 
to 0.64) 
0.88 (0.82 
to 0.92) 
4.47 (3.02 
to 6.62) 
0.53 (0.43 
to 0.64) 
1 min ≤ 4 2 0.69 (0.64 
to 0.74) 
0.77 (0.62 
to 0.88) 
3.62 (2.09 
to 6.25)* 
0.37 (0.31 
to 0.43)* 
1 min ≤ 5 1 0.76 (0.71 
to 0.81) 
0.79 (0.77 
to 0.81) 
3.66 (3.30 
to 4.07) 
0.30 (0.25 
to 0.37) 
1 min ≤ 6 6 0.82 (0.74 
to 0.88) 
0.71 (0.62 
to 0.79) 
2.87 (2.23 
to 3.69) 
0.25 (0.18 
to 0.34) 
1 min ≤ 7 2 0.81 (0.70 
to 0.88) 
0.66 (0.56 
to 0.75) 
2.34 (1.84 
to 2.98)* 
0.30 (0.19 
to 0.46)* 
1 min ≤ 8 1 0.93 (0.90 
to 0.96) 
0.35 (0.33 
to 0.37) 
1.44 (1.38 
to 1.51) 
0.19 (0.13 
to 0.29) 
1 min ≤ 9 1 0.99 (0.97 
to 1.00) 
0.10 (0.09 
to 0.11) 
1.09 (1.07 
to 1.11) 
0.13 (0.05 
to 0.35) 
5 min ≤ 3 7 0.41 (0.32 
to 0.52) 
0.98 (0.94 
to 0.99) 
18.19 (8.29 
to 39.91) 
0.60 (0.51 
to 0.71) 
5 min ≤ 4 1 0.67 (0.22 
to 0.96) 
0.92 (0.88 
to 0.96) 
8.71 (4.21 
to 18.02) 
0.36 (0.12 
to 1.12) 
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5 min ≤ 5 1 0.31 (0.23 
to 0.40) 
0.94 (0.92 
to 0.95) 
4.90 (3.33 
to 7.19) 
0.74 (0.65 
to 0.83) 
5 min ≤ 6 10 0.63 (0.53 
to 0.71) 
0.90 (0.80 
to 0.96) 
6.58 (3.10 
to 14.00) 
0.41 (0.33 
to 0.52) 
10 min ≤ 3 1 0.25 (0.19 
to 0.33) 
0.995 
(0.994 to 
0.996) 
50.01 
(36.71 to 
68.13) 
0.75 (0.69 
to 0.82) 
10 min ≤ 6 1 0.40 (0.32 
to 0.48) 
0.987 
(0.986 to 
0.988) 
30.49 
(24.60 to 
37.77) 
0.61 (0.54 
to 0.69) 
 
*= Values calculated using Meta-Disc software 
Table 7.4 The predictive ability of the Apgar score for cerebral palsy 
Apgar 
score 
No. of 
studies 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
likelihood 
ratio (95% 
CI) 
Negative 
likelihood 
ratio (95% 
CI) 
Unrestricted population 
1 min ≤ 3 1 0.25 (0.18 
to 0.32) 
0.95 (0.95 
to 0.96) 
5.28 (4.01 
to 6.95) 
0.79 (0.72 
to 0.86) 
1 min ≤ 4 1 0.28 (0.21 
to 0.35) 
0.97 (0.94 
to 0.99) 
9.20 (4.43 
to 19.07) 
0.75 (0.68 
to 0.83) 
1 min ≤ 6 1 0.43 (0.35 
to 0.51) 
0.82 (0.81 
to 0.82) 
2.33 (1.94 
to 2.80) 
0.70 (0.61 
to 0.80) 
1 min ≤ 7 1 0.60 (0.51 
to 0.67) 
0.81 (0.75 
to 0.85) 
3.07 (2.32 
to 4.04) 
0.50 (0.41 
to 0.62) 
5 min ≤ 3 2 0.09 (0.06 
to 0.15) 
0.997 
(0.986 to 
0.999) 
35.19 (7.40 
to 167.32)* 
0.90 (0.84 
to 0.97)* 
5 min ≤ 4 1 0.46 (0.37 
to 0.56) 
0.95 (0.94 
to 0.96) 
9.46 (7.39 
to 12.12) 
0.56 (0.47 
to 0.67) 
5 min ≤ 6 2 0.21 (0.16 
to 0.27) 
0.98 (0.95 
to 0.99) 
13.68 (3.77 
to 49.61) 
0.80 (0.76 
to 0.85) 
5 min ≤ 7 1 0.48 (0.40 
to 0.57) 
0.93 (0.90 
to 0.96) 
7.20 (4.48 
to 11.58) 
0.55 (0.47 
to 0.65) 
10 min ≤ 3 1 0.26 (0.15 
to 0.39) 
0.98 (0.98 
to 0.99) 
14.11 (8.62 
to 23.08) 
0.76 (0.65 
to 0.89) 
10 min ≤ 6 1 0.44 (0.30 
to 0.58) 
0.90 (0.89 
to 0.91) 
4.32 (3.17 
to 5.89) 
0.63 (0.50 
to 0.79) 
Pre-term/ low birth weight 
5 min ≤ 3 3 0.07 (0.03 
to 0.13) 
0.99 (0.98 
to 0.99) 
6.92 (4.74 
to 10.10) 
0.95 (0.93 
to 0.97) 
Term/ normal birth weight 
1 min ≤ 3 2 0.28 (0.22 
to 0.35) 
0.96 (0.95 
to 0.96) 
13.22 (1.13 
to 154.22)* 
0.74 (0.65 
to 0.85)* 
5 min ≤ 3 3 0.10 (0.07 0.998 40.95 (9.53 0.90 (0.86 
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to 0.14) (0.991 to 
0.999) 
to 175.92)* to 0.94)* 
5 min ≤ 6 3 0.20 (0.17 
to 0.23)* 
0.992 
(0.992 to 
0.992)* 
8.65 (2.04 
to 36.80)* 
0.82 (0.79 
to 0.85)* 
10 min ≤ 3 1 0.38 (0.22 
to 0.56) 
0.99 (0.98 
to 0.99) 
26.47 
(16.24 to 
43.17) 
0.63 (0.48 
to 0.82) 
10 min ≤ 6 1 0.50 (0.32 
to 0.68) 
0.92 (0.91 
to 0.93) 
6.36 (4.48 
to 9.02) 
0.54 (0.39 
to 0.76) 
*= Values calculated using Meta-Disc software 
7.5 Discussion 
 
A low Apgar score showed a strong, consistent association with neonatal 
mortality. The relationship was highest at lower thresholds, and generally 
decreased (but remained strong) as the threshold increased. The fact that the 
association remained significant at a 1 minute Apgar thresholds of 8 and 9 was 
surprising, but is likely to reflect that these cut offs include all of the lower 
scores which are very strongly associated with poor outcome, as the higher 
scores were not considered in isolation. A lower score at later time intervals was 
most strongly associated with this outcome, which reflects the fact that babies 
who are in poorer condition for longer are more likely to have undergone a 
significant pathological process causing compromise, increasing the risk of 
death. The relationship between a low Apgar score and neonatal mortality 
appeared stronger in a term (≥ 37 weeks gestation) or normal birth weight (≥ 
2.5kg) population than a pre-term or unrestricted population.  For a term 
population, the association between a low Apgar score and neonatal morbidity, 
infant mortality, childhood cerebral palsy and other childhood morbidity, was 
significant at all but one threshold of the Apgar score assessed. The magnitude 
of the association was less than that for neonatal mortality. However, the 
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association between a low Apgar score and other adverse outcomes in a pre-
term or low birth weight population was less consistent. This is likely to reflect 
the fact that a low Apgar score in pre-term infants may reflect the differing 
physiology of infants born prior to term, and be low as a result of immaturity 
rather than a pathological process with sequelae. Also, this population is at 
higher risk of adverse outcomes related to prematurity, and as such the 
condition at birth may not reflect their overall risk of developing complications, 
thus diluting the relationship. 
Strengths and limitations of this review 
The strengths of this review lie in the methodology used. Extensive literature 
searches were performed without language restrictions, and every effort was 
made to search for unpublished data. The review complies with the most recent 
guidance on performing and reporting of systematic reviews of observational 
studies.78;84 The most up to date techniques have been used for performing and 
interpreting meta-analysis.102;130;131  
However, despite attempts to include all available data, Peter’s test suggested 
the presence of a small study effect in the only meta-analysis group large 
enough for this to be performed. Another limitation is the varying number of 
studies that contributed to each analysis. The majority of studies used an Apgar 
score threshold of ≤ 3 or ≤6 to define a low score, with only 2 papers providing 
data on the Apgar score at each threshold (Apgar and James 1962 and Jennett 
et al 1981), therefore direct comparisons were only possible for these; others 
are indirect and the magnitude in association may be affected by differences in 
population or other study characteristics.   
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The Apgar score at 1, 5 and 10 minutes in a single infant are not independent, 
i.e. an infant with a low score at 10 minutes is likely to have also had a low 
score at 1 and 5 minutes. Due to the nature of the reporting in the primary 
studies, where multiple time points were reported, it was not possible to analyse 
the outcome following a low score at more than one time point e.g. less than 5 
at both 1 and 5 minutes. However, by only performing meta-analysis for 
individual thresholds at a particular time point (as reported in the primary 
studies), and only including each study once in any given meta-analysis, care 
was taken to ensure that individuals were not counted multiple times in any 
analysis. 
The reporting quality of included studies was particularly poor regarding the 
execution of the index test, i.e. very few provided descriptions of how the score 
was assigned or the personnel performing this. Given the subjective nature of 
some components of the score, the inter-observer variability is an important 
consideration of this test, but none of the included studies reported this. 
O’Donnell et al assessed the inter-observer variability of the 5 minute Apgar 
score through showing video clips to observers and comparing these with 
scores assigned by the member of staff attending the delivery.141 They found 
that scores assigned varied widely, both between the observers watching the 
video clip and between the scores actually assigned at delivery and the video 
scores, with a mean difference of 2.4.141 In another study by Clark and 
Hakansen, inter-rater reliability was found to be 68% among paediatric staff, but 
24% among community hospital nurses.142  
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It was not possible to investigate within this review whether different 
components of the Apgar score were particularly correlated with adverse 
outcome. Only two of the included studies reported on components of the Apgar 
score, one found that a greater proportion of infants with a 1 minute Apgar 
score ≤6 who died had a heart rate below 100 (72.5% of infants that died versus 
33% of survivors)(Colburn 1960). The other study found that heart rate and 
reflex irritability at 1 minute were the best discriminators between babies that 
were ‘healthy or relatively healthy’ and ‘severely ill’ in the neonatal period 
(Valentin et al 1993).  
Heygi et al investigated the relationship between components of the 1 minute 
Apgar score in pre-term infants, and found that the strongest correlations were 
between respiratory rate, tone and reflex.143 The heart rate corresponded less 
well with other components, and colour had the lowest correlation. They 
constructed a model to compare the contribution of each factor to the 1 minute 
Apgar score from 0-10, and found that respiratory rate, tone and reflex 
produced the largest increase in total score, followed by heart rate and colour, 
reflecting the large contribution of heart rate at lower Apgar scores and smaller 
contribution at higher scores. Tone contributed more to higher scores than heart 
rate in this population.143  
Subgroup analyses were planned within this review to assess the implications 
of a low Apgar score in pre-term and term born populations separately, however 
due to the fact that many studies reported birth weight rather than gestational 
age in the population characteristics, a broader subgroup of infants born at less 
than 37 weeks gestation, or of birth weight less than 2.5 kg, was used. This may 
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therefore lead to some crossover between pre-term and small for gestational 
age infants in both subgroups and affect the extrapolation of the results to 
clinical practice. Other potential factors which may affect either the Apgar score 
of an individual, or the relationship between a low score and adverse outcome, 
were addressed. Subgroup analyses for study quality, location, year of birth ≥ 
1990 and exclusion of congenital anomalies were performed. In general, the 
subgroup analyses performed did not affect the significance or direction of the 
results. In the cases where the results did change, this most commonly 
occurred in the pre-term population, where limiting the analysis according to 
these factors made the association between low Apgar score and adverse 
outcome non-significant. However, the results were inconsistent and the same 
subgroup analysis did not produce the same effect at all thresholds of the Apgar 
score examined. Due to the reporting quality of the primary studies, it was not 
possible to address the effect of other factors which may affect the Apgar score, 
such as medication administered to the mother.  
 
Comparison with other studies 
The only other systematic review reporting the association between a low Apgar 
score and neonatal mortality and cerebral palsy found a significant association 
between a low score and these outcomes.77 The current review supports these 
findings, and has performed a more in depth investigation into these 
relationships at different thresholds and subgroups.  
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Implications for clinical practice 
Meta-analysis confirms that a low Apgar score has a strong prognostic 
association with neonatal mortality, particularly in a population born at term. The 
association between a low Apgar score and neonatal morbidity, childhood 
cerebral palsy and other morbidities was also significant, suggesting that the 
Apgar score is a valid measure of neonatal wellbeing that has implications for 
long term health. However, no single threshold showed both high sensitivity and 
specificity for the adverse outcomes examined, therefore it is not possible to 
choose a standard cut-off that should be employed in clinical practice. 
Recommendations 
Future research is necessary to further explore subgroups to allow 
prognostication of a low Apgar score at an individual level to facilitate 
counselling of parents and target observation and intervention in the neonatal 
period.  This could be performed through an individual patient data meta-
analysis.121 Another option would be to perform a large prospective cohort study 
in which further risk factors could be recorded, or individual components of the 
Apgar score used to predict outcome.  
Finally, it is likely that more accurate predictions could be made using the Apgar 
score in combination with other tests of neonatal wellbeing that are performed 
at birth.  
7.6 Conclusion 
A low Apgar score at birth is strongly associated with neonatal mortality, 
morbidity and childhood cerebral palsy, particularly in a population born at term, 
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or with normal birth weight. Further research is required to identify the 
subgroups in which Apgar score may best predict adverse outcome. This may 
be done through individual patient data meta-analysis.  Prognostic models also 
containing other factors may optimise the prediction of adverse outcome on an 
individual level. Adherence of future studies to the STARD criteria will facilitate 
meta-analysis.
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CHAPTER 8: SUMMARY OF THE EXISTING 
LITERATURE TO SUPPORT THERAPEUTIC 
NEONATAL HYPOTHERMIA TO PREVENT 
SEQUELAE FOLLOWING HYPOXIA 
 
8.1 Introduction 
Peripartum asphyxia affects 3 to 5 per 1000 live births in developed countries, with 
moderate or severe hypoxic ischaemic encephalopathy occurring in 0.5 to 1 per 
1000.12 Moderate encephalopathy carries a 10 percent risk of death, and 30 percent 
risk of disability, and where encephalopathy is severe, 60 percent die and most 
survivors have neurological abnormalities.144 The Sarnat grading of severity of 
encephalopathy is given in Table 8.1.144 At a tissue level, hypoxic ischaemia initiates 
energy depletion, the accumulation of extracellular glutamate, and activation of 
receptors, loss of membrane homeostasis and increases in intracellular calcium and 
osmotic dysregulation, resulting in cell death.11;144 It is thought that the process of 
cellular damage is an evolving course, and that although neurons may die during the 
initial event, many recover and undergo a latent phase, only to die hours or days later 
(secondary or delayed cell death).145 The mechanisms of delayed neuronal death 
include hyperaemia, cytotoxic oedema, mitochondrial failure, accumulation of 
excitotoxins, nitric oxide synthesis, free radical damage and cytotoxic actions of 
activated microglia.146 
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Initial studies of intentionally inducing hypothermia in neonates were performed in the 
1940s and 50s. The purpose of the treatment at this time was to resuscitate 
asphyxiated infants. Animal studies and a small case series of severely asphyxiated 
human infants showed successful resuscitation and increased survival in subjects 
who had undergone whole body cooling.147 However, controversy existed due to data 
published on the adverse effects of neonatal exposure to cold,148;149 and alternative 
techniques for resuscitation developed, therefore it was not until recent years that 
neonatal therapeutic hypothermia to prevent neurologic injury has gained credence 
and become an established treatment. 
Table 8.1 Sarnat staging of encephalopathy 
Sarnat Stage 1 (Mild) Sarnat Stage 2 
(Moderate) 
Sarnat Stage 3 (Severe) 
Hyperalert Lethargic Stuporous 
Normal tone Mild hypotonia Flaccid 
Overactive stretch reflexes Overactive stretch reflexes Decreased or absent 
stretch reflexes 
Weak suck Weak/absent suck Absent suck 
No seizures Common, focal or 
multifocal 
Uncommon 
Less than 24 hours 
duration 
2-14 days Hours to weeks 
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8.2 Summary of the evidence to support neonatal hypothermia 
8.2.1 Cochrane review: ‘Cooling for newborns with hypoxic ischaemic 
encephalopathy’ 
A Cochrane review published in 2008 included randomised controlled trials 
comparing the use of therapeutic hypothermia with standard care in encephalopathic 
newborns, with evidence of peripartum asphyxia and without major congenital 
anomalies. The primary outcome measure was death or long term major 
neurodevelopmental disability.150 Eight studies were included, comprising 638 infants 
born at near term gestation. Evidence of perinatal asphyxia to satisfy the inclusion 
criteria for the review was one of: Apgar score ≤ 5 at 10 minutes, mechanical 
ventilation or resuscitation at 10 minutes, or cord pH <7.1 or arterial pH <7.1 or base 
deficit of ≥ 12 within 60 minutes of birth. Evidence of encephalopathy was according 
to Sarnat staging. Method of therapeutic hypothermia was either by whole body or 
selective head cooling. Four trials performed selective head cooling with mild 
systemic hypothermia, meta-analysis showed that the risk ratio (RR) for mortality was 
0.83 (95% CI 0.59 to 1.16),151-154 compared to four trials that performed whole body 
cooling (RR 0.66, 95% CI 0.47 to 0.93).155-158 For the outcome of major 
neurodevelopmental disability, three studies were included in the meta-analysis. The 
relative risk for this outcome was 0.73 (95% CI 0.53 to 0.99).151;153;156 Of these, one 
study used a pH threshold of ≤ 7.09,151 and the others used <7.00 as one of the 
inclusion criteria. The overall conclusion of the review was that cooling reduces 
mortality without increasing major disability in survivors, with the benefits outweighing 
short-term adverse effects. However, it was known that further trials were ongoing 
when the review was published, and it was felt that clarification regarding the best 
 136 
 
method of administering hypothermia (selective head cooling versus mild systemic 
hypothermia), were required before recommending the treatment for clinical practice. 
8.2.2 The TOBY trial (Whole body hypothermia for the treatment of perinatal 
asphyxial encephalopathy) 
The TOBY trial, published in 2009, randomised infants who were at least 36 weeks 
gestation, less than six hours of age, with evidence of asphyxia defined as an Apgar 
score of 5 or less at 10 minutes of age, or umbilical cord, arterial or capillary pH of 
<7.00 or base deficit of ≤ 16mmol/L within 60 minutes of birth. Included infants had to 
have moderate- to-severe encephalopathy and abnormal background activity of at 
least 30 minutes duration or seizures on amplitude integrated 
electroencephalography (aEEG). Infants with congenital anomalies requiring surgery, 
or chromosomal anomalies involving brain dysgenesis, were excluded.159 This was 
the largest randomised controlled trial to date of hypothermia for perinatal 
encephalopathy.  Infants assigned to the treatment arm had hypothermia maintained 
by a cooling blanket, with a target rectal temperature of 33-34◦C. The period of 
cooling was for 72 hours after randomisation. Temperature was then returned to 
normal in a controlled fashion, and neonates were monitored with daily cranial 
ultrasound scans for the first four days, and magnetic resonance imaging (MRI) 
within 5-14 days of birth. Infants were followed up until 18 months of age, at which 
point they underwent a structured neurologic examination, and the presence and 
type of cerebral palsy determined. The Bayley scales of Infant Development II (BSID-
II) were also applied, and adverse outcomes prior to this point recorded. The main 
findings were that infants who were cooled and survived had a reduced risk of 
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cerebral palsy (RR 0.67, 95% CI 0.47 to 0.96), and improved scores of the Mental 
and Psychomotor development Index of the BSID-II.  
Following the publication of this trial, neonatal hypothermia for the treatment of 
hypoxic-ischaemic encephalopathy has become widespread in UK practice; the 
criteria most commonly used to determine treatment, and the type and duration of 
cooling are those used in the TOBY protocol as described above.58 
8.2.3 Meta-analysis of Randomised Controlled Trials 2010 
Following publication of the TOBY trial results, a meta-analysis160 was published 
comprising three trials, with data on neurological outcomes up to at least 18 months 
of age, and similar entry criteria.153;156;159 A total of 767 infants were included of which 
518 survived: fixed effects meta-analysis demonstrated a reduced risk of cerebral 
palsy in survivors (RR 0.69, 95% CI 0.54 to 0.89). The authors felt that the results 
strongly supported the use of therapeutic hypothermia in neonates with hypoxic 
ischaemic encephalopathy, and that any remaining ongoing studies would have to 
show very large adverse effects to change the results, given that the current studies 
are homogeneous in their findings favouring treatment. 
8.2.4 Neo.nEURO.Network RCT 2010 
A further randomised controlled trial, conducted in central Europe, allocated infants to 
systemic hypothermia based on the same entry criteria as the TOBY trial. In addition 
to systemic hypothermia for 72 hours, they also administered 0.1mg/kg of morphine 
to all participants every four hours, with the rationale of reducing discomfort 
attributable to encephalopathy and counteracting the stress response induced by 
hypothermia.161 129 neonates were included, recruitment was stopped early due to 
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ethical concerns about withholding treatment in the control group. The results 
favoured treatment when the composite adverse outcome of death or severe 
disability (OR 0.21, 95% CI 0.09 to 0.54) was considered, and for cerebral palsy in 
survivors (OR 0.15, 95% CI 0.04 to 0.60). The apparent greater magnitude of effect 
seen in this study was thought by the authors to be potentially due to the smaller 
sample size in this study, or the possible added benefit of administering opioids in 
addition to hypothermia. 
8.2.5 ICE (Infant Cooling Evaluation) trial 
This randomised controlled trial was conducted in neonatal intensive care units in 
Australia, New Zealand, Canada and the United States and published in 2011.162 
Neonates of 35 weeks gestation or more with moderate or severe encephalopathy 
defined according to modified Sarnat criteria, and evidence of peripartum hypoxia-
ischaemia (at least two of: Apgar score of 5 or less at 10 minutes, continued need for 
mechanical ventilation at 10 minutes, and/ or metabolic acidosis defined as pH <7.00 
or base deficit of ≥ 12mmol/L within 60 minutes of birth) were included. Cooling was 
administered via refrigerated gel packs applied across the chest and/ or under the 
head and shoulders, to maintain the core temperature at 33-34◦C. 221 infants were 
randomised. There was a statistically significant difference in the primary outcome of 
death or major disability (RR 0.77, 95% CI 0.62 to 0.98).  There was no significant 
difference in rates of cerebral palsy at 2 years of age (RR 0.92, 95% CI 0.54 to 1.59). 
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8.2.6 Cost-effectiveness of therapeutic hypothermia to treat neonatal 
encephalopathy 
Regier et al163 published a cost-effectiveness analysis based on the effectiveness 
data of the three trials included in the meta-analysis summarised in section 8.2.3.160 
The cost data was obtained from the TOBY trial, as this was the only source of 
prospectively collected resource utilisation data for encephalopathic infants.159 A 
decision-analytic model based analysis from the perspective of the NHS and 
personal social services was performed, and incremental effectiveness was 
estimated in terms of disability free life years (DFLY) gained. The time horizon was 
the first 18 months after birth. 
The incremental cost per DFLY gained was £19,931. The baseline cost effectiveness 
acceptability curve showed that if the willingness to pay threshold is £30,000, there is 
a 69% probability that cooling is cost-effective, although this increased when the 
number of infants was increased to reflect the national incidence of encephalopathy, 
as per the UK Cooling Register, or the time horizon was lengthened.  
8.3 Mechanisms of neuroprotection 
A number of mechanisms by which hypothermia may improve outcome after hypoxic 
ischaemic insult have been suggested, and summarised by Drury et al.145 The 
cerebral metabolism is reduced by hypothermia, delaying the onset of anoxic cell 
depolarisation, and cooling during the reperfusion phase may reduce free radicals 
and lipid peroxidation. This supports the use of passive cooling during the period of 
assessment before a decision for active cooling is made, but does not account for the 
protective effects of delayed, post insult cooling. A period of secondary 
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hypoperfusion in the latent phase following a cerebral insult has been noted. This 
was initially thought to be an adverse outcome, however evidence suggests that this 
effect is mediated by suppressed cerebral metabolism, and is associated with 
increased tissue oxygen levels. Prolonging the phase of secondary hypoperfusion 
through hypothermia has been shown in animal studies to improve neural outcome. 
 Hypothermia may additionally have a particular role in suppressing post-ischaemic 
cell death, through suppression of the Caspase pathway, a crucial component in 
apoptosis. Sheep studies have demonstrated suppression of activated Caspase-3 in 
association with hypothermic survival. Additionally, cooling potentially suppresses 
multiple aspects of the inflammatory cascade, which in non-cooled cases increases 
release of cytokines and interleukins, which may exacerbate injury through direct 
neurotoxicity and induction of apoptosis. It is likely to be the intracytoplasmic effects 
that are critical to protection.145 
8.4 Potential side-effects of therapeutic hypothermia 
Side effects include arrhythmias, most commonly sinus bradycardia. This represents 
a normal physiological response to hypothermia, however infants need to be 
monitored closely for hypoperfusion: the hypothermia in combination with 
cardiovascular effects resulting from the hypoxic insult may lead to the need for 
volume resuscitation and inotropic support.144 Minor respiratory and cardiovascular 
effects were frequently observed in the TOBY trial.159  Within the Cochrane review, 
there was a significantly higher risk of sinus bradycardia in the treatment groups of 
included studies (RR 5.96, 95% CI 2.15 to 16.49).150 Coagulopathy is another 
potential side effect of hypothermia; this should be monitored during treatment and 
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blood products administered as necessary.144 There was no significant difference 
between the treatment and control groups for this outcome in the Cochrane meta-
analysis.150 Fat necrosis is a rare side effect but infants should be closely monitored 
for skin changes suggestive of this, and their position changed regularly while cooling 
is underway.144 No significant differences in severe adverse outcomes between the 
cooling and the standard care arms were reported in the largest randomised 
controlled trials.153;156;159;161;162 
8.5 Summary 
In summary, neonatal hypothermia appears to reduce neurodevelopmental disability 
in survivors of neonatal hypoxic-ischaemic encephalopathy, and is likely to be cost-
effective. It has now become an established treatment within UK practice. However, 
some concerns exist that there is a potential for bias in the published trials, given that 
the nature of the treatment blinding is impossible, and that a clinician’s decision to 
withdraw treatment to a neonate may be influenced by awareness of the treatment 
allocation and trial participation.164 In order to monitor the ongoing effects of 
therapeutic hypothermia, within the UK all infants who undergo this treatment should 
be added to the TOBY Cooling Register.165 
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CHAPTER 9: ASSESSING THE IMPACT ON 
THE COST-EFFECTIVENESS OF 
NEONATAL HYPOTHERMIA OF VARYING 
THE THRESHOLD OF CORD PH FOR 
TREATMENT. A DECISION- ANALYTIC 
MODEL BASED ANALYSIS 
 
9.1 Abstract 
9.1.1 Background 
Neonatal therapeutic hypothermia has been shown to be a cost-effective treatment in 
reducing the risk of cerebral palsy in infants with hypoxic ischaemic encephalopathy. 
A low umbilical cord pH at birth is one of the criteria used to define eligibility for this 
treatment. However, the threshold used to define a low pH is based on consensus 
statement rather than high quality evidence. The purpose of this analysis was to 
investigate the economic impact of varying the threshold of umbilical cord pH used to 
determine the need for neonatal cooling.  
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9.1.2 Methods 
A decision-analytic model based cost-effectiveness analysis, based on data from 
systematic reviews. The analysis was performed from the UK NHS perspective and 
the main outcome was cost per case of cerebral palsy avoided. 
9.1.3 Results 
Using a cord pH threshold of <7.00 in combination with neonatal cooling dominated 
the higher threshold of <7.10. The incremental cost effectiveness ratio (ICER) for a 
cord pH threshold of <7.00 in combination with neonatal cooling in comparison to no 
test or treatment was £18733459 per case of cerebral palsy avoided. Sensitivity 
analyses varying the cerebral palsy prevalence rate, accuracy of cord pH testing and 
costs reduced the ICER but did not change the overall result. 
9.1.4 Conclusion 
When compared to a higher threshold of <7.10, the current cord pH threshold of 
<7.00 as one of the factors to indicate a neonate should receive therapeutic 
hypothermia is more effective and less costly and therefore the dominant strategy. 
Further research is needed to determine the cost-effectiveness of cord pH as a test 
in the general neonatal population. 
9.2 Introduction 
Cerebral palsy is a disorder affecting voluntary movement and posture, and is the 
commonest cause of motor impairment and significant physical disability in 
childhood.2 Therapeutic neonatal hypothermia, as described in section 8.2.2, has 
been shown to improve neurologic outcomes in survivors of perinatal asphyxia, 
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compared to standard care.159 An economic evaluation (Section 8.2.6) showed that 
cooling was likely to be cost effective.163  
Neonatal cooling is now widely used within the UK to reduce the incidence of 
adverse outcome after a hypoxic insult. The eligibility criteria for treatment most 
commonly employed are those for the TOBY trial inclusion criteria, as described in 
section 8.2.2.58;159  
Umbilical cord pH at birth is a measure of hypoxia, and a low cord pH has been 
associated with cerebral palsy. However, the threshold of 7.00 has been defined by 
consensus statement rather than clinical evidence, and the optimal cut-off for a low 
pH in predicting adverse outcome remains uncertain.71 The systematic review 
reported in Chapter 5 collated primary studies, defining a low arterial pH at a variety 
of thresholds (7.00-7.20) and established a prognostic association for cerebral palsy. 
However, the data was insufficient to determine the pH threshold which should be 
used in clinical practice.166 
This chapter reports the results of a model based cost-effectiveness analysis, which 
uses evidence from systematic reviews166 (Chapter 5) on test accuracy of umbilical 
artery pH, and effectiveness150 (meta-analysis reported in section 8.2.2) from the 
perspective of the NHS in the UK, to assess the impact of varying the pH threshold 
used to define eligibility for neonatal cooling. The primary outcome is based on the 
additional cost per case of cerebral palsy avoided.  
 
 
 145 
 
9.3 Methods 
9.3.1 Model structure 
A decision tree model was used to perform an economic evaluation comparing 
different test- treatment strategies. A decision tree was felt to be the most appropriate 
model type for this analysis due to the short term nature of the decision problem:167 
cerebral palsy is a chronic condition, without possibility of cure, and the treatment is a 
single course, performed within 6 hours of delivery,58 without scope for change in 
effectiveness over time. The tree was constructed in Data Treeage Pro 2012.168  
The evaluation performed was a cost-effectiveness analysis based on the cost per 
case of cerebral palsy avoided. The analysis was performed from a UK health 
provider perspective, both community and hospital based costs were considered. A 
time horizon of 18 months was utilised on pragmatic grounds, based on the 
availability of cost data for this period.163 Analyses from a societal perspective, which 
might attempt to include private costs to the individual, were considered beyond the 
scope of this evaluation, although it is acknowledged that the nature of the condition 
is likely to carry lifelong additional costs at an individual, health care and societal 
level.  
Five different treatment strategies were compared: 
1. No umbilical cord pH or cooling performed (‘no test/ no treatment’) 
2.  Umbilical cord pH performed (threshold considered positive <7.00), no 
treatment regardless of result. (‘cord pH <7.00/no treatment’) 
3. Umbilical cord pH performed (threshold considered positive <7.00), neonatal 
cooling if positive. (‘cord pH <7.00/neonatal cooling_positive’) 
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4. Umbilical cord pH performed (threshold considered positive <7.10), no 
treatment regardless of result. (‘cord pH <7.10/no treatment’)  
5. Umbilical cord pH performed (threshold considered positive <7.10), neonatal 
cooling if positive. (‘cord pH <7.10/neonatal cooling_positive’) 
A subsection of the tree is presented in Figure 9.1. This shows branches 1-3. The 
other branches are analogous. In the figure, each branch to the right of the chance 
node (round symbol) indicates a possible outcome. The formula given beneath the 
branch (and in the box to the left of the root node (square symbol)) indicates how the 
probability of each outcome is calculated: for example when a test/ treatment 
combination is used, this considers the positive or negative predictive value of the 
test and the relative risk of the treatment for cerebral palsy. The terminal node 
(triangle symbol) indicates the end of the pathway and whether the condition is 
present or absent. The formula for calculating costs accrued through the test, 
treatment and the cost of the condition are given following the terminal node. The 
model inputs are described subsequently. 
Pathway 1 (no test/ no treatment) is the comparator for pathways 2-5. Pathway 3 
((‘cord pH <7.00/neonatal cooling_positive’) represents current clinical practice; the 
threshold of <7.00 to define acidosis and therefore a significant hypoxic insult is the 
most commonly accepted. Pathway 4 and 5 represent comparisons with using a 
threshold of <7.10 to define acidosis to determine the impact on cost-effectiveness of 
this alternative threshold. Testing of other thresholds was not possible due to a lack 
of accuracy or effectiveness data or both. 
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9.3.2 Model inputs 
Accuracy data 
Full details of the systematic review to evaluate the association of umbilical cord pH 
with cerebral palsy are reported elsewhere (Chapter 5). A total of 51 articles were 
selected for final inclusion in the review, including seven which had data allowing the 
generation of 2 x 2 tables (true positive, false positive, false negative, true negative) 
for a low umbilical cord pH and cerebral palsy. All of these studies had a population 
solely consisting of pre-term infants. 
For the purposes of this analysis, the searches were updated to October 2011 (the 
search strategy is given in Appendix 7). However no further studies with data relating 
umbilical cord pH and cerebral palsy were identified. There were no studies reporting 
the use of pH in combination with the Apgar score or HIE to predict cerebral palsy. Of 
the seven studies presented in the original review, two used a threshold of cord pH 
<7.00 (Socol et al 1994, Ingemarrson et al 1997) and two a threshold of <7.10 
(Beeby et al 1994, Murphy et al 1995) 2 x 2 data from these four studies were re-
analysed to calculate sensitivity, specificity and positive and negative likelihood ratios 
of umbilical arterial cord pH at birth to predict cerebral palsy. There was insufficient 
data to analyse other thresholds. Random effects meta-analysis was performed for 
each threshold (7.00 and 7.10); the data are presented in Table 9.1. Analyses were 
performed using Meta-Disc.105 The pooled sensitivity and specificity results for each 
threshold were used, and converted to positive and negative predictive values within 
the model using the following formulae: Positive predictive value (PPV)= (sensitivity x 
prevalence)/((sensitivity x prevalence)+((1- specificity)x(1-prevalence))); Negative 
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predictive value (NPV)= (specificity x(1-prevalence))/(((1-sensitivity)x 
prevalence)+(specificity x(1-prevalence))). 
Effectiveness data 
A Cochrane review of the effectiveness of cooling for neonates with hypoxic 
ischaemic encephalopathy was identified, and the findings reported in section 
8.2.1.150 A subsequent meta-analysis published by Edwards et al (summarised in 
section 8.2.3) gives effectiveness data on the rate of cerebral palsy following 
neonatal hypothermia of the three trials using pH <7.00, with follow up to 18 months 
of age.160 Data from this analysis regarding the relative risk and 95 % confidence 
intervals of cerebral palsy in survivors following hypothermia were included in the 
model; this data is reproduced in Table 9.2. The data from the two trials published 
following this meta-analysis (summarised in sections 8.2.4 and 8.2.5) were not 
included due to differences between the protocols used for treatment and UK 
practice.161;162 Data regarding the relative risk of major neurodisability following 
hypothermia in the single trial using a threshold of pH <7.10151 are also presented in 
Table 9.2, reproduced from the Cochrane review.150 The primary study was obtained, 
but as unpublished data were provided to the Cochrane reviewers this data was felt 
to be the most complete and accurate.  
Prevalence 
A search of Medline and EMBASE was performed using the search terms 
‘prevalence’ and ‘cerebral palsy’. A paper estimating the 2007 rate of newly 
diagnosed cases based on Surveillance of Cerebral Palsy in Europe (SCPE)169 and 
Office of National Statistics (ONS) data regarding the prevalence and live birth rate 
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was identified, and felt to contain the most recent and relevant data.2 A prevalence 
rate of 2 to 2.5 per 1000 live births was quoted. The lower estimate of 2 per 1000 
was included for the base case analysis. 
Costs 
A search of Medline, EMBASE, the Cochrane Library and Web of Science was 
performed in October 2011. A combination of MeSH headings and keywords 
including ‘cerebral palsy’, ‘cost- benefit analysis’, and ‘neonatal cooling’ were used. 
The search strategy is given in Appendix 17. Only one existing UK based economic 
evaluation of the cost-effectiveness of therapeutic hypothermia was identified, the 
findings are summarised in section 8.2.6.163  
The data presented in this paper represent the most recent and accurate data 
regarding the cost of neonatal hypothermia and the associated course. No alternative 
estimates of the cost of cerebral palsy was identified, therefore the data presented in 
this paper was used for this as well.163 For the purposes of this model, the costs 
reported for the non-cooled group until 12 months of age were used for all infants in 
the non-treatment arms who had a low umbilical cord pH at either threshold. The cost 
for neurodevelopmental delay in the non-cooled group (from 12-18 months) was 
added for those who subsequently developed cerebral palsy. The same cost was 
used in the ‘no test, no treatment’ arm. In those who did not develop cerebral palsy, 
the costs for the non-cooled group without developmental delay (12-18months) were 
used. In the branches where those who had a low pH were treated with therapeutic 
hypothermia, the costs related to those undergoing treatment in the TOBY trial were 
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used. This allowed a timescale for the model and associated costs of 18 months. 
Details of all these costs are presented in Table 9.3. 
All infants entering the TOBY trial had evidence of a hypoxic ischaemic insult, 
including a cord pH <7.00. As this model also includes neonates who had a normal 
pH at birth, and did not suffer hypoxia, the health care costs until 18 months of age of 
a neonate without hypoxic ischaemic encephalopathy, representing the general 
population, were also defined. No single cost defining this was identified from the 
literature, and therefore a variety of sources were used. The summary costs entered 
into the model are given in Table 9.3. The full calculations for costs of a non-
encephalopathic infant are presented in Appendix 18, and summarised below. 
At delivery, a healthy baby does not incur costs for delivery events separately from 
the mother.170 Centre for Health Economics data estimate that, of the activity within 
obstetric departments, 0.1 % of obstetric patients would have a neonate with multiple 
minor diagnoses, and 0.7% would have a neonate with one minor diagnosis.171 When 
restricted to delivery events only, this translated to 0.2% and 1.4% respectively. 
These were multiplied by the reported Healthcare Resource Group (HRG) costs, 
given in the same paper, to obtain a neonatal inpatient cost for the average obstetric 
delivery.171  
According to Office of National Statistics (ONS) data for 2007/2008, the hospital 
admission rate in the 0-5 year age group was 128.9 per 1000.172 This was used to 
calculate the likelihood of an admission for an individual during the first 18 months of 
life and multiplied by the cost of a bed day163. The frequency of GP consultations in 
the 0-4 month age group in 2008/2009 were identified from the literature.173 These 
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were multiplied by reported costs of a 10 minute consultation.174 The cost of child 
health surveillance to age 18 months was also obtained.175 It was assumed that the 
average child would visit the practice nurse on four occasions for immunisations and 
these costs were included.174  
The cost of the umbilical cord blood analysis for pH was obtained from Nottingham 
University Hospitals NHS trust. This was added to the cost of 10 minutes of midwifery 
time to perform the test.174 All costs, where otherwise reported, were inflated to 
2010/2011 costs using recommended methods.174 
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Figure 9.1 Diagram showing pathways 1-3 of the decision tree 
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Table 9.1 Summary of the accuracy of umbilical arterial cord pH to predict 
cerebral palsy 
Study Cord pH 
threshold 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
Likelihood 
ratio (95% 
CI) 
Negative 
Likelihood 
ratio (95% 
CI) 
Ingemarrson 
et al 1997 
7.00 0 (0-0.84) 0.70 (0.63-
0.76) 
0.55 (0.04-
6.90) 
1.20 (0.72-
2.01) 
Socol 1994 7.00 0.83 (0.34-
0.97) 
0.50 (0.12-
0.88) 
1.67 (0.69-
4.00) 
0.33 (0.05-
2.37) 
Meta-
analysis (2 
studies) 
7.00 0.63 (0.25-
0.92) 
0.69 (0.62-
0.75) 
1.48 (0.65- 
3.38) 
0.77 (0.16- 
3.83) 
Beeby et al 
1994 
7.10 0.05 (0.001-
0.25) 
0.93 (0.89-
0.96) 
0.73 (0.10-
5.26) 
1.02 (0.92-
1.13) 
Murphy et al 
1995 
7.10 0.25 (0.10-
0.47) 
0.88 (0.81 -
0.93) 
2.00 (0.87-
4.59) 
0.86 (0.67-
1.09) 
Meta-
analysis (2 
studies) 
7.10 0.16 (0.07-
0.30) 
0.91 (0.88-
0.94) 
1.72 (0.80-
3.70) 
0.95 (0.77-
1.19) 
 
Table 9.2 Summary of the effectiveness of neonatal therapeutic hypothermia 
versus standard care on neurodevelopmental outcome in survivors 
Outcome Number 
of 
primary 
studies 
Source Cord pH 
threshold for 
intervention 
Relative risk 
(95 % CI) 
Cerebral palsy in 
survivors 
3 Edwards et 
al meta-
analysis160 
<7.00 0.69 (0.54 to 
0.89) 
Major 
neurodevelopmental 
disability in 
survivors 
1 Cochrane 
review150 
≤ 7.09 2.67 (0.35-
20.51) 
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Table 9.3 Summary NHS costs per patient for tests, intervention and outcome 
Cost Item Cost (UK£ 2010/2011) 
(95% CI)a 
Source 
Test 
Umbilical cord pH (midwife 
to perform test (10mins) 
and run on point of care 
analyser) 
18.59 1. Nottingham University 
Hospitals NHS Trust 
2. Curtisb 
 
Treatment cost  
Cost of cooling per infant 
including equipment and 
aEEG 
6539 (1488-15806) Regier et alc 
Inpatient costs per cooled 
infant (survivors) 
13747 (11416-16323) Regier et alc 
Transfer costs per cooled 
survivor 
162 (136-193) Regier et alc 
Costs of hospital 
readmission per cooled 
survivor 
1200 (694-1835) Regier et alc 
Community care costs to 6 
months of age per cooled 
survivor 
753 (614-902) Regier et alc 
Community care costs 6-
12 months of age per 
cooled survivor 
486 (336-1769) Regier et alc 
Inpatient costs per 
surviving encephalopathic 
infant (non-cooled) 
14064 (11661-16664) Regier et alc 
Transfer costs per 
encephalopathic survivor 
(non-cooled) 
159 (131-190) Regier et alc 
Cost of hospital 
readmission per 
encephalopathic infant 
(non-cooled) 
2,649 (1260-4434) Regier et alc 
Community costs to 6 
months of age per 
encephalopathic infant 
(non-cooled) 
789 (610-991) Regier et alc 
Community costs 6-12 
months of age per 
encephalopathic infant 
(non-cooled) 
756 (482-1098) Regier et alc 
Community costs per non-
encephalopathic infant to 
18 months of age 
440 1.Hippisley-Cox et ald 
2.Curtisb  
3.Sanderson et ale 
Hospital costs per non- 120.82 1. Laudicella et alf 
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encephalopathic infant to 
18 months of age 
2. Regier et alg 
3. ONS datah 
Inpatient costs per case of 
cerebral palsy 12-18 
months of age (cooled 
encephalopathic infants) 
1744 (670-3309) Regier et alc 
Community costs per case 
of cerebral palsy 12-18 
months of age (cooled 
encephalopathic infants) 
373 (197-611) Regier et alc 
Inpatient costs per 
encephalopathic infant 
without cerebral palsy 12-
18months of age(cooled) 
137 (46-281) Regier et alc 
Community costs per 
encephalopathic infant 
without cerebral palsy (12-
18 months of age (cooled) 
236 (125-385) Regier et alc 
Inpatient costs per case of 
cerebral palsy 12-18 
months of age (non-cooled 
encephalopathic infants) 
1221 (411-2484) Regier et alc 
Community costs per case 
of cerebral palsy 12-18 
months of age (non-cooled 
encephalopathic infants) 
507 (287-783) Regier et alc 
Inpatient costs per 
encephalopathic infant 
without cerebral palsy 12-
18months of age(non-
cooled) 
143 (32-338) Regier et alc 
Community costs per 
encephalopathic infant 
without cerebral palsy (12-
18 months of age (non-
cooled) 
236 (125-385) Regier et alc 
a. All costs inflated to common price year of 2010/2011 as per payment and 
prices index.150;174 
b. Cost of midwife, GP and practice nurse patient contact time.174  
c. Costs are mean costs per cooled and non-cooled infant in the TOBY trial163 
d. Average number of GP visits per year in the 0-4 year age group173 
e. Cost of routine child health surveillance to 18 months (3 visits)175 
f. Number and HRG cost of minor neonatal illnesses associated with delivery 
in obstetric unit171 
g. Cost of a hospital readmission163 
h. Average number of hospital admissions per year in 0-5 year age group172
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9.3.3 Analysis 
The main outcome of the model was cost per case of cerebral palsy avoided. The 
base case analysis was deterministic, in which the point estimates for test accuracy 
and treatment effectiveness were used to compare the cost effectiveness of the 
different pathways described above. Incremental cost effectiveness ratios (ICER) of 
the different strategies were calculated, and the results presented in a cost-
effectiveness plane.  
Deterministic sensitivity analysis 1: As the cost of a non-encephalopathic baby 
was estimated rather than obtained from an existing source, a sensitivity analysis 
was performed where this cost was doubled, and multiplied by 10, and 100, to 
assess the impact on the results of the true cost being higher than estimated.  
Deterministic sensitivity analysis 2: The prevalence of cerebral palsy was 
increased to 2.5 per 1000 as this was the higher estimate obtained from the 
literature. 
Deterministic sensitivity analysis 3: A sensitivity analysis was performed to 
determine if improving the accuracy of the cord pH test would change the relative 
cost effectiveness of the strategies examined. The sensitivity and specificity of cord 
pH <7.00 to predict cerebral palsy were increased. It was recognised that in reality 
sensitivity and specificity are related and there is a trade-off in that when sensitivity is 
increased, specificity is reduced. However, the purpose of this analysis was to 
explore the effect of a more accurate test overall, and therefore arbitrary figures of 
higher sensitivity were selected, without altering the specificity accordingly. 
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Probabilistic sensitivity analysis (PSA): The purpose of this analysis was to reflect 
the uncertainty surrounding the input parameters into the decision model, and 
examine the influence of uncertainty on the cost-effectiveness analysis. In order to 
perform this analysis, each of the model inputs (sensitivity, specificity, relative risks 
and, where 95% confidence intervals available, costs) were assigned a distribution. 
For the prevalence, a beta (β) distribution was used, with the parameters α = number 
of events of interest and β= total population- events of interest.176 A β distribution was 
also used for sensitivity and specificity. In order to calculate α,β, an Excel 
spreadsheet was used to compare actual mean values, lower and upper 95% 
confidence intervals with fitted values to obtain the ‘best fit’ distribution. For relative 
risks, a log normal distribution was used, through taking the natural logs of the point 
estimate and 95% confidence intervals and using the following formula to calculate 
the estimate of log scale standard error:176 
SE [ln (RR)]= ln (upper 95% confidence interval)- ln (lower 95% confidence interval) 
      2 x 1.96 
The log value of the point estimate and the SE[ln (RR)] were then used to define the 
distribution. For costs, a gamma distribution was assigned, again using an Excel 
spreadsheet to obtain α and λ values according to the best fit as described above. A 
definition of the variables and distributions used in the Treeage model are given in 
Appendix 19. 
A Monte Carlo simulation with 10000 iterations was then performed to assess the 
effect of the uncertainty around parameters on the likely cost-effectiveness of any 
given test- treatment pairing. 
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9.4 Results  
Base case: The results of the deterministic cost- effectiveness analysis are 
presented in Table 9.4. ‘No test, no treatment’ dominated all strategies except ‘cord 
pH <7.00, cooling test positive’. The ICER for this strategy was £18733459 per case 
of cerebral palsy avoided. When ‘no test, no treatment’ was removed from the model, 
‘cord pH <7.00, cooling test positive’ dominated the other strategies.  The results are 
presented graphically on the cost-effectiveness plane in Figure 9.2. The nearer a 
strategy is to the bottom right corner of the graph, the greater the effectiveness, and 
cheaper the cost. A strategy will dominate others if it is both cheaper and more 
effective.  
Deterministic sensitivity analysis 1: Table 9.5 gives the results of the deterministic 
analysis when the estimated costs of hospital and community care for a non-
encephalopathic baby to age 18 months are increased. The ICER for ‘cord pH <7.00/ 
neonatal cooling positive’ is reduced with the increasing cost of a ‘well’ baby, but 
remains large even when the estimated cost is multiplied by 100 from the base case. 
All other strategies remained dominated. 
Deterministic sensitivity analysis 2: A further sensitivity analysis was performed 
where the prevalence of cerebral palsy was increased to 2.5 per 1000, the higher 
figure quoted in the literature. This resulted in a reduction in the ICER for ‘cord pH 
<7.00, neonatal cooling positive’ to £14982150 per case of cerebral palsy avoided 
but did not alter the overall results. 
Deterministic sensitivity analysis 3: Cord pH <7.00 does not have high accuracy 
to predict cerebral palsy, with the pooled sensitivity and specificity included in the 
 159 
 
base case analysis being 0.63 and 0.69 respectively. Increasing the sensitivity of 
cord pH was to 0.80 led to both ‘cord pH <7.00, no treatment’ and ‘cord pH <7.10, no 
treatment’ being no longer dominated, and a reduction in the ICER for ‘cord pH 
<7.00, neonatal cooling positive’ to £2978551.32 per case of cerebral palsy avoided. 
However, increasing the sensitivity further to 0.9 led to a higher ICER of £13014159. 
PSA: The results are presented in Figure 9.3 as a ‘cost-effectiveness acceptability 
curve’ (CEAC), which illustrates the probability that a given strategy is cost-effective 
according to the ‘willingness to pay’ threshold.  It is not until a threshold of 
£25000000 that it becomes more likely that ‘cord pH <7.00, neonatal cooling positive’ 
is more cost-effective than ‘no test, no treatment’. At a threshold of £30000, the 
conventionally accepted cut-off of willingness to pay in the UK health service, there is 
a very low probability that neonatal cooling in combination with cord pH is cost 
effective.177
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Table 9.4 Base case analysis results, costs, effectiveness and ICER for test/ treatment combinations for all neonates 
Strategy 
Cost (£ 
2010/2011) 
Increment
al Cost Effectiveness 
Incremental  
Effectiveness 
ICERa(£ 2010
/2011) C/E 
 
       
 
Excluding dominated 
    
 
No test/ no treatment 599.99 
 
1 
  
601.19  
Cord pH <7.00/ neonatal 
cooling positive 7727.34 7127.35 1 0 18733459 7739.87 
 
All 
      
 
No test/ no treatment 599.99 0 1 0 0 601.19  
Cord pH <7.10/ no 
treatment 2220.1 1620.11 1 0 0 2224.55 
Domina
ted 
Cord pH < 7.10/ neonatal 
cooling positive 2796.27 2196.28 1 -0 -1926385 2805.08 
Domina
ted  
Cord pH <7.00/ no 
treatment 6278.49 5678.5 1 0 0 6291.07 
Domina
ted 
Cord pH <7.00/ neonatal 
cooling positive 7727.34 7127.35 1 0 18733459 7739.87 
 
       
 
All by Increasing effectiveness 
    
 
Cord pH < 7.10/ neonatal 
cooling positive 2796.27 
 
1 
  
2805.08 
 
No test/ no treatment 599.99 
 
1 
  
601.19  
Cord pH <7.00/ no 
treatment 6278.49 
 
1 
  
6291.07 
 
Cord pH <7.10/ no 
treatment 2220.1 
 
1 
  
2224.55 
 
Cord pH <7.00/ neonatal 
cooling positive 7727.34 
 
1 
  
7739.87 
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Figure 9.2 Base case results for cost-effectiveness analysis   
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Figure 9.3 Results of probabilistic sensitivity analysis. Probability that different strategies are cost-effective at 
different ‘willingness to pay’ thresholds 
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Table 9.5 Deterministic sensitivity analysis 1: Varying the cost of a care of a non-encephalopathic baby is varied from 
the base case cost of £ 560.82 
Strategy 
Cost (£ 
2010/2011) 
Incremental 
Cost Effectiveness 
Incremental  
Effectiveness 
ICER 
(2010/2011) C/E 
       Base cost  doubled (£1121.64) 
      No test/ no treatment 1159.69 
 
1 
  
1162.01 
Cord pH <7.00/ neonatal 
cooling_positive 8112.97 6953.28 1 0 18275945 8126.13 
Base cost x 10 (£5608.20) 
      No test/ no treatment 5637.27 
 
1
  
5648.57
Cord pH <7.00/ neonatal 
cooling_positive 11198.03 5560.75 1 0 14615833 11216.19 
Base cost x 100 (£56,082) 
      Cord pH <7.00/ no treatment 44456.08
 
1 
  
44545.17
Cord pH <7.00/ neonatal 
cooling_positive 45904.92 1448.85 1 0 3808136 45979.39 
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9.5 Discussion 
The main finding is that in all analyses using a cord pH threshold of <7.00 and 
treating those who were test positive with neonatal cooling dominated the 
strategy of using a cord pH threshold of < 7.10 to determine treatment. The 
results support current clinical practice, where a threshold of <7.00 is used in 
conjunction with other criteria to identify neonates to undergo neonatal 
therapeutic hypothermia, and suggest that raising the threshold of pH used 
would be a less effective (in terms of cases of cerebral palsy avoided) and more 
costly strategy. 
Strengths of the economic evaluation 
The strengths of this evaluation lie in the methodology used. The author 
received training in decision-analytic modelling and advice from experts in 
health economic evaluation (Professor Tracy Roberts) and regarding the clinical 
assumptions (Dr Helen Budge, Dr Andy Ewer, Dr Katie Morris). The data used 
to inform the model were based upon high quality systematic reviews with 
recently updated searches and was felt to be as complete as possible. A 
thorough literature search was performed to obtain the most recent cost data, 
and where none were available to calculate the cost in a thorough manner 
considering all major community and hospital factors.  
Limitations of the economic evaluation 
There are several limitations to the analysis. A number of assumptions had to 
be made due to the availability of data and scope of the evaluation, which may 
have affected the results. These are set out in Table 9.6.
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Table 9.6 Limitations of the economic evaluation 
Area of evaluation Details of limitation Implications 
Accuracy data 
1.Quality of primary studies The studies on which the accuracy data was 
provided are small and of low quality 
The reliability of the accuracy data may be affected 
2. Population of primary 
studies 
The infants included in the primary studies were all 
preterm, and the population in which neonatal 
hypothermia is performed is greater than 36 weeks 
gestation 
The accuracy in this population may differ from that 
in the target population 
3. Accuracy data available 
for cord pH alone 
The criteria for a neonate to be treated with 
hypothermia are not based on the cord pH result 
alone, but also other evidence of a hypoxic 
ischaemic encephalopathy including low Apgar 
score, and abnormal neurological signs. No data 
were available for different combinations of these 
tests and signs so these were not included in the 
model 
The exclusion of other factors which would affect the 
decision to cool may be valid for a comparison 
between the strategies of treating at cord pH 
threshold <7.00 and <7.10 but this cannot be 
proven.  
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4. Differences in tests 
performed in clinical trials of 
treatment effectiveness 
The criteria for cooling are not only based on an 
umbilical cord pH at birth below the specified 
threshold, but also a pH sample from the baby’s 
arterial blood up to an hour after delivery. Accuracy 
data from the systematic reviews focused on cord 
pH only. 
The accuracy data from the systematic reviews 
regarding pH may differ from the entry criteria in the 
trials providing the effectiveness data. 
5. Only 2 thresholds of pH 
could be analysed 
There were only sufficient accuracy and 
effectiveness data available to explore a pH 
threshold of <7.00 and <7.10 
Other thresholds could not be compared to the 
current standard of pH <7.00 
Effectiveness data 
1.Quality of primary studies The three studies which used a pH threshold of 
<7.00 were well powered, high quality randomised 
controlled trials. The single study using a threshold 
of <7.10 was smaller and of lower quality 
The effectiveness data for a neonatal hypothermia 
at a pH threshold of <7.10 is likely to be a less 
reliable estimate 
2. Outcome defined in 
primary studies 
For the three studies with a threshold of <7.00, 
data was available regarding the specific outcome 
of cerebral palsy. However, for the study with a 
threshold of <7.10, the outcome was 
neurodevelopmental delay, which may include 
other diagnoses. 
The effectiveness data for the <7.10 study may 
differ from the diagnosis in question. However, for 
the other three studies (threshold <7.00) data on 
neurodevelopmental delay were also available and 
the effectiveness (relative risk) was similar to that of 
cerebral palsy so this assumption is likely to be valid 
Costs 
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1.Cost of cerebral palsy The only cost data available in the literature was 
obtained from a cost-effectiveness analysis run 
alongside a trial of neonatal cooling. The cost data 
specified was of neurodevelopmental delay to age 
18 months, diagnosed at age 12 months 
The costs of cerebral palsy were assumed to be the 
same for neurodevelopmental delay, but this may 
not be the case. 
2. Medicolegal costs are not 
included 
Cerebral palsy resulting from a hypoxic insult 
suffered during the perinatal period is a significant 
source of medicolegal claims and may result in 
large sums being paid in compensation  
It was felt that trying to calculate the number and 
amount of successful medicolegal claims was 
beyond the scope of this analysis. The true cost of 
cerebral palsy including these is likely to be higher, 
reducing the ICER of a strategy including neonatal 
cooling. 
3. Cost of a non-
encephalopathic baby 
These costs were calculated from a variety of 
sources, based on data regarding the average 
number of GP visits and hospital admissions for 
the general population in the 0-5 age group. 
The data for the 0-18 month period, the time horizon 
of the model, may differ from this and the cost 
estimations may be inaccurate. However, this was 
addressed through sensitivity analysis by increasing 
the cost. 
Model structure and assumptions 
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1.Time horizon The time horizon in the model is 18 months. 
However, cerebral palsy is an incurable condition 
with implications for lifelong health.  
The costs of cerebral palsy with a longer time 
horizon are likely to be significantly higher and 
therefore it is likely that the true ICER of a strategy 
including neonatal hypothermia is much less than 
estimated in this model 
2. Babies who have a 
normal pH at birth assumed 
to be non-encephalopathic 
A ‘test negative’ baby with a normal pH at birth who 
did not develop cerebral palsy was assumed to be 
non-encephalopathic without any other specific 
health concerns. Babies who had a low pH were 
assumed to be encephalopathic and assigned a 
higher cost, however in reality cord pH is not a 
perfect test for encephalopathy and many babies 
with a low pH will be otherwise well, not requiring 
further intervention or special care, and conversely 
babies with a normal pH may have other problems 
Attempting to define the number of babies with a 
normal pH who had encephalopathy and those with 
a low pH who were normal and include this in the 
model was felt to be beyond the scope of this 
evaluation. However, this is a significant deviation 
from the clinical reality and therefore likely to affect 
the true ICER. 
  1
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3. Babies who did not go on 
to develop cerebral palsy in 
the ‘no test, no treatment’ 
strategy were assumed not 
to have had neonatal 
encephalopathy in the costs 
assigned 
Of the babies who have neonatal encephalopathy, 
only a small proportion develop cerebral palsy, and 
therefore the cost of those without cerebral palsy is 
likely to be higher as some will have had neonatal 
encephalopathy and required a higher level of 
hospital and community care than assigned in the 
model. 
Attempting to calculate the proportion of babies who 
did not have cerebral palsy but had neonatal 
encephalopathy or another significant diagnosis 
requiring extra care was felt to be beyond the scope 
of this evaluation, the main purpose of which was to 
compare the two thresholds of cord pH and neonatal 
cooling. Attempts were made to address this by 
increasing the cost assigned to a non-
encephalopathic infant in the sensitivity analysis. 
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Where possible, attempts were made to address these limitations. The 
systematic review searches for accuracy data were updated, however no further 
studies were obtained and no data were available relating to a population born 
at 36 weeks gestation or greater. Similarly, no data were identified relating to 
the combined accuracy of cord pH with other factors, such as Apgar score or 
neurological status in the prediction of cerebral palsy, and it was therefore felt 
that attempting to factor these into the model would be overly complex and rely 
on too many assumptions.    
The potential inaccuracy of the mean estimates of sensitivity, specificity and 
relative risks were recognised, however as these were the best available 
according to the current literature, probabilistic sensitivity analysis was 
performed, allowing sampling from distributions around the point estimate 
derived from the 95% confidence intervals to explore this uncertainty. This did 
not significantly affect the results. The differences in the population from which 
the accuracy data was derived may mean that the true accuracy in the target 
population is different, and the analysis where the estimated sensitivity was 
varied was performed to address this (deterministic sensitivity analysis 3). A 
higher sensitivity changed the magnitude of the results but did not affect the 
ranking according to cost effectiveness of the strategies examined.  
In this evaluation, a strategy of not performing a cord pH test or treating with 
hypothermia appeared more cost-effective than testing and treating those with a 
cord pH <7.00 with neonatal cooling to prevent cerebral palsy, with the ICERs in 
all analyses being large and well above current ‘willingness to pay’ thresholds in 
the setting of the UK health service. The sensitivity analyses performed show 
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that this may be partly explained by the cost assumptions made, as raising the 
cost of a non-encephalopathic baby reduced the ICER, and it is likely that the 
true cost of these infants is higher than estimated. However, none of the 
analyses brought the ICER down to £20000- £30000 or less, which is the typical 
threshold used to approve a treatment as cost-effective.177 
In comparison with the results of the analysis by Regier et al, they found that 
the incremental cost per disability free life year (DFLY) gained was £19931, with 
a 69% probability that cooling is cost effective at a willingness to pay threshold 
of £30000, also stating that neonatal hypothermia is likely to be cost-effective if 
a longer time horizon is considered.163 The differences in results compared to 
their analysis is likely to be due to the fact that in their analysis all infants 
included were encephalopathic, therefore providing a homogeneous population 
in which to compare the cooling treatment, and test results were not considered. 
Despite the limitations of this evaluation, the main finding, that a cord pH of 
threshold <7.00 is more appropriate than a threshold of < 7.10 as a criterion for 
performing neonatal hypothermia, is likely to be valid, as the assumptions apply 
to both branches of the model. Inferences regarding the actual cost 
effectiveness of this test treatment strategy cannot be made from this model, 
due to the fact that the ICER obtained is likely to be inaccurate as a result of the 
limitations described in table 9.6. Several important questions regarding cord 
pH testing remain, such as the use of other thresholds of pH; whether cord pH 
testing should be performed on all neonates at birth; and the implications of an 
abnormal test in combination with the presence or absence of other features 
such as a low Apgar score and abnormal neurological signs.  
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Recommendations for research 
A primary study such as a large cohort or population study whereby neonatal 
tests and observations are prospectively recorded, and long term follow up data 
obtained to obtain neurodevelopmental outcomes would provide the ideal 
dataset to examine the cost-effectiveness of performing neonatal tests, 
including cord pH. The outcome data of such a study could be used in 
conjunction with individual patient decision modelling to answer a number of 
outstanding questions, such as the optimum threshold and combination of 
neonatal tests, including neurological status, Apgar score and cord pH, to define 
the population in which neonatal cooling is most cost-effective. It could also be 
used to determine the cost-effectiveness of cord pH testing for all neonates, or 
whether the current strategy of just testing those believed to be at higher risk of 
a hypoxic episode is valid. Standardised reporting of smaller studies, including 
compliance with the STARD checklist, to facilitate IPD meta-analysis, may 
present a more feasible alternative to a single large study. 
9.6 Conclusion 
The conclusion of this health economic evaluation is that, when compared to a 
higher threshold of <7.10, the current cord pH threshold of <7.00 as one of the 
factors to indicate a neonate should receive therapeutic hypothermia is more 
effective and less costly than the alternative high threshold and therefore the 
dominant strategy. Further research is needed to determine the cost-
effectiveness of cord pH as a test in the general neonatal population. 
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CHAPTER 10: CONCLUSION 
 
10.1 Introduction 
This thesis evaluated the prognostic and predictive ability of neonatal tests for 
short and long term outcomes. It explored the effect of varying the threshold of 
umbilical cord pH on the cost-effectiveness of neonatal therapeutic 
hypothermia. The objectives were achieved in that it reports: 
1. Summary estimates for the prognostic association and, where possible, 
predictive ability of the following tests for adverse outcomes: umbilical 
cord pH and base excess at birth, all current standards for defining low 
birth weight, and the Apgar score. 
2. A decision-analytic model based evaluation comparing the use of 
umbilical cord pH at thresholds of 7.00 and 7.10 combined with neonatal 
therapeutic hypothermia for acidotic infants. 
Each of the previous chapters in this thesis includes a detailed discussion of the 
main findings and conclusions, considering any limitations. This chapter focuses 
on the main findings of the work and discusses general strengths and 
limitations, leading to recommendations for clinical practice and future research. 
10.2 Summary of main findings 
10.2.1 Summary of reviews of prognostic and predictive ability 
 In total, 2383 manuscripts were read in full. 218 papers were included, 
51 in the review of umbilical cord pH, 92 in the birth weight standards 
review and 87 in the Apgar score review. The total number of individuals 
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included per review were 479022 (cord pH and base excess), 3690080 
(Apgar) and 23051541 (birth weight standards). The majority of the 
included studies were of retrospective cohort design, and most were of 
high or moderate quality. 
 All of the neonatal tests assessed had a strong association with neonatal 
mortality, however even where the association was strong, the sensitivity 
and negative likelihood ratios were generally poor, indicating that a 
negative test does not change the odds of an adverse outcome. 
 The association between the tests and long term outcomes varied. 
10.2.2 Summary of decision-analytic modelling 
 When compared to a higher threshold of <7.10, the pH threshold of 
<7.00 used in current practice as one of the factors to indicate a neonate 
should receive therapeutic hypothermia is more effective and less costly 
and therefore the dominant strategy. Comparison with other thresholds 
was not possible due to a lack of accuracy and effectiveness data. 
10.3 Strengths of the thesis 
To the best of the author’s knowledge there have been no other systematic 
assessments of the prognostic and predictive ability of neonatal tests for short 
and long term adverse outcomes. The only other systematic review identified in 
this area considered the association of low umbilical cord pH and low Apgar 
score with neonatal mortality and cerebral palsy, but did not consider the 
predictive ability or address the effects of confounding factors as attempted in 
this thesis.77 No other reviews have compared different standards of low birth 
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weight and their association with adverse outcomes throughout the life course. 
It thus allows a very comprehensive evaluation of the knowledge to date, and 
with consideration of the strengths of limitations, recommendations for clinical 
practice and future research. 
10.4 Limitations of the thesis 
10.4.1 Reviews of prognostic and predictive ability 
The limitations in the systematic reviews were generally related to: 
 Reporting quality of the primary studies. In particular, poor reporting of 
the population characteristics, or failure to report results according to 
population subgroups, limited the analyses that could be done for 
different risk groups within a population, and therefore the extent to 
which the results can be extrapolated to clinical practice. 
 The review methods: the fact that the tests were assessed in isolation 
and that individual patient data meta-analysis was not performed. 
However, given the age of some of the included studies and the overall 
poor response from authors when asked to provide data, the potential to 
acquire sufficient data for IPD or to assess tests in combination may be 
limited at this time. 
It is felt however, that the robust methods used within the reviews addressed 
the limitations as far as possible, and that these reviews still represent the most 
up to date evidence synthesis for the tests investigated, and the use of 
advanced statistical techniques including the generation of prediction intervals 
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ensures the validity of the results including the likelihood of future studies in this 
area to generate similar point estimates. 
10.4.2 Decision- analytic modelling 
The limitations of the economic evaluation relate to both the model design and 
the primary data used to inform the model.  
The design of the model was limited by: 
 In order to avoid the model becoming over complex, and with the data 
available, many assumptions had to be made, including the fact that in 
practice other factors including the Apgar score and neurological signs 
and symptoms are taken into account in the decision to treat with 
hypothermia, and in the model the assumption was made that all other 
elements did not vary, and a baby with a normal pH was neurologically 
normal, which may not be the case in reality. 
 The time horizon was limited to 18 months, from the NHS perspective, 
where cerebral palsy is a life-long condition, with many costs from a 
societal or individual perspective that are not be accounted for within the 
scope of the model. 
The primary data was limited by: 
 Due to the available accuracy and effectiveness data, only two 
thresholds of umbilical cord pH could be assessed. 
 The population in which the accuracy data was obtained consisted of 
pre-term infants, whereas neonatal hypothermia is used in neonates of 
36 weeks gestation or greater. 
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These limitations affect the overall cost-effectiveness estimate of cooling, which 
in this model is well beyond thresholds that would be funded by UK governing 
bodies. However, as the limitations apply to both thresholds examined, the 
finding that a cord pH threshold of 7.00, as used in current practice, dominates 
the use of a higher threshold of 7.10, is valid. 
10.5 Recommendations for practice 
The reviews in this thesis have shown that umbilical cord pH at birth, low birth 
weight and a low Apgar score have significant associations with a variety of 
adverse outcomes and are therefore important tests to consider. However, 
given the fact that in most cases a negative test was not found to change the 
likelihood of an adverse outcome, and the inability to fully assess the 
performance of tests in population subgroups or compare multiple tests in the 
same population, there are many unanswered questions regarding their use 
and interpretation in clinical practice. The main recommendations of this thesis 
are thus for future research, to clarify these issues. 
10.6 Recommendations for research 
Measurement of birth weight and recording the Apgar score are tests that are 
routinely performed after delivery. Further research, either in the form of 
individual patient data meta-analysis, or a large cohort study with long term 
follow up, are necessary to determine which definition of low birth weight most 
accurately predicts adverse outcome. Absolute birth weight by any threshold 
appeared to be more strongly associated with neonatal mortality than any other 
measure, however the different standards need to be compared in the same 
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population, and birth weight assessed as a continuous measure, to identify the 
optimum standard and threshold that can be used. Important subgroups, 
including different ethnic origins and body mass index, could also be considered 
by either of these methods. Again, more detailed subgroup analysis is 
necessary to identify the threshold of Apgar score which can be used to predict 
adverse outcome.  
Umbilical cord pH at birth is not a test that is currently recommended for routine 
use. At present, targeted testing of infants deemed to be at high risk of asphyxia 
is performed. However, the findings of the systematic review performed in this 
thesis suggest that the associations with adverse outcome are stronger in an 
unrestricted population, suggesting that the cost effectiveness of performing the 
tests for all infants should be assessed. Additionally, further work assessing the 
pH as a continuous measure and assessing the result in combination with other 
tests or clinical findings are likely to improve the ability to predict adverse 
outcome through neonatal tests, facilitating counselling or targeting 
interventions.  
A large cohort study or individual patient data meta-analysis of existing cohorts, 
such as population registry data, are likely to be the most effective methods of 
addressing the outstanding questions raised by this thesis. Standardised 
reporting of future studies, with adherence to the STARD checklist, would 
facilitate meta-analysis and would be an alternative to a single large cohort. 
High quality primary data could then be combined with effectiveness data in 
individual patient decision analytic modelling to determine the cost-effectiveness 
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of different test treatment strategies, including combinations of tests, to inform 
NHS practice. 
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MEDLINE (Database inception – December 2006) 
# Search History Results Display 
1 exp Infant, Newborn/ 359997  
DISPLAY 
2 neonate.mp. 13149  
DISPLAY 
3 newborn.mp. 441692  
DISPLAY 
4 exp Birth Weight/ 24194  
DISPLAY 
5 exp ANTHROPOMETRY/ 63612  
DISPLAY 
6 exp Skinfold Thickness/ 4431  
DISPLAY 
7 anthropometry.mp. 21342  
DISPLAY 
8 birthweight.mp. 7539  
DISPLAY 
9 
birth weight.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
43797  
DISPLAY 
10 
(birth weight adj gestation$).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
1395  
DISPLAY 
11 
(birthweight adj gestation$).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
496  
DISPLAY 
12 
(birthweight adj ratio$).mp. [mp=title, original 
title, abstract, name of substance word, 
subject heading word] 
49  
DISPLAY 
13 
(birth weight adj ratio$).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
70  
DISPLAY 
14 
(customised adj birth weight).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
1  
DISPLAY 
15 (customised adj birthweight).mp. [mp=title, 6  
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original title, abstract, name of substance 
word, subject heading word] 
DISPLAY 
16 
neonatal ponderal index.mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
20  
DISPLAY 
17 
mid-arm circumference.mp. [mp=title, original 
title, abstract, name of substance word, 
subject heading word] 
273  
DISPLAY 
18 
MAC.mp. [mp=title, original title, abstract, 
name of substance word, subject heading 
word] 
8725  
DISPLAY 
19 
skinfold thickness.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
5387  
DISPLAY 
20 
weight for length.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
1880  
DISPLAY 
21 1 or 2 or 3 444090  
DISPLAY 
22 
4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
120997  
DISPLAY 
23 21 and 22 40179  
DISPLAY 
24 limit 23 to humans 38999  
DISPLAY 
25 limit 23 to animals 2022  
DISPLAY 
26 25 not 23 0  - 
27 exp Cohort Studies/ 547114  
DISPLAY 
28 exp MORTALITY/ 158377  
DISPLAY 
29 exp MORBIDITY/ 183577  
DISPLAY 
30 
natural history.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
21030  
DISPLAY 
31 
prognos$.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
313190  
DISPLAY 
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32 
course.mp. [mp=title, original title, abstract, 
name of substance word, subject heading 
word] 
260108  
DISPLAY 
33 
predict$.mp. [mp=title, original title, abstract, 
name of substance word, subject heading 
word] 
420338  
DISPLAY 
34 exp "Outcome Assessment (Health Care)"/ 263287  
DISPLAY 
35 
outcome$1.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
550128  
DISPLAY 
36 
(inception adj cohort$1).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
679  
DISPLAY 
37 
disease progression.mp. [mp=title, original 
title, abstract, name of substance word, 
subject heading word] 
47608  
DISPLAY 
38 exp Survival Analysis/ 64631  
DISPLAY 
39 exp PROGNOSIS/ 472662  
DISPLAY 
40 
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 or 37 or 38 or 39 
1887895  
DISPLAY 
41 23 and 40 19664  
DISPLAY 
42 
(sensitivity and specificity$).mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
181215  
DISPLAY 
43 exp "Sensitivity and Specificity"/ 193291  
DISPLAY 
44 
sensitivity.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
420307  
DISPLAY 
45 
specificity.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
503082  
DISPLAY 
46 
((pre-test or pretest) adj probability).mp. 
[mp=title, original title, abstract, name of 
substance word, subject heading word] 
490  
DISPLAY 
47 post-test probability.mp. [mp=title, original 148  
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title, abstract, name of substance word, 
subject heading word] 
DISPLAY 
48 
predictive value$.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
83781  
DISPLAY 
49 
likelihood ratio$.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
3044  
DISPLAY 
50 
likelihood functions.mp. [mp=title, original 
title, abstract, name of substance word, 
subject heading word] 
7810  
DISPLAY 
51 exp Diagnostic Errors/ 61428  
DISPLAY 
52 
area under curve.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
16886  
DISPLAY 
53 
((single or double or triple) adj blind$3).mp. 
[mp=title, original title, abstract, name of 
substance word, subject heading word] 
111293  
DISPLAY 
54 
reproducibility of results.mp. [mp=title, 
original title, abstract, name of substance 
word, subject heading word] 
114540  
DISPLAY 
55 double blind method/ or single blind method/ 92858  
DISPLAY 
56 
(randomized controlled trial or controlled 
clinical trial).mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
13043  
DISPLAY 
57 
practice guideline.mp. [mp=title, original title, 
abstract, name of substance word, subject 
heading word] 
971  
DISPLAY 
58 
consensus development conference$.mp. 
[mp=title, original title, abstract, name of 
substance word, subject heading word] 
1628  
DISPLAY 
59 
42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 
50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 
58 
1050543  
DISPLAY 
60 41 and 59 1968  
DISPLAY 
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The search strategy was adapted for use in Embase (2125 citations retrieved) 
and Cinahl (170 citations retrieved). A total of 3698 citations were available 
when duplicates were excluded. 
Appendix 2. The STARD (Standards of Reporting for Diagnostic accuracy 
studies) checklist 
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Section and 
Topic 
Item 
# 
 On page 
# 
TITLE/ABSTRA
CT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic accuracy 
(recommend MeSH heading 'sensitivity and specificity'). 
 
INTRODUCTIO
N 
2 State the research questions or study aims, such as 
estimating diagnostic accuracy or comparing accuracy 
between tests or across participant groups. 
 
METHODS    
Participants 3 The study population: The inclusion and exclusion 
criteria, setting and locations where data were collected. 
 
 4 Participant recruitment: Was recruitment based on 
presenting symptoms, results from previous tests, or the 
fact that the participants had received the index tests or 
the reference standard? 
 
 5 Participant sampling: Was the study population a 
consecutive series of participants defined by the 
selection criteria in item 3 and 4? If not, specify how 
participants were further selected. 
 
 6 Data collection: Was data collection planned before the 
index test and reference standard were performed 
(prospective study) or after (retrospective study)? 
 
Test methods 7 The reference standard and its rationale.  
 8 Technical specifications of material and methods 
involved including how and when measurements were 
taken, and/or cite references for index tests and 
reference standard. 
 
 9 Definition of and rationale for the units, cut-offs and/or 
categories of the results of the index tests and the 
reference standard. 
 
 10 The number, training and expertise of the persons 
executing and reading the index tests and the reference 
standard. 
 
 11 Whether or not the readers of the index tests and 
reference standard were blind (masked) to the results of 
the other test and describe any other clinical information 
available to the readers. 
 
Statistical 
methods 
12 Methods for calculating or comparing measures of 
diagnostic accuracy, and the statistical methods used to 
quantify uncertainty (e.g. 95% confidence intervals). 
 
 13 Methods for calculating test reproducibility, if done.  
RESULTS    
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Participants 14 When study was performed, including beginning and 
end dates of recruitment. 
 
 15 Clinical and demographic characteristics of the study 
population (at least information on age, gender, 
spectrum of presenting symptoms). 
 
 16 The number of participants satisfying the criteria for 
inclusion who did or did not undergo the index tests 
and/or the reference standard; describe why participants 
failed to undergo either test (a flow diagram is strongly 
recommended). 
 
Test results 17 Time-interval between the index tests and the reference 
standard, and any treatment administered in between. 
 
 18 Distribution of severity of disease (define criteria) in 
those with the target condition; other diagnoses in 
participants without the target condition. 
 
 19 A cross tabulation of the results of the index tests 
(including indeterminate and missing results) by the 
results of the reference standard; for continuous results, 
the distribution of the test results by the results of the 
reference standard. 
 
 20 Any adverse events from performing the index tests or 
the reference standard. 
 
Estimates 21 Estimates of diagnostic accuracy and measures of 
statistical uncertainty (e.g. 95% confidence intervals). 
 
 22 How indeterminate results, missing data and outliers of 
the index tests were handled. 
 
 23 Estimates of variability of diagnostic accuracy between 
subgroups of participants, readers or centers, if done. 
 
 24 Estimates of test reproducibility, if done.       
DISCUSSION 25 Discuss the clinical applicability of the study findings.  
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Appendix 3. The QUADAS (Quality Assessment of Diagnostic Accuracy Studies) checklist 
Quality item Response 
Was the spectrum of participants representative of the patients who will receive the test in practice? Yes/ No/ Unclear/ 
Were selection criteria clearly described? Yes/ No/ Unclear/ 
Was the reference standard likely to classify the target condition correctly? Yes/ No/ Unclear/ 
Was the period between performance of the reference standard and the index test short enough to be 
reasonably sure that the target condition did not change between the two tests?  
For these reviews the answer 
will always be Not applicable 
Did the whole sample or a random selection of the sample receive verification using the reference 
standard? 
Yes (if ≥ 90%)/ No/ Unclear 
Did participants receive the same reference standard regardless of the index test result? Yes/ No/ Unclear/ 
Was the reference standard independent of the index test? (that is, the index test did not form part of the 
reference standard) 
Yes/ No/ Unclear/ 
Was the execution of the index test described in sufficient detail to permit its replication? Yes/ No/ Unclear/ 
Was the execution of the reference standard described in sufficient detail to permit its replication?  Yes/ No/ Unclear/ 
Were the index test results interpreted without knowledge of the results of the reference standard? For these reviews the answer 
will always be Yes 
Were the reference standard results interpreted without knowledge of the results of the index test? Yes/ No/ Unclear/ 
Were the same clinical data available when the test results were interpreted as would be available when 
the test is used in practice? 
Yes/ No/ Unclear/ 
Were uninterpretable, indeterminate or intermediate test results reported?  Yes/ No/ Unclear/ 
Were withdrawals from the study explained? Yes/ No/ Unclear/Not 
applicable 
Were interventions between the index test and reference standard reported? Yes/ No/ Unclear/Not 
applicable 
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Data Collection Sheet Cord pH 
Date: ____________________ 
Reviewer ID:______________   Paper No:_______________ 
Year Of Publication:_______   Language:______________ 
Region study performed:_______________________________________ 
 
Section A: Study Selection 
 
Population:  
Inclusion:  Children or adults who have had cord pH performed at birth 
     Yes □ (Include)   No  □ (study excluded) 
Index test: 
Cord pH performed: 
Yes  □ (include)         No   □ (study excluded) 
Reference Test / Outcome Measure: 
A reference standard looking at childhood or adult morbidity is performed 
    Yes  □ (include) No    □ (study excluded) 
2 x 2 Table Possible: 
Yes  □  (include)                No  □ (exclude and case series ≤ 10, if other data e.g. sens, 
spec can include) 
Study Selected: 
Yes  □  (must answer yes to ALL include questions) 
 No  □  Give reason if NO ________________________  
 
 
 
 
 
1)Ref ID:  4)Publication year:  
2)Rev  5)First Author:  
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name: 
3)Country:  6)Language:  
 
Section B: Data Retrieval for Cord pH Study 
Population 
7) Healthcare Centre: 
Secondary care  □ Tertiary care   □     Mixed □    Other   □        Unreported  □ 
 
8) Setting: 
 In-patient  □  Unreported  □       Other  □________________ 
 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of delivery: 
 20-24 weeks □  24-28 weeks □    28-34 weeks □  34-37 weeks □    37-40 weeks □    
>40 weeks □      Unreported  □          Other _______________________ 
 
10.i) Mean (range)______________________________________         Unreported  □ 
 
10.ii) Median (range) ____________________________________        Unreported  □ 
 
11) Pregnancy: 
Low Risk      □  High Risk    □  Unselected  □  Unreported  □ 
 
11.i) State high risk conditions:       Unreported   
     
 
 
        
 
12) Did all mothers have singleton pregnancies?: 
Yes □  No  □          Unreported   □ 
13) Were mothers primigravid?: 
Yes □  No  □         Unreported   □ 
14) What was the mode of delivery? 
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SVD □  Instrumental  □            Emergency Caesarean section  □                                  
Elective Caesarean section   □           Mixed  □      Unreported   □ 
15) Birthweight:   < 3rd centile  □  < 5th centile  □   < 10th centile  □  < 25th centile □     
> 2SD  □   
<500g     □      500-1000g    □     1001-1500g    □       1500-2000g  □     2500-4000g 
□    >4000g □   
  Other □ ________________________________________________      Unclear   □ 
Unreported □   
 
16) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
 
17) Study population: (describe age (mean +/- SD or median/range), ethnicity, social class, 
breastfeeding etc. 
 
 
 
 
 
18) Start of patient inclusion (year) :                               Unreported □   
 
 
 
 
          Not applicable  □ 
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19) End of patient inclusion (year) :        Unreported 
□ 
 
20) Study Design:    
cohort  □    case control  □     RCT/CCT  □        cross sectional  □     before and after  □         
case series   □ (no ______)      other  □ 
20.i) Data collection:  prospective □      retrospective   □      unreported  □        other  □ 
20.ii) Enrolment:    consecutive  □       arbitrary (random) □      unreported  □        other  □ 
21) Numbers: 
 
 
21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □     81-90%  □     < 81%  □ 
 
 
A Eligible Patients 
n=  
C Index Test 
n=  
E Reference Test 
n=  
D Post Enrolment 
Exclusions 
                 n= 
B Excluded 
Patients 
n=  
 
 
B Reasons ________________ 
 
D Reasons ________________ 
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Index Test 
 
22) Description of technique:      
Adequate  □   Inadequate  □ 
Cord pH: 
23) Arterial:     <6.90 □   6.90-7.00 □ 7.01-7.10    □   7.11-7.20 □  7.21-7.30  □    
7.31-7.35 □  >7.35  □   
Median_______________ Mean ______________   Unreported  □ 
 Dataset used to establish threshold________________________________   
Base excess: <2.0  □   2.0-6.0 □   6.1-10.0 □   10.1-12.0  □ 12.1-16  □    >16 □ 
Median ______________ Mean_______________ Unreported □ 
24) Venous:     <6.90 □   6.90-7.00 □ 7.01-7.10  □   7.11-7.20 □  7.21-7.30  □    
7.31-7.35 □  >7.35  □   
Median_______________ Mean ______________   Unreported  □ 
 Dataset used to establish threshold________________________________   
Base excess: <2.0  □   2.0-6.0 □   6.1-10.0 □   10.1-12.0  □ 12.1-16  □    >16 □ 
Median ______________ Mean_______________ Unreported □ 
Reference Standard / Outcome 
25) Measured blind from diagnostic test:   Yes  □    No  □   Unclear  □ 
Reference standard used:____________________________________________ 
_________________________________________________________________ 
Threshold_________________________________________________________ 
Dataset used to establish threshold_____________________________________   
_________________________________________________________________ 
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26)Timing of measurement:  Age(yrs): Range_____________ 
27) Schools: 
 Mainstream  □  Special needs  □  Mixed  □  Unreported  □       Other  □ 
 
_____________ 
 
 
 
 
 
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Results 
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Data Collection Sheet Birth weight standard 
Date: ____________________ 
Reviewer ID:______________   Paper No:_______________ 
Year Of Publication:_______   Language:______________ 
Region study performed:_______________________________________ 
 
Section A: Study Selection 
 
Population:  
Inclusion:  Infants born at term (≥ 37 weeks) gestation 
     Yes □ (Include)   No  □ (study excluded) 
Index test: 
Birth weight, ponderal index or other growth measurements performed: 
Yes  □ (include)         No   □ (study excluded) 
Reference Test / Outcome Measure: 
A reference standard looking at childhood or adult morbidity is performed 
    Yes  □ (include) No    □ (study excluded) 
2 x 2 Table Possible: 
Yes  □  (include)                No  □ (exclude and case series ≤ 10, if other data e.g. sens, 
spec can include) 
Study Selected: 
Yes  □  (must answer yes to ALL include questions) 
 No  □  Give reason if NO ________________________  
 
 
 
 
1)Ref ID:  4)Publication year:  
2)Rev 
name: 
 5)First Author:  
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3)Country:  6)Language:  
 
Section B: Data Retrieval for Birth weight standards review 
Population 
7) Healthcare Centre: 
Secondary care  □ Tertiary care   □     Mixed □    Other   □        Unreported  □ 
 
8) Setting: 
 In-patient  □  Unreported  □       Other  □________________ 
 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of delivery: 
34-37 weeks □    37-40 weeks □    >40 weeks □      Unreported  □          Other 
_______________________ 
 
10.i) Mean (range)______________________________________         Unreported  □ 
 
10.ii) Median (range) ____________________________________        Unreported  □ 
 
10.iii) 
 
11) Pregnancy: 
Low Risk      □  High Risk    □  Unselected  □  Unreported  □ 
 
11.i) State high risk conditions:       Unreported   
     
 
 
        
 
12) Did all mothers have singleton pregnancies?: 
Yes □  No  □          Unreported   □ 
13) Were mothers primigravid?: 
Yes □  No  □         Unreported   □ 
14) What was the mode of delivery? 
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SVD □  Instrumental  □            Emergency Caesarean section  □                                  
Elective Caesarean section   □           Mixed  □      Unreported   □ 
15) Index test:   < 3rd centile  □  < 5th centile  □   < 10th centile  □  < 25th centile □     
> 2SD  □   
 
<500g     □      <1000g    □     <1500g    □       <2000g  □     <2500g □     
  Other □ ________________________________________________      Unclear   □ 
Unreported □   
Timing of measurement__________________ 
Method of measurement__________________ 
No. of operators/ experience_________________ 
 
 
16) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
 
17) Study population: (describe age (mean +/- SD or median/range), ethnicity, social class, 
breastfeeding etc. 
 
 
 
 
 
 
 
 
          Not applicable  □ 
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18) Start of patient inclusion (year) :                               Unreported □  
19) End of patient inclusion (year) :        Unreported 
□ 
 
20) Study Design:    
cohort  □    case control  □     RCT/CCT  □        cross sectional  □     before and after  □         
case series   □ (no ______)      other  □ 
20.i) Data collection:  prospective □      retrospective   □      unreported  □        other  □ 
20.ii) Enrolment:    consecutive  □       arbitary (random) □      unreported  □        other  □ 
21) Numbers: 
 
 
21) Completeness of Verification: 
(= E / C x 100 = %) 
A Eligible Patients 
n=  
C Index Test 
n=  
E Reference Test 
n=  
D Post Enrolment 
Exclusions 
                 n= 
B Excluded 
Patients 
n=  
 
 
 
B Reasons ________________ 
 
D Reasons ________________ 
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> 90%  □     81-90%  □     < 81%  □ 
 
 
 
Index Test 
 
22) Description of technique:      
Adequate  □   Inadequate  □ 
15) Index test:   
Birthweight < 3rd centile  □  < 5th centile  □   < 10th centile  □  < 25th centile □     
<2SD  □   
 
<500g     □      <1000g    □     <1500g    □       <2000g  □     <2500g □     
  Other □ ________________________________________________      Unclear   □ 
Unreported □   
Timing of measurement__________________ 
Method of measurement__________________ 
No. of operators/ experience_________________ 
Reference Standard / Outcome 
25) Measured blind from diagnostic test:   Yes  □    No  □   Unclear  □ 
Reference standard used:____________________________________________ 
_________________________________________________________________ 
Threshold_________________________________________________________ 
Dataset used to establish threshold_____________________________________   
_________________________________________________________________ 
26)Timing of measurement:  Age(yrs): Range_____________ 
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Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Other Information: (ie. other statistics, measures of uncertainty etc) 
Results 
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Data Collection Sheet Apgar 
Date: ____________________ 
Reviewer ID:______________   Paper No:_______________ 
Year Of Publication:_______   Language:______________ 
Region study performed:_______________________________________ 
 
Section A: Study Selection 
 
Population:  
Inclusion:  Infants with apgar score performed at birth 
     Yes □ (Include)   No  □ (study excluded) 
Index test: 
Apgar score performed:   
Yes  □ (include)         No   □ (study excluded) 
Reference Test / Outcome Measure: 
A reference standard looking at neonatal, childhood or adult morbidity/mortality  is 
performed 
    Yes  □ (include) No    □ (study excluded) 
2 x 2 Table Possible: 
Yes  □  (include)                No  □ (exclude and case series ≤ 10, if other data e.g. sens, 
spec can include) 
Study Selected: 
Yes  □  (must answer yes to ALL include questions) 
 No  □  Give reason if NO ________________________  
 
 
 
 
1)Ref ID:  4)Publication year:  
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2)Rev 
name: 
 5)First Author:  
3)Country:  6)Language:  
 
Section B: Data Retrieval for Apgar Study 
Population 
7) Healthcare Centre: 
Secondary care  □ Tertiary care   □     Mixed □    Other   □        Unreported  □ 
 
8) Setting: 
 In-patient  □  Unreported  □       Other  □________________ 
 
 
9) Number of participating centres: ____________________________________ 
 
10) Gestation at time of delivery: 
20-24 weeks □  24-28 weeks □    28-34 weeks □  34-37 weeks □    37-40 weeks □    
>40 weeks □      Unreported  □          Other _______________________ 
 
10.i) Mean (range)______________________________________         Unreported  □ 
 
10.ii) Median (range) ____________________________________        Unreported  □ 
 
10.iii) 
 
11) Pregnancy: 
Low Risk      □  High Risk    □  Unselected  □  Unreported  □ 
 
11.i) State high risk conditions:       Unreported   
     
 
 
        
 
12) Did all mothers have singleton pregnancies?: 
Yes □  No  □          Unreported   □ 
13) Were mothers primigravid?: 
Yes □  No  □         Unreported   □ 
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14) What was the mode of delivery? 
SVD □  Instrumental  □            Emergency Caesarean section  □                                  
Elective Caesarean section   □           Mixed  □      Unreported   □ 
15) Birth weight:   < 3rd centile  □  < 5th centile  □   < 10th centile  □  < 25th centile □     
> 2SD  □   
 
<500g     □      <1000g    □     <1500g    □       <2000g  □     <2500g □  2500-4000g 
□    >4000g □   
   
  Other □ ________________________________________________      Unclear   □ 
Unreported □   
Timing of measurement__________________ 
Method of measurement__________________ 
No. of operators/ experience_________________ 
 
 
16) List other eligibility/ in-/exclusion criteria: 
 
 
 
 
 
 
17) Study population: (describe age (mean +/- SD or median/range), ethnicity, social class, 
breastfeeding etc. 
 
 
 
 
          Not applicable  □ 
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18) Start of patient inclusion (year) :                               Unreported □  
19) End of patient inclusion (year) :        Unreported 
□ 
 
20) Study Design:    
cohort  □    case control  □     RCT/CCT  □        cross sectional  □     before and after  □         
case series   □ (no ______)      other  □ 
20.i) Data collection:  prospective □      retrospective   □      unreported  □        other  □ 
20.ii) Enrolment:    consecutive  □       arbitary (random) □      unreported  □        other  □ 
 
 
 
 
 
 
 
 
 
 
 
21) Numbers: 
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21) Completeness of Verification: 
(= E / C x 100 = %) 
> 90%  □     81-90%  □     < 81%  □ 
 
 
 
Index Test 
 
22) Description of technique:      
Adequate  □   Inadequate  □ 
15) Index test:   
Apgar score  1 min □ 5min □ 10 min □ 
Threshold: _________________________ 
  Other □ ________________________________________________      Unclear   □ 
Unreported □   
Timing of measurement__________________ 
A Eligible Patients 
n=  
C Index Test 
n=  
E Reference Test 
n=  
D Post Enrolment 
Exclusions 
                 n= 
B Excluded 
Patients 
n=  
 
B Reasons ________________ 
 
D Reasons ________________ 
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Method of measurement__________________ 
No. of operators/ experience_________________ 
Reference Standard / Outcome 
25) Measured blind from diagnostic test:   Yes  □    No  □   Unclear  □ 
Reference standard used:____________________________________________ 
_________________________________________________________________ 
Threshold_________________________________________________________ 
Dataset used to establish threshold_____________________________________   
_________________________________________________________________ 
26)Timing of measurement:  Age(yrs): Range____________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Population:                           Reference Test: 
                          Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive Negative Total 
Positive 
 
TP FP  
Negative FN TN  
 Total    
Other Information: (ie. other statistics, measures of uncertainty etc) 
Results 
Appendix 7. Medline search strategy for the association of umbilical cord pH 
and base excess with neonatal and long term outcomes 
 
207 
 
The following MESH headings (exp indicates selection expanded) and keywords 
(followed by ‘mp’) were used:  
1. cord gases.mp. 
2. cord pH.mp. 
3. umbilical artery pH.mp. 
4. umbilical cord blood.mp. 
5. Blood Gas Analysis 
6. exp Umbilical Cord 
7. exp Hydrogen-Ion Concentration 
8. Blood/ or blood.mp. 
9. exp Infant, Newborn 
10. Asphyxia Neonatorum 
11. exp Brain Damage, Chronic 
12. exp Hypoxia-Ischemia, Brain 
13. exp Mental Disorders Diagnosed in Childhood 
14. cerebral palsy.mp. 
15. developmental delay.mp. 
16. hypoxic ischaemic encephalopathy.mp. 
17.  handicap*.mp. 
18.  mental retard*.mp. 
19. feeding difficulties.mp. 
20. Infant Mortality 
21. Child Mortality 
The search terms were combined as follows: 
22. 1 or 2 or 3 or 4 or 5 
23. 6 and 7 and 8 
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24. 22 or 23 
25. 9 and 24 
26. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
27. 25 and 26 
28. Limit 27 to humans 
 
Search results: 
Medline 2983 citations 
Embase 2701 citations 
Web of Science 1179 citations 
Cochrane library 5 citations 
MEDION 0 citations 
SIGLE 0 citations 
 
Excluding duplicates Total = 5690 
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Author Study 
design 
Population 
risk (total 
number) 
Risk Factor Index Test Outcome Measure 
Baenziger et 
al 
1999 
Switzerland 
Prospective 
cohort 
High (10) Total number included=10 
All ventilated neonates. 
Risk factors for HIE inc meconium 
liquor, CTG abnormalities, low Apgar 
or pH. > 34 weeks gestation 
Arterial cord pH < 
7.00 
Death
a 
HIE (Sarnat gd >1)
a 
Neurological Optimality 
Score (age 1 yr) 
Griffiths Developmental 
Scale (age 1 yr) 
Beeby et al 
1994 
Australia
 
Prospective 
cohort 
High (623) Gestation <32 weeks. Congenital 
anomalies excluded 
Arterial cord pH < 
7.1 
Death
a 
Cerebral Palsy (diagnostic 
criteria not specified) (age 1 
yr) 
Intra-ventricular 
haemorrhage Gd 3 or 4 on 
cranial USS or at autopsy
a
 
Blackwell et al
 
2001 
USA 
Retrospective 
cohort 
High (48) All required ventilation > 48 hrs for 
meconium aspiration syndrome 
Gestation >37 weeks 
Arterial cord pH < 
7.2 
Seizures
a 
(diagnostic criteria 
not described) 
Bresadola et 
al
 
1995 
Italy 
Cohort, 
unclear if 
prospective/ 
retrospective 
High (452) Gestation > 24 weeks < 37 weeks  
Birth weight >700g 
Congenital anomalies excluded 
Arterial cord pH < 
7.2 
Death
a
 
Casey et al
 
2001 
USA 
Retrospective 
cohort 
High (1691) Neonates who developed respiratory 
symptoms postnatally 
Gestation >37 weeks 
Arterial cord pH < 
7.2 
Death
a
  
Seizures(1
st
 24 hours)
a 
Respiratory Distress 
(requiring ventilation)
a 
Meconium aspiration 
syndrome (radiographically 
diagnosed)
a
 
Engle
 
1999 
USA 
Retrospective 
cohort 
High (73) Neonates admitted to Neonatal unit 
directly from Delivery suite 
Gestation > 37 weeks 
Arterial cord pH < 
7.00 
HIE including seizures
a 
(threshold unreported) 
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Ertan 
2001 
Germany 
Case control 
study 
High (120) Gestation 24-34 weeks Arterial cord pH 
<7.10 
Arterial base 
excess (BE) > 
16mmol/l 
Intra-cranial haemorrhage 
(all grades- Papile) on 
cranial USS
a
 
Gaudier et al 
1994 
USA 
Retrospective 
cohort 
High (216) Birth weight 500-1000g 
Gestation 23-34 weeks 
Congenital anomalies excluded 
Arterial cord pH < 
7.05 
Weschler intelligence scale 
for children (IQ < 70)  
Cerebral palsy (chronic non 
progressive motor disability 
characterised by abnormal 
posture and 
movements)(follow up to age 
7 years) 
Motor or mental deficit 
severe enough to interfere 
with normal function 
including  one or more of 
mental retardation, cerebral 
palsy, deaf, blind, 
hydrocephaly 
 
Gea 
2007 
Brazil 
Prospective 
cohort 
High (25) Birth weight < 2000g 
Gestation < 37 weeks 
Excluded congenital anomalies, 
maternal diabetes and rhesus 
incompatibility 
Venous pH < 
7.20 
Venous BE > 
10mmol/l 
Periventricular or intra-
ventricular haemorrhage on 
cranial USS
a 
Ventilation > 24 hours
a 
Necrotising enterocolitis 
(Grade 2 Bell’s 
Classification)
a 
 
Gonzalez de 
Dios et al 
2000 
Spain 
Prospective 
cohort 
High (180) At least one risk factor for asphyxia 
e.g. Apgar <6, cord pH < 7.00, 
antenatal risk factors. Exc if 
congenital anomaly, sepsis, 
metabolic disorder, PN depression 
Gestation > 37 weeks 
Arterial cord pH ≤ 
7.00 
Serum creatinine 
>1.2mg/dl
a,c 
HIE(Levine’s criteria all 
grades)
a 
Abnormal neurological status 
(Amiel-Tison criteria) (age 2 
years) 
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Graham et al 
2004 
USA 
Case control 
study 
High (220) Gestation 23-34 weeks Arterial cord pH 
<7.00 
Periventricular leukomalacia 
or ventricular dilatation on 
cranial USS
a,b
 
Haddad et al 
2000 
USA 
Retrospective 
cohort 
High (28) Neonates with Apgar 0 at 1 and 5 
mins resuscitated and tranferred to 
Neonatal unit,  excluding congenital 
malformations, chromosone 
abnormalities, Birth before arrival 
Gestation 25.5-42.1 wks 
 
Arterial cord pH 
<7.00 
Death
a 
HIE
a
 (diagnostic criteria not 
described) 
Hernandez et 
al 
1993 
USA 
Retrospective 
cohort 
High (82) Clinical and radiological evidence of 
meconium aspiration syndrome. 
Excluded if congenital anomaly, 
cytomegalic inclusion disease, 
delivery outside hospital 
Arterial cord pH 
<7.00 
Arterial cord pH 
<7.10 
Arterial cord pH 
<7.20 
Ventilation required
a 
Ventilation ≥ 3 days
a
 
Hibbard et al
 
1991 
USA 
Retrospective 
cohort 
High (171) Birth weight 500-1500g Arterial cord pH ≤ 
7.05 
Arterial cord pH ≤ 
7.15 
 
Death
a 
Intraventricular haemorrhage 
(Gd 1-4) on Cranial USS
a 
Abnormal neurological status 
defined as seizures, cortical 
atrophy, need for shunt 
placement
a 
Hyaline membrane disease 
(CXR)
a 
Bronchopulmonary dysplasia 
(CXR)
a 
Necrotising enterocolitis
a
 
Holmes et al 
2001 
Canada 
Case control 
study 
High (76) BW 750-2500g. 
Gestation 25-35 weeks 
Excluded if CS before labour, 
congenital anomalies, uninterpretable 
FHR trace 
 
Arterial cord pH 
<7.10 
Death
a
  
Intraventricular haemorrhage 
(Grade 3 or 4 Papile)
a 
Periventricular leukomalacia
a 
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Kato
 
1997 
Japan 
Retrospective 
cohort 
High (195) Birth weight <1500g. Congenital 
anomalies excluded 
Arterial cord pH < 
7.20 
Death
a 
Cerebral palsy or mental 
retardation (threshold 
unreported) (at least 12 
months old) 
Loh et al
 
1998 
Singapore 
Prospective 
cohort 
High (69) Included if one or more of the 
following risk factors: CTG 
abnormality, scalp pH< 7.25, thick 
mec/no liquor, cord prolapse/ 
bradycardia, antepartum 
haemorrhage, EFW<1.5kg, <34 
weeks, breech, poorly controlled 
IDDM, PET, suspected fetal 
anomalies, transverse/oblique lie at 
CS, multiple preg 
Arterial cord pH 
<7.00 
HIE (diagnostic criteria 
unreported) 
Luthy et al
 
1987 
USA 
Prospective 
cohort 
High (199) Gestation 26 – 32 weeks 
Excluded multiple pregnancy, non-
cephalic presentation, malformations, 
delivered before labour, antenatal 
haemorrhage 
Arterial cord pH ≤ 
7.20 
Death
a 
Cerebral palsy (diagnostic 
criteria unreported) (18 
months of age) 
IVH on cranial USS (Grade 3 
/ 4 Papile)
a 
 
Murphy et al 
1995 
UK 
Case control 
study 
High (152) Gestation 23-32 weeks. 
Excluded multiple pregnancy 
Arterial cord pH ≤ 
7.10 
Cerebral palsy (permanent 
impairment of voluntary 
movement or posture)(age 
unreported) 
Salafia et al 
1995 
USA 
Retrospective 
cohort 
High (406) Gestation < 32 weeks. 
 Excluded if  congenital  anomalies, 
multiple pregnancy, maternal 
diabetes mellitus or chronic 
hypertension, fetal hydrops, placenta 
praevia, intra-uterine growth 
restriction 
Arterial cord pH 
<7.10 
Venous cord pH 
<7.10 
Germinal matrix or 
intraventricular haemorrhage 
diagnosed on cranial 
USS(Grade 1-4)
a
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Socol
 
1994 
USA 
Retrospective 
cohort 
High (28) APGAR score ≤3 at 5 minutes. 
Excluded birthweight < 2000g and 
gestation < 34 weeks 
Arterial cord pH 
<7.00 
Arterial base 
excess 
>12mmol/l 
Cerebral palsy / motor deficit 
(diagnostic criteria 
unreported) (age 1-7 years) 
Seizures
a 
Renal impairment (Serum 
creatinine >1.5mg/dl or 
oliguria)
a 
Cognitive impairment on 
Welscher Scale (cut off <70) 
(age 1-7 years) 
Spinillo et al 
1995 
Italy 
Case control 
study 
High (159) Birth weight < 2500g Arterial cord pH 
<7.20 
Bayley Index abnormal (71-
84). (Age 2 years) 
Tejani and 
Verma 
1989 
USA 
Cohort, 
unclear  if 
prospective/ 
retrospective 
High (392) Birth weight ≤2000g.  
Excluded major congenital anomalies 
Arterial cord pH ≤ 
7.10 
Death
a 
Intraventricular haemorrhage 
on cranial USS (Gd 1-4 
Papile)
a 
RDS (radiological evidence 
of reticulogranular pattern 
and air bronchograms)
a
 
 
Yudkin et al 
1994 
UK 
Retrospective 
cohort  
High (122) APGAR score ≤3 at 1 minute 
Gestation >37 weeks 
Excluded multiple pregnancies and 
death related to congenital anomaly 
or rhesus disease  
Arterial cord pH < 
7.15 
Death
a 
Any impairment (age 5 
years)
 
Serious impairment (global 
delay, lateralising signs and 
severe deficit in a specific 
area) (age 5 years) 
Yoon et al
 
1996 
Korea 
1996 High (153) Gestation 25 – 36 weeks 
Excluding major congenital 
malformations or death before 
examination 
Arterial cord pH < 
7.15 
Periventricular leukomalacia 
on cranial USS (cystic 
lesions in PV white matter or 
bulging ventricle adjacent to 
white matter or persistent 
increase in echogenicity)  or 
at autopsy
a
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Dennis et al 
1989 
UK 
Retrospective 
cohort 
Unselected 
(189) 
Gestation > 37 weeks 
Singletons surviving to age 4.5 years 
Arterial cord pH ≤ 
7.10 
Arterial Base 
Excess > 12 
mmol/l 
Griffiths Developmental 
scales age 4.5 years(<10
th
 
percentile): 
Locomotor 
Personal/social 
Hearing/speech 
Performance 
Overall impairment 
Dijxhoorn et al 
1986 
Netherlands 
 
Retrospective 
cohort 
Low (803) Gestation > 37 weeks 
Excluding caesarean delivery or 
breech presentation 
Arterial cord pH ≤ 
7.10 
Arterial cord pH ≤ 
7.20 
 
Neurological status 
(abnormal if one of 
hyper/hypokinesia, 
hyper/hypotonia, 
hemisyndrome, apathy 
syndrome, hyperexcitability 
syndrome)
a 
 
D'Souza et al 
 
1983 
UK 
 
Cohort 
unclear  if 
prospective/ 
retrospective 
Low (453) Normal pregnancy,  vaginal delivery 
39-42 weeks 
Venous pH < 
7.27 
Neurological status 
(abnormal if one of 
hypotonia, lethargy, feeding 
difficulties, jittery)
a 
 
Ghosh et al 
2003 
India 
 
Prospective 
cohort 
Low (75) Gestation >37 weeks 
Singletons excluded if Rhesus 
isoimmunisation, maternal anaemia 
or diabetes mellitus 
Arterial pH ≤ 7.15 HIE(threshold unreported)
a 
Death
a
 
Gilstrap et al
 
1989 
USA 
Retrospective 
cohort 
Low (2738) Gestation > 37 weeks, cephalic 
presentation, birth weight > 2500g 
Excluding  congenital anomalies 
Arterial cord pH < 
7.00 
Hypotonia > 24-48 hours
a 
Respiratory disease 
requiring oxygen
a 
Seizures
a
 
Graham
 
2002 
USA 
 
Case control 
study 
Unselected 
(34) 
Excluding congenital anomalies  Arterial cord pH 
<7.00 
Seizures
a
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Heller et al 
2003 
Germany 
 
Retrospective 
cohort 
Unselected 
(464345) 
Excluding congenital anomalies 
 
Arterial cord pH ≤ 
7.00 
Arterial cord pH ≤ 
7.10 
Arterial cord pH ≤ 
7.20 
Death
a
 
Hogan 
2007 
Sweden 
Case control 
study 
Unselected  
(313) 
Gestation >37  weeks Arterial cord pH ≤ 
7.15 
 
Composite reference 
standard HIE(Sarnat all 
grades) or hypoxic death
a 
Huisjes and 
Aarnoudse 
1979 
Netherlands 
Cohort 
unclear  if 
prospective/ 
retrospective 
Unreported 
(838) 
Population characteristics unreported Arterial cord pH ≤ 
7.09 
Neonatal neurological status 
abnormal (Prechtl)
a
 
Ingemarrson 
et al
 
1997 
Sweden 
Case control 
study 
Unreported 
(308)  
Population characteristics unreported Arterial cord pH 
<7.05 
Arterial cord pH 
<7.00 
Death
a 
Cerebral palsy (age 4 years) 
HIE (Sarnat Grade 1-3)
a 
Attention deficit (age 4 yrs) 
Speech difficulty (age 4 yrs) 
Motor delay (age 4 yrs) 
Jurgens- van 
der Zee et al 
1979 
Netherlands 
Prospective 
cohort 
Unselected 
(1343) 
Neonates. Excluded if neonatal death 
or parents refused examination 
Venous pH < 
7.20 
Neuro exam abnormal 
(Prechtl): 1 or more of 
increased/decreased 
excitability, seizures, apathy, 
coma. Abnormal motility or 
tone. Peripheral/central 
nervous system lesions
a
 
Larma et al
 
2007 
USA 
Case control 
study 
Unselected 
(214) 
Gestation ≥ 24 weeks Arterial cord pH < 
7.00 
Seizures
a 
Periventricular leukomalacia
a 
Intra-ventricular 
haemorrhage
a 
Respiratory dysfunction
a 
Renal dysfunction
a 
(thresholds unreported) 
Litschgi et al 
1974 
Germany 
Prospective 
cohort 
Unreported 
(1000) 
Population characteristics unreported Arterial cord pH < 
7.09 
Neurological examination 
abnormal (24 hours after 
birth)
a
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Low 
1997 
Canada 
Case control 
study 
Unselected 
(174) 
Gestation ≥ 37 weeks Arterial base 
excess > 
12mmol/l 
Composite outcome score
a 
Neurological abnormality 
(lethargy/ abnormal 
tone/coma/seizures)
a 
Respiratory dysfunction 
(CPAP or ventilation 
required)
a 
Cardiovascular dysfunction 
(hypo/hypertension/abnormal 
ECG or echocardiogram)
a 
Renal dysfunction (Serum 
creatinine  >100umol/l 
/anuria / oliguria <1ml/kg/hr)
a
 
Perlman and 
Risser 
1996 
USA 
Prospective 
cohort 
Unselected 
(96) 
Gestation ≥ 37 weeks Arterial cord pH ≤ 
7.00 
Seizures
a
 
Sakuraba and 
Saling 
1989 
Germany 
 
Prospective 
cohort 
Unreported 
(178) 
Population characteristics unreported Arterial cord pH ≤ 
7.19 
Arterial cord pH ≤ 
7.24 
Intracranial haemorrhage 
diagnosed on cranial 
USS(threshold unreported)
a,b
 
Schneider and 
Tanner 
1985 
Germany 
Retrospective 
cohort 
Unselected 
(29) 
Twins only included Arterial cord pH 
<7.20 
Binet Simon Kramer 
(intelligence) 
Language test 
Emotional intelligence test 
Raven Intelligence test(non-
spoken) 
Neurological status 
(All tests performed age 5-7 
years) 
Silva et al 
2008 
USA 
Case control 
study 
Unselected 
(174) 
Gestation ≥ 34 weeks. 
Congenital malformations and 
chromosome anomalies excluded 
Arterial cord pH < 
7.00 
Arterial cord pH < 
7.10 
Hypotonia at birth 
necessitating NNU 
admission
a 
HIE (threshold unreported)
a 
Seizures
a
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Svirko et al 
2008 
UK 
Retrospective 
cohort 
Unselected 
(87) 
Gestation≥ 36 weeks. Included if had 
one of reference tests performed and 
cord pH available. Excluded if 
delivered by pre-labour elective CS 
Arterial cord pH < 
7.10 
Weschler Objective Reading 
Dimensions (WORD) (age 6-
8 yrs) 
Test for Comprehension of 
Grammar (TROG) (age 5-7 
yrs) 
Naglieri non-verbal ability 
(NNAT) (age 6-8 yrs) 
(cut off <100 age 
standardised score used for 
all tests) 
Thoulon et al
 
1972 
France 
 
Cohort 
unclear  if 
prospective/ 
retrospective 
Unreported 
(487) 
Population characteristics unreported Venous cord pH 
< 7.20 
Death
a 
Abnormal neurological 
examination (threshold 
unreported)(age 18months) 
Valentin et al 
1993 
Sweden 
Cohort 
unclear  if 
prospective/ 
retrospective 
Unselected 
(178) 
Anomalies not excluded Arterial cord pH ≤ 
7.00 
Arterial cord pH ≤ 
7.10 
Venous cord pH 
≤ 7.10 
Venous cord pH 
≤ 7.20 
Composite measure of 
neonatal sequelae including 
severe symptoms requiring 
treatment e.g ventilation, IV 
fluids or death or survival 
with sequelae
a
 
Van den Berg 
1996 
Netherlands 
Retrospective 
cohort 
Unselected 
(168) 
Excluded chromosomal or major 
congenital anomalies or intrauterine 
infection 
Arterial cord pH < 
7.00 
(compared to 
group of 
neonates with 
cord pH > 7.24) 
Seizures
a 
Intracranial haemorrhage on 
Cranial USS
a,b 
Periventricular leukomalacia 
on cranial USS
a 
Renal impairment (serum 
creatinine > 90
a 
Abnormal liver function (AST 
>33U/L, ALT >25U/L)
a,e 
Necrotising enterocolitis 
(criteria unreported)
a 
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a=outcomes within the neonatal period 
USS= ultrasound scan, Mg/dl= milligrams per decilitre, CXR= chest x-ray, U/L = units per litre, RDS= respiratory distress syndrome, HIE= hypoxic 
ischaemic encephalopathy, CS= Caesarean section, CPAP= continuous positive airway pressure, NNU= neonatal unit, ECG= electrocardiogram, 
AST= aspartate transaminase, ALT= alanine aminotransferase, Gd= Grade, IQ= intelligence quotient
Vintzileos et al
 
Greece 
 
 
Prospective 
cohort 
Unselected 
(678) 
Gestation ≥26 weeks 
Excluding known congenital or 
chromosomal anomalies 
Arterial cord pH 
<7.10 
Death
a
 
Wildshut et al 
2005 
Netherlands 
Prospective 
cohort 
Low (44) Gestation 37- 42 weeks 
Neonates included if growth between 
2.3-97.7th percentiles, vertex 
position, stay in hosp at least 3 days 
after birth. Excluded if HIE if caused 
by meconium aspiration, RDS, 
infection, born after complicated 
pregnancy, congenital malformations, 
maternal medication, alcohol or drug 
use, metabolic disorders. 
Arterial cord pH < 
7.10 
Movement ABC test (score < 
16 or unable to perform due 
to movement disorder) (age 
4 years) 
Winkler 
1991 
USA 
Case control 
study 
Unselected 
(713) 
Gestation ≥ 37 weeks Arterial cord pH < 
7.20 
Composite reference 
standard: seizures or 
neonatal death
a
 
Wu et al
 
1998 
Chinas 
 
Case control 
study 
Unselected 
(194) 
Gestation ≥ 37 weeks 
Singletons only 
Arterial cord pH < 
7.19 
Motor delay 
Speech delay 
Difficulty concentrating  
(all assessed age 4 years) 
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1. Birth Weight/ 
2. birth weight.mp. 
3. birth-weight.mp. 
4. birthweight.mp. 
5. Infant, Very Low Birth Weight/ or Infant, Low Birth Weight/ 
6. lbw.mp. 
7. small-for-gestational-age.mp. 
8. small for gestational age.mp. 
9. small for date*.mp. 
10. small for gestation*.mp. 
11. sga.mp. 
12. Infant, Small for Gestational Age/ 
13. intrauterine growth restrict*.mp. 
14. intrauterine growth retard*.mp. 
15. IUGR.mp. 
16. Fetal Growth Retardation/ 
17. ponderal index.mp. 
18. abdominal circumference.mp. 
19. head circumference.mp. 
20. exp body constitution/ or "body weights and measures"/ 
21. neonat*.mp. 
22. infant*.mp. 
23. newborn.mp. 
24. 22 or 21 or 23 
25. 11 or 7 or 2 or 1 or 16 or 13 or 6 or 3 or 9 or 12 or 14 or 15 or 8 or 4 or 10 
or 5 
26. 18 or 19 or 17 or 20 
27. 24 and 26 
28. 27 or 25 
29. Diabetes Mellitus/ 
30. diabetes mellitus.mp. 
31. Hypertension/ or hypertension.mp. 
32. cardiovascular disease.mp. or Cardiovascular Diseases/ 
33. Metabolic Syndrome X/ or metabolic syndrome.mp. 
34. cerebral palsy.mp. or Cerebral Palsy/ 
35. Developmental Disabilities/ 
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36. developmental delay.mp. 
37. learning difficulties.mp. 
38. Learning Disorders/ 
39. neonatal morbidity.mp. 
40. Infant Mortality/ 
41. neonatal mortality.mp. 
42. infant mortality.mp. 
43. 35 or 33 or 32 or 39 or 40 or 36 or 41 or 42 or 38 or 34 or 30 or 37 or 29 or   
      31 
44. 28 and 43 
45. limit 44 to humans
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Author, Year and 
Country 
Study design Population (total number) Method of defining 
gestational age 
Birth weight parameter Outcome Measure 
Algert et al 2009
 
Australia 
Retrospective 
cohort 
(475455) 
Singleton 
All live births in state within 
study period  
Year of birth2000-2005 
Excluded those who moved 
out of area, no others 
specified 
Ethnicity unreported 
Unreported Birth weight <2.5 kg Type 1 Diabetes Mellitus (age 
3-6 years) (ICD-10 
classification coded from 
hospital records) 
Als et al 1976
 
USA 
Prospective cohort (20) 
Unclear if singleton/ mixed 
Infants with IUGR and 
same number of control 
infants 
Year of birth 
No congenital anomalies 
included 
Ethnicity: all Caucasian 
LMP and Dubowitz 
method 
Ponderal Index <2.25 1. Brazelton motor score 
(10 days old), below 
average  3 
Amigo et al 2010
 
Brazil/Chile 
Retrospective 
cohort 
(2793) 
Singleton 
Two cohorts 1. Stratified 
sample (3 social levels) of 
adults who were singletons 
born between June 1978 
and May 1979. 2. Adult 
subjects aged 22-28 years 
randomly selected from a 
sampling frame of 
newborns registered jan 
1974- dec 1978 in small 
agricultural area 
No exclusions specified 
Ethnicity unreported 
Unreported Absolute birth weight <2.5 
kg 
2. BMI ≥ 30 aged 20-
28years 
3. Fasting total 
cholesterol ≥ 5mmol/L 
aged 20-28 years 
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Ananth and Vintzelios 
2009
 
USA 
Retrospective 
cohort 
(18169349) 
Singleton 
General population in USA 
during study period 
Year of birth 1995-2004 
Congenital anomaly 
excluded 
Ethnicity 77.4% white, 
17.5% black,5.2% other 
Clinical estimate 
(combination of USS, 
obstetrical and 
newborn examination)  
Population chart <10
th
 
centile 
(internal chart based on this 
population) 
Neonatal death (28 days, from 
national dataset) 
Andersson et al 2000
 
Sweden 
Retrospective 
cohort 
(438) 
Singleton 
General, all women born in 
years 1918,1922 and 1930  
residing in city invited to 
participate 
No exclusions specified 
Ethnicity unreported 
LMP Birth weight <3.1kg Hypertension at age 50 and 
age 60 years (under treatment 
and/ or BP ≥ 160mmHg 
systolic and/ or diastolic 
>95mmHg)  
 
Arora, Paul and Singh 
1987
 
India 
Prospective cohort (200) 
Unclear if singleton/ mixed 
Consecutive hospital born 
infants with IUGR and 
same number of control 
infants  
Year of birth 1984-1985 
Congenital anomaly NOT 
excluded 
Ethnicity unreported 
Unreported Population chart <10
th
 
centile 
(Singh chart) 
1. Neonatal mortality 
(precise age unclear) 
2. Neonatal 
hypoglycaemia 
≤30mg/dL (2-20 hours 
of age) 
Balcazar and Haas 1990
 
Mexico 
Retrospective 
cohort 
(9201) 
Singleton 
Infants born to women of 
low social class at a mother 
and child centre 
Year of birth 1981-1983 
Congenital anomaly NOT 
excluded 
Ethnicity unreported 
LMP 1.Population chart < 10
th
 
centile(Lubchenco chart) 
2.Birth weight <2.9kg 
 
Neonatal death (72 hours) 
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Berle et al 2006
 
Norway 
Retrospective 
cohort 
(7415) 
Singleton 
General population study, 
all those in age range in 
the country invited 
Year of birth 1967 onwards 
No exclusions specified 
Ethnicity unreported 
LMP Population chart <10
th
 
percentile (based on all live 
births in Norway 28-43 
weeks) 
1. Questionnaire: education 
level completed (primary 
school vs higher) (aged 20-30 
years) 
2.Questionnaire: 
socioeconomic functioning 
(receiving disability pension, 
un rehabilitation, being 
unemployed, or on sick leave) 
(aged 20-30 years) 
3. Hospital Anxiety and 
Depression Rating Scale 
(HADS) cut off 8 (aged 20-30 
years) 
Bhargava, Sachdev and 
Ghosh 1985
 
India 
Prospective cohort (15596) 
Singleton 
Hospital population, 
consecutive births 
Year of birth unreported 
No exclusions specified 
Ethnicity unreported 
LMP, confirmed by 
neonatal physical and 
neurological 
examination 
1 Birth weight > -1 
Standard Deviation (from 
population mean) 
2. Birth weight> -2 
Standard deviations (from 
population mean) 
Neonatal mortality (7 days) 
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Bilge et al 2011
 
Turkey 
Retrospective 
cohort 
(59) 
Singleton 
Children born SGA at 
tertiary centre, with age- 
matched, non-obese 
controls 
Year of birth unreported 
Congenital anomaly 
excluded 
Ethnicity 100% Caucasian 
LMP Birth weight and /or length 
<-2 Standard Deviations for 
gestational age (unclear 
how standard derived) 
1.Systolic blood pressure> 95
th
 
percentile for sex, age and 
height- single measurement 
(5.5-12.2 years old) 
2. Diastolic blood pressure> 
95
th
 percentile for sex, age and 
height- single 
measurement(5.5-12.2 years 
old) 
3. Systolic blood pressure> 
95
th
 percentile for sex, age and 
height-mean of 24 hour 
ambulatory monitoring (5.5-
12.2 years old) 
4. Diastolic blood pressure> 
95
th
 percentile for sex, age and 
height-mean of 24 hour 
ambulatory monitoring (5.5-
12.2 years old 
Burke et al 2004
 
Australia 
Prospective cohort (1913) 
Singleton 
Hospital population, 
offspring of women 
recruited during pregnancy 
Year of birth 1989 onwards 
Congenital anomaly 
excluded 
Ethnicity: 90% white, 5% 
Chinese, Indian 2%, Other 
3% 
Unclear Birth weight < 2.5kg Systolic blood pressure ≥ 
120mmHg (8 years old) 
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Catalano et al 2009
 
USA 
Prospective cohort (89) 
Singleton 
Hospital population, 
offspring of pregnant 
women recruited with 
gestational diabetes or 
normal glucose tolerance 
Year of birth 1990-1999 
Congenital anomaly 
excluded 
Ethnicity: 91% white, 3% 
African American, 4% 
Hispanic, 2% Asian 
Unclear Birth weight <2.5kg 1. BMI> 95
th
 percentile (CDC 
criteria) (6-11 years) 
2. Systolic blood pressure 
>95
th
 percentile (reference 
unreported) (6-11 years) 
3. Diastolic blood pressure > 
95
th
 percentile for (reference 
unreported) (6-11 years) 
4. Serum cholesterol > 95
th
 
percentile (6-11 years) 
Chaudhari et al 1996
 
India 
Prospective cohort (198) 
Hospital population, high 
risk infants (one or more of 
birth weight <2000g, Apgar 
<5 at 5 minutes or HIE, 
septicaemia or 
hyperbilirubinaemia, 
apnoea, seizures, IVH). 
Control infants of normal 
weight with uncomplicated 
antenatal and postnatal 
course 
Year of birth 1987-1992 
Not specified if singleton/ 
multiple pregnancy 
Congenital anomalies 
excluded 
Ethnicity unreported 
Unclear Population chart <10
th
 
percentile (Singh criteria) 
Cerebral palsy (definition 
unreported) (up to 12 months 
of age) 
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Cornelius et al 2009
 
USA 
Prospective cohort (1005) 
Hospital population: 
women who attended 
prenatal clinic, one group 
selected on the base of 
alcohol use (mixture of > or 
< 3 units per week, and 
women who used 
marijuana, and a random 
sample of those who did 
not. Also cohort of teenage 
mothers, from same clinic. 
Year of birth 1982-1985 
Excluded if mother diabetic 
or child had sickle cell 
anaemia 
Singletons 
Ethnicity:  55% African 
American 
Unclear Absolute birth weight 
<2.5kg 
BMI >95
th
 percentile (CDC 
criteria) (age 6 years) 
De Almeida and de 
Mello Jorge 1998
 
Brazil 
Retrospective 
cohort 
(2024) 
Hospital population (11 
centres) 
Year of birth 1992 
Singleton 
Excluded if gestational age 
unknown 
Ethnicity unreported 
LMP  Population chart <10th 
percentile (Lubchenco 
chart) 
Neonatal death (28 days) 
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Doctor et al 2001
 
USA 
Retrospective 
cohort 
(744) 
Hospital population 
Year of birth 1997 
Mixed singleton and 
multiple pregnancy 
Infants with birth weight < 
10
th
 percentile, and 
matched controls birth 
weight 10
th
-90
th
 percentile 
Excluded if gestational age 
unreliable 
Ethnicity: 38% Caucasian, 
60% African American, 2% 
other 
Second trimester 
ultrasound scan 
Population chart <10th 
percentile (Alexander et al 
reference chart) 
Population chart  <5
th
 
percentile (Alexander et al 
reference chart) 
1.Neonatal intubation required 
(at birth) 
2.Neonatal intensive care unit 
admission required (neonatal) 
3.Respiratory distress 
(transient tachypnoea requiring 
oxygen RR>60/min for more 
than 4 hours/pneumonia 
clinical and 
radiological/meconium 
aspiration with supportive 
radiology (neonatal) 
4.Hypoglycaemia (blood 
glucose < 40mg/dL and 
symptoms- jittery/ 
tachypnoeic/hypothermic ) 
(neonatal) 
5.Seizures (threshold 
unreported) (neonatal) 
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Evensen et al 2009
 
Norway 
Prospective cohort (142) 
Multiparous hospital 
population (multicentre) 
Year of birth 1986-1988 
Cohort of birth weight <10
th
 
centile and random sample 
of birth weight ≥ 10
th
 centile 
Excluded congenital 
anomaly or cerebral palsy 
Unclear if singleton or 
multiple pregnancy 
Ethnicity unreported 
 
 
LMP + USS if 
discrepancy of more 
than 14 days or if 
could not be recalled 
accurately 
Population chart <10
th
 
percentile (adjusted for 
parity, gestation and sex) 
1. Visual acuity (<1.0 Snellen 
decimal) 
2. Poor contrast sensitivity 
(Vistech chart, 1 or more 
values below normal) 
3. Stereoacuity (above 240s of 
arc) 
4. Strabismus 
(esodeviation/exodeviation 
larger than -8 at near, or -2PD 
at distance, any vertical 
deviations) 
5. Nystagmus (pathological) 
6. Accommodation (<6.5 
diopters) 
7. Convergence (near point 
convergence <10cm) 
8. Visual perception ( VMI-IV 
Developmental test of Visual 
Motor Integration test <22) 
9. Overall visual abnormality (≥ 
1 of above impairments) (age 
14 years) 
Evensen et al 2009
 
Norway 
Prospective cohort Same population as above 
study 
LMP + USS if 
discrepancy of more 
than 14 days or if 
could not be recalled 
accurately 
Population chart <10
th
 
percentile (adjusted for 
parity, gestation and sex) 
Systolic blood pressure 
>140mmHg (age 18 years) 
Evensen et al 2004
 
Norway 
Prospective cohort Same study population as 
above 
LMP + USS if 
discrepancy of more 
than 14 days or if 
could not be recalled 
accurately 
Population chart <10
th
 
percentile (adjusted for 
parity, gestation and sex) 
1. Movement ABC score ( total 
<14) (age 14 years) 
2. Weschler IQ (> 2SD below 
control group mean) (age 14 
years) 
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Ferdynus et al 2009
 
France 
Retrospective 
cohort 
(121312) 
Births in the Burgundy 
region from 2000 to 2006 
Singleton 
Chromosomal anomalies 
excluded 
Ethnicity not reported 
 
LMP and early USS 1. Population chart <10
th
 
percentile (based on whole 
study population) 
2. ‘Healthy population’ chart 
<10
th
 percentile (excluding 
maternal diabetes, 
hypertension, pre-
eclampsia/eclampsia, 
abruption placentae, 
placenta praevia, presumed 
chorioamnionitis) 
1.  Neonatal mortality (death 
during hospital stay) 
2. HIE (definition not specified) 
(neonatal) 
 
Figueras et al 2007
 
Spain 
Retrospective 
cohort 
(12705) 
Hospital population 
Year of birth 2001-2005 
Singleton  
Congenital and 
chromosomal anomalies 
excluded 
58% multiparous mothers 
Ethnicity: 73.9% White, 
4.6% South East Asian, 
2.3% Central African, 
18.2% South American, 
Other 0.9% 
Early second trimester 
ultrasound 
1. Population chart <10
th
 
percentile (Santamaria 
Spanish population chart) 
2. Customised centile chart 
<10
th
 percentile (Gardosi et 
al) 
1. Neurological morbidity 
(Seizures, IVH> grade 2, PVL, 
HIE or abnormal EEG) 
(neonatal) 
2. Non-neurological morbidity 
(NICU stay > 10 days, NEC 
(Walsh criteria), renal failure 
(SCr > 132.6 µmol/l / 
1.5mg/dl), cardiac failure (need 
for inotropes) 
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Fitzhardinge and Steven 
1972
 
Canada 
Prospective cohort (132) 
Hospital population 
Year of birth 1960-1966 
Singleton 
Excluded major congenital 
anomalies, prenatal rubella 
infection, chromosomal 
anomalies, marked 
discrepancies in 
gestational age from LMP 
and neonatal findings 
Group of low birth weight 
infants and comparison 
groups of siblings of the 
low birth weight group who 
were of normal weight and 
birth history 
Ethnicity unreported 
LMP, and neonates 
appearance and 
neurological 
development 
30% under expected 
(Streeter's table, below 3rd 
percentile Stuart's table) 
 
1. Speech defect (delayed 
onset, articulation defect, 
immature speech with poor 
receptive/ expressive ability or 
absent speech) (age 3-4 
years) 
2.  CNS  abnormality (including 
hyperactivity, short attention 
span, learning problems 
especially perceptive, poor fine 
co-ordination, hyper-reflexia, 
abnormal EEG) (age 5 years) 
3. Convulsions (age 5 years) 
4. Cerebral palsy (age 5 years) 
Specific thresholds for these 
conditions unreported 
Gagliardo et al 2004
 
Brazil 
Prospective cohort (34) 
Hospital population, SGA 
neonate recruited followed 
by next 2 AGA neonates. 
All considered in good 
health for going home 
within 2 days of birth 
Year of birth 2000-2001 
Excluded genetic 
syndromes, multiple 
anomalies, congenital 
infections 
Unclear if singleton or 
multiple pregnancies 
Ethnicity unreported 
Capurro method  Population chart <10
th
 
percentile (Lubchenco) 
(AGA defined as 25
th
-90
th
 
percentile) 
1. Bayley scale of motor 
development (BSD-II) <85 (age 
3 months) 
2. Bayley scale of mental 
development (BSD-II) <85 (age 
3 months) 
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Gardner et al 2009
 
UK 
Retrospective 
cohort 
(242) 
Healthy children recruited 
from randomly selected 
schools, stratified for 
socioeconomic status 
Birth weight obtained from 
child health registry 
Year of birth >1994 
Unclear if singleton or 
mixed 
No specific exclusions 
reported  
Ethnicity: 98% white 
 
 
Unreported Birth weight <2.5kg 1. Obese (>98
th
 percentile UK 
1990 growth charts) (age 9 
years) 
2. Overweight or obese (>91
st
 
percentile 1990 UK growth 
charts)(age 9 years) 
Glinianaia et al 2010
 
UK 
Retrospective 
cohort 
(107461) 
All singleton births in 
Newcastle upon Tyne 
1961-2000 
Excluded individuals with 
missing data (congenital 
anomalies not excluded) 
Ethnicity unreported 
  
Unreported 1. Birth weight <2.5kg 
2. Birth weight <1.5kg 
1. Neonatal death (28 days) 
2. Infant death (≤ 12 months) 
Gouyon et al 2003
 
France 
Prospective cohort (27008) 
General population, all live 
full term births in Burgundy 
region 
Year of birth 2000-2001 
Ethnicity unreported 
Not specified if singleton/ 
multiple births 
No exclusions reported 
Unreported 1. Population chart <10
th
 
percentile (French growth 
curves) 
2. Population chart <3
rd
 
percentile (French growth 
curves) 
1. Severe neurological 
disorders (threshold 
unreported) (neonatal) 
2. Respiratory distress 
syndrome (threshold 
unreported) (neonatal) 
3. Neonatal death 
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Gray et al 1991
81 
Brazil 
Prospective cohort (2977) 
Hospital and maternity unit 
population (5 centres) All 
low birth weight infants and 
control group (selection 
method unclear) 
Year of birth 1984-1986 
Singleton 
Congenital anomalies not 
excluded 
Ethnicity unreported 
Capurro method Birth weight <2.5kg 1. Early neonatal death 
(7days) 
Haas, Balcazar and 
Caulfield 1987
 
Mexico 
Retrospective 
cohort 
(16321) 
2 maternity hospitals, one 
serving lower 
socioeconomic class, one 
mixed population. 
Year of birth 1981-1984 
Excluded outliers <500g or 
> 5500g, length <40 cm or 
> 56cm. 
Ethnicity Latin American 
Classified by neonatal 
clinical examination as 
term or preterm, LMP 
addition if available 
1.Population chart <10
th
 
percentile (Brandt) 
2.Rohrer's Index (wt (g) 
x100/length (cm)3) 
Early neonatal death (48 
hours) 
Hands et al 2009
 
Australia 
Prospective cohort (1555) 
Hospital population, 
women recruited from 
tertiary centre antenatal 
clinic 
Year of birth 1989 onwards 
Singleton 
Congenital anomaly 
excluded 
Ethnicity: 84.9% 
Caucasian, 2.1 % 
Aboriginal, 12.1% Other 
Unreported Birth weight <2.0kg Mild motor disability 
(Neuromuscular development 
index (NDI) from scores of 
McCarron Assessment of 
neuromuscular development 
(MAND) mild disability 71-85, 
>85 normal) (age 10 years) 
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Hemachandra et al 2006
 
USA 
Retrospective 
cohort 
(24951) 
Pregnant women enrolled 
at 12 academic medical 
centres  
Year of birth 1959-1965 
Mixed singleton and 
multiple births 
Exclusions: Deaths 0-7 
years of age, implausible 
data (≥ 4SD from mean), 
children diagnosed with 
cardiac or renal disease 
Ethnicity: 52% white and 
48% black  
 
LMP Birth weight ≤ 2.5kg Systolic BP>90th percentile 
(study population blood 
pressure distributions) (age 7 
years) 
Hindmarsh et al 2010
 
UK 
Prospective cohort (339) 
Pregnant women enrolled 
at tertiary referral centre 
Year of birth 1996-1997 
Singleton 
Excluded if congenital 
anomalies or maternal 
steroid use 
Caucasian mothers 
LMP, corrected by 
USS if CRL <12 weeks 
or BPD 12-20 weeks 
differed from LMP date 
by >7 days 
1.Birth weight <2.5kg 
2. Birth weight <1.5kg 
1. Systolic BP >90
th
 centile (4th 
task force on blood pressure in 
children) (age 3 years) 
2. Diastolic BP >90
th
 
centile(4th task force on blood 
pressure in children) (age 3 
years)  
Indredavik et al 2010
 
Norway 
Prospective cohort (140) 
Year of birth 1986-1988 
Cohort of birth weight <10
th
 
centile and random sample 
of birth weight ≥ 10
th
 centile 
Excluded congenital 
anomaly or cerebral palsy 
Unclear if singleton or 
multiple pregnancy 
Ethnicity unreported 
LMP + USS if 
discrepancy of more 
than 14 days or if 
could not be recalled 
accurately  
Population chart <10
th
 
percentile (Vik definition, 
percentiles adjusted for 
gestational age, sex and 
parity) 
Psychiatric diagnosis (DSM-IV  
anxiety disorder, Attention 
Deficit Hyperactivity disorder, 
Autism Spectrum Disorder) 
(age 14 years) 
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Jacobsson et al 2008
 
Sweden 
Case control study (654) 
Cases from cerebral palsy 
register, born in Sweden 
and had lived in the study 
area at 4-8 years of life. 
Matched with 2 controls 
from national birth register, 
closest births to index case 
matched for gestational 
age, gender, age, sex, 
multiple pregnancy and 
delivery ward 
Year of birth 1983-1990 
Singleton 
Excluded if postnatal cause 
of cerebral palsy or 
incomplete data 
Ethnicity unreported 
USS between 16 and 
19 weeks 97% cases, 
3% LMP only. 
1. Customised chart <10
th
 
percentile (Gardosi) 
2. Customised chart <5
rd
 
percentile (Gardosi) 
3. Customised chart <1
st
 
percentile (Gardosi) 
Cerebral palsy (Swedish 
classification non progressive 
motor impairment) (4-8 years 
old) 
Jeliffe- Pawlowski and 
Hansen 2004 
USA 
Retrospective 
cohort 
(27791) Pregnant women 
enrolled at 12 academic 
medical centres  
Year of birth 1959-1965 
Singleton 
Exclusions: Deaths 0-7 
years of age, implausible 
data (≥ 4SD from mean), 
born after 44 weeks 
gestation 
Ethnicity: 50% white and 
50% black 
LMP Population chart <10
th
 
percentile (gender and 
weight specific for this 
cohort) 
(AGA= 25
th
to 90
th
 
percentile) 
1. Bayley mental development 
index (MDI)  score ≤85(age 8 
months) 
2. Bayley psychomotor 
development index score(PDI) 
≤85(age 8 months) 
3. Combined delay (MDI and 
PDI≤85) (age 8 months) 
4. Mental retardation 
(Stamford-Binet IQ <70) (age 
4years) 
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Johnson 1985
 
USA 
Case control study (303) 
Cases of neuroblastoma 
and random sample of 
controls born in Texas 
Unclear if singleton/ mixed 
Year of birth 1964 to 1978 
No exclusions specified 
Ethnicity: mixed White, 
Hispanic and Black 
population 
LMP Birth weight <2.5kg Death from neuroblastoma 
(death certificate cause of 
death) (age before age 15 
years) 
Kajante et al 2006
 
Finland 
Retrospective 
cohort 
(13830) 
Individuals born in 
University hospital, went to 
school in Helsinki and still 
resident in Finland at time 
of study. 
Year of birth 1924-1944 
Singleton 
No exclusions specified 
Ethnicity unreported 
LMP Birth weight <2.5kg 1. All cause mortality (Finnish 
death register) (26.7-74.9 
years) 
2. All cause mortality (<55 
years of age)  
3. Cancer mortality  (26.7-74.9 
years) 
4. Cardiovascular mortality 
(26.7-74.9 years) 
Kindlund et al 2010
 
Denmark 
Retrospective 
cohort 
(4989) 
Live born twins in Denmark 
during study period who 
were included in 
nationwide Danish Twin 
Registry 
Year of Birth 1994-2000 
No other exclusions 
specified 
Ethnicity unreported 
Unreported Birth weight <2.5kg Asthma (questionnaire to 
parents about diagnosis ) (age 
3-9 years) 
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KlungsØyr Melve and 
Skjaerven 2003
 
Norway 
Retrospective 
cohort 
(527157) 
Births in the Norwegian 
Medical Birth Registry, 
mothers with at least 2 
singletons 
Year of Birth 1967 to 1998 
Singleton 
No exclusions specified 
Ethnicity unreported 
LMP 1.Birth weight <2.5kg 
2.Birth weight <2.0kg 
3.Birth weight <1.5kg 
Neonatal death (28 days) 
Kotecha et al 2010
 
UK 
Retrospective 
cohort 
(5770) 
Population study open to 
pregnant women residing 
in Avon 
Year of birth 1991-1992 
Singleton 
Not specified if anomalies 
excluded 
Ethnicity: 100% Caucasian 
LMP, confirmed by 
scan in a proportion of 
the population 
Z score (birth weight and, 
adjusted for gestational age 
and gender ) < 1.28 (10th 
centile) 
Asthma (American thoracic 
society standards) (age 91 
months) 
Kramer et al 1990
 
Canada 
Retrospective 
cohort 
(5305) 
Hospital born infants at 
single centre. 
Year of birth 1980-1986 
Singleton 
Excluded congenital 
anomalies, chromosomal 
anomalies and evidence of 
intrauterine infection 
Ethnicity unreported 
USS BPD 16-18 
weeks  gestation + 
LMP 
1.Fetal growth ratio <0.75 
(observed birth weight/ 
mean birth weight for 
gestational age for this 
hospital population) 
2. Fetal growth ratio 
<0.80(observed birth 
weight/ mean birth weight 
for gestational age for this 
hospital population) 
1.Neonatal death (in hospital, 
age range unspecified) 
2. Hypoglycaemia  (plasma 
glucose <40mg/dL) (neonatal) 
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Kuhle, Allen and 
Veugelers 2010 
Canada 
Retrospective 
cohort 
(3190) 
Population based study, 
Grade 5 students in Nova 
Scotia region, linked to 
perinatal database. 
Year of birth: 1991-1992 
Unclear if singleton/ 
multiple births 
Exclusions missing or 
improbable birth weight for 
gestational age, invalid 
health insurance number 
Ethnicity unreported 
Unreported Population chart <10
th
 
percentile (Kramer 
definition) 
Overweight or obese (CDC 
classification) (age 11 years) 
Lamb et al 2010
 
USA 
Retrospective 
cohort 
(1178) 
Two groups of children: 
one recruited in infancy 
(unaffected first degree 
relatives of patients with 
type 1 diabetes, identified 
through childhood diabetes 
centre; second group 
babies born at single 
hospital in Denver region. 
Year of birth: unreported 
Unclear if singleton/ 
multiple births 
Ethnicity: non-Hispanic 
white 72.1% 
Unreported Population chart <10
th
 
percentile (Oken USA 
reference chart) 
1. BMI ≥ 85th percentile (CDC 
growth charts) (age 2-11.5 
years) 
2. BMI ≥ 95th percentile (CDC 
growth charts) (age 2-11.5 
years) 
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Larroque et al 2001
 
France 
Retrospective 
cohort 
(496) 
Population based birth 
registry in and around the 
city of Haguenau, all full 
term singletons born SGA, 
control first AGA infant 
listed in registry after SGA 
infant 
Year of birth 1971 to 1978 
Singleton 
Excluded aberrant growth 
measurements, 
psychomotor disorder or 
institutionalised, or chronic 
illness including congenital 
anomaly, adoption, death 
Ethnicity unreported 
LMP, physical 
examination, 
confirmed by USS 
where available 
Population chart <3rd 
percentile birth weight or 
length (Haguenau local 
reference curves) 
School difficulties (Late entry 
into secondary school) (age 
11-12 years) 
Levitt et al 2000
 
South Africa 
Prospective cohort (113) 
Single hospital population, 
primigravid mothers. All 
infants born SGA included, 
and random sample of 
AGA 
Year of birth 1975-1976 
Singleton 
No exclusions reported 
Ethnicity: mixed Koi San, 
European, East Indian, 
Malaysian and Black 
African 
Dubowitz method Population chart <10
th
 
centile, compared with 
individuals 25
th
-75
th
 
percentile 
1. Impaired glucose tolerance 
and type 2 diabetes (1985 
WHO criteria) (age 20 years) 
2. Hypertension 
(BP>140/90mmHg) (age 20 
years) 
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Li, Law and Power 2007
 
UK 
Retrospective 
cohort 
(8520) 
Infants born in England, 
Wales and Scotland in one 
week period 
Year of birth 1958 
Not specified if singleton/ 
multiple births 
No exclusions reported 
Ethnicity unreported 
Unreported Birth weight <2.5kg 1. Hypertension (BP ≥ 
140/90mmHg) (age 45 years ) 
2. BMI ≥ 30 (age 45 years) 
Libby et al 2008
 
UK 
Retrospective 
cohort 
(1065) 
Population study: Dundee 
birth cohort, record linked 
to adult health factors in 
Scottish working population 
Year of birth 1952-1966 
Unclear if singleton/ 
multiple births 
No exclusions reported 
Ethnicity unreported 
LMP Birth weight <2.5kg Total cholesterol >5mmol/L 
(non-fasting) (age 24 to 42 
years) 
Liew et al 2008
 
USA 
Retrospective 
cohort 
(609) 
Population based cohort, 
adults recruited in middle 
age by probability sampling 
in 4 US communities 
Year of birth 1923-1944 
Unclear if singleton/ mixed 
Excluded if retinopathy not 
classifiable 
Ethnicity: 79% White 
Self- report of 
prematurity 
Birth weight >2.5kg Diabetic retinopathy any grade 
(American academy of 
opthalmologists 2007) 
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Lira, Ashworth and 
Morris 1996
 
Brazil 
Prospective cohort (393) 
Infants recruited from the 
maternity wards of two 
state hospitals, one private 
hospital and three 
government health centers.  
Eligible if 1500-2499g, 
controls of weight  3000-
3499g matched for sex and 
season of birth  
Year of birth 1993-1994 
Congenital anomalies 
excluded 
Singleton 
Ethnically diverse (not 
specified) 
Capurro method Birth weight >2.5kg Death (up to 26 weeks of age) 
Low et al 1992
 
Canada 
Prospective cohort (104) 
Cohort of high risk infants, 
recruited if FGR <10th 
centile, infants of IDDM 
mothers, intrapartum 
asphyxia with um artery 
buffer base < 34mmol/L, 
respiratory complications or 
encephalopathy 
Year of birth 1978-1982 
Mixed singleton and 
multiple births 
Excluded congenital or 
genetic anomaly 
Ethnicity unreported 
Unclear Population chart <10
th
 
centile (reference chart 
unreported) 
Learning deficit (< 15th 
percentile than expected for 
age Woodcock reading 
mastery test) (age 9-11 years) 
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Low et al 1982
 
Canada 
Prospective cohort (124) 
Group of IUGR infants 
(birth weight <10
th
 
percentile) and group of 
control infants (birth weight 
>25
th
 percentile) 
Year of birth: unreported 
Mixed singleton/multiple 
birth 
Ethnicity:96% of control 
infants and 86% of IUGR 
infants Caucasian 
LMP 1. Population chart <10
th
 
percentile (Gruenwald 
curve) 
2. Population chart <5
th
 
percentile (Gruenwald 
curve) 
1. Intelligence (Weschler Pre-
school and primary scale of 
Intelligence <85) (age 60 
months) 
2. Motor handicap (minor 
abnormalities of tone, co-
ordination or motor function or 
McCarthy's motor score ≤39, 
or cerebral palsy) (age 60 
months) 
Lubchenco, Searls and 
Brazie 1972
 
USA 
Retrospective 
cohort 
(11197) 
All live born infants at 
single university centre 
during the study period, 
with adequate information 
on gestational age 
Year of birth: 1958 to 1968 
Mixed singleton/ multiple 
birth 
No exclusions reported 
Ethnicity 55% Anglo-
American, 30% Mexican 
American, 15% African 
American 
Unreported 1.Birth weight <2.5kg 
2.Birth weight <2.0kg 
Neonatal death (28days) 
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Lurbe et al 2009
 
Spain 
Case control study (422) 
Obese adolescents 
attending Paediatric unit, 
non- obese subjects drawn 
from a parallel study, all 
well and not taking 
medication. Birth details 
obtained from obstetric 
records. All mothers 
normotensive during 
pregnancy 
Year of birth: unclear 
Excluded if: severe obesity, 
secondary obesity 
Unclear if singleton/ 
multiple birth 
Ethnicity: all white 
European 
Unreported Population chart <10
th
 
percentile (Lubchenco) 
Obesity (BMI >97
th
 percentile 
for age and sex) (age 10-18 
years) 
Manji, Massawe and 
Mgone 1998
 
Tanzania 
Prospective cohort (800) 
Neonatal unit at teaching 
hospital, admissions over a 
4 months period 
Year of birth 1990-1991 
Exclusions unreported 
Mixed singleton/ multiple 
births 
Ethnicity unreported 
Dubowitz method 1.Birth weight < 2.5kg 
2.Birth weight <2.0kg 
3.Birth weight <1.5kg 
Death (up to 6 weeks of age) 
Mardones et al 2008
 
Chile 
Retrospective 
cohort 
(216315) 
Live births and neonatal 
death information from 
Chilean Civil Registry 
service 
Year of birth: 2000 
Mixed singleton and 
multiple births 
Excluded if data incomplete 
Ethnicity unreported 
LMP, USS before 20 
weeks, postnatal 
clinical examination. 
Majority have USS 
dating but exact no not 
reported 
 
1. Birth weight <2.5kg 
2. Birth weight <1.5kg 
Neonatal death (28 days) 
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Matijasevich et al 2008
 
Brazil 
Prospective cohort (4130, 4171, 3392)Three 
separate birth cohorts in 
city of Pelotas. Maternity 
wards visited on daily basis 
and mothers interviewed. 
Perinatal mortality 
surveillance: visiting 
maternity wards, 
intermediate care centres, 
registry offices and 
cemeteries 
Year of birth : 1982, 1993, 
2004 
Mixed singleton and 
multiple births 
Excluded if gestational age 
incompatible with birth 
weight. Congenital 
anomalies not excluded. 
Ethnicity unreported 
LMP, in 1993 and 
2004 Dubowitz score 
also used, in 2004 
large number also had 
early pregnancy USS 
Population chart < 10
th
 
percentile (Williams curve) 
Early neonatal death (7 days) 
McIntire et al 1999
 
USA 
Retrospective 
cohort 
(82361) 
Live births at single 
hospital during study 
period. Outcomes 
abstracted from medical 
records, birth information 
prospective database. 
Year of birth 1988-1996 
Singleton 
Congenital anomalies 
excluded, and birth weight 
>75
th
 centile 
Ethnicity: 54% Hispanic, 
28% black, 15% white, 3% 
other 
LMP, if fundal height 
discrepancy (18-30 
weeks gestation) > 
2cm confirmed by USS 
 
1. Population chart ≤ 10
th
 
percentile (this population) 
2. Population chart ≤ 5
th
 
percentile (this population) 
3. Population chart ≤ 3
rd
 
percentile (this population)  
1. Neonatal death (28 days) 
2. Seizures  (definition 
unreported)(1
st
 24 hours) 
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McKinney et al 1999
 
UK 
Case control study (598) 
Cases registered to York 
Childhood diabetes 
Register, two matched 
controls (year and month of 
birth) randomly selected 
from primary care 
registrations of FHSA 
Year of Birth: 1978-1994 
Mixed singleton and 
multiple births 
Congenital malformations 
not excluded 
Ethnicity: 95% White, 3.5% 
Indian/Pakistani 
Unreported Birth weight <2.5kg Type 1 Diabetes (diagnostic 
criteria unreported) (age 0-16 
years) 
Meas et al 2010
 
France 
Retrospective 
cohort 
(1308) 
Population based registry 
from Haguenau, SGA 
group individuals born 
<10
th
 percentile, AGA 
group 25
th
 -75
th
 percentile 
Year of birth: 1971 - 1985 
Singleton 
Excluded chronic disease 
including metabolic 
disorders 
Ethnicity unreported 
Unreported Population chart (<10
th
 
percentile) (Local growth 
curves) 
1.Metabolic syndrome (at least 
3 of: fasting blood glucose ≥ 
6.1mmol/l, waist circ ≥ 102 cm 
(m) 88cm (f), triacylglycerol 
≥1.69mmol/l, HDL cholesterol 
<1.04mmol/l (m ) or 
(1.29mmol/l (f) and BP 
≥130/85mmHg or treated 
hypertension) (age30 years) 
2. Diabetes mellitus (criteria 
unreported) (age 30 years) 
3. Diabetes mellitus or 
impaired glucose tolerance 
(OGTT, threshold unreported) 
(age 30 years) 
Meas et al 2008
 
France 
Retrospective 
cohort 
As above Unreported Population chart <10
th
 
percentile (Local growth 
curves) 
BMI >30 (age 30 years) 
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Menezes et al 2006
 
Brazil 
Prospective cohort (3931) 
All hospital deliveries in 
Pelotas region  
Year of birth 1993 
Unclear if singleton/ 
multiple  births 
No exclusions specified 
Ethnicity unreported 
Dubowitz method Birth weight <2.5kg Systolic BP ≥ 120mmHg (1. 
Age 11 years 2. Age 15 years) 
Mi et al 2008
 
China 
Retrospective 
cohort 
(932) 
Sequential live births at 
single hospital during the 
study period. Infants traced 
in adulthood 
Year of birth 1948-1954 
Singleton 
No exclusions specified 
Ethnicity unreported 
LMP 1.Birth weight <2.5kg 
2. Ponderal Index 
(kg/m
3
)<24.5  
1. Metabolic syndrome (Alberti 
et al International Diabetes 
Federation definition)  
2. Total cholesterol >5mmol/L  
3. BMI >30  
4. Diabetes mellitus type 2 
(WHO criteria)  
5. Diabetes mellitus or 
impaired glucose tolerance 
(OGTT,2hr 
glucose>7.8mmol/L)  
6.Hypertension (pre-existing 
diagnosis)  
7. Systolic BP ≥140mmHg 
8. Diastolic BP ≥90mmHg 
All above at age 41-52 years 
Minikami, Izumi and 
Sato 1999
 
Japan  
Retrospective 
cohort 
(54802) 
Japanese Ministry of 
Health and Welfare data 
regarding births and deaths 
Year of birth: 1989-1993 
All multiple births 
No exclusions specified 
Ethnicity unreported 
Exact numbers 
unreported: "early USS 
widely practiced in 
Japan/ many multiple 
pregnancies conceived 
after IVF" 
Birth weight > -1SD below 
mean (calculated from 
study population) 
Early neonatal death (7days) 
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Minior and Divon 1998
 
USA 
Retrospective 
cohort 
(268) 
Cohort of SGA infants born 
following uncomplicated 
pregnancies (excluded 
maternal medical 
conditions e.g. pre-
eclampsia, diabetes, renal 
or automimmune disease), 
matched to three AGA 
controls 
Year of birth 1988-1995 
Singleton 
Congenital or chromosomal 
anomalies excluded 
Ethnicity 35% white, 31% 
Black, 27% Hispanic, 7% 
Other 
Early USS  1.Population chart <10
th
 
percentile (Brenner) 
2.Population chart <5
th
 
percentile (Brenner) 
Neonatal morbidity (one of 
more of: hypoglycaemia, 
respiratory distress, 
thrombocytopenia, 
hyperbilirubinaemia, intubation, 
sepsis, IVH, apnoea) 
(thresholds unreported) 
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Moser et al 2007
 
UK 
Retrospective 
cohort 
(590430) 
Routine birth and death 
registration records, and 
NHS Numbers for Babies 
data for babies born in 
England and Wales 
Year of Birth: 2005 
Mixed singleton/ multiple 
birth 
Excluded if incomplete data 
Ethnicity unreported 
 
 
Unreported 1.Birth weight <2.5kg 
2.Birth weight <1.5kg 
1. Neonatal death (up to 28 
days) 
2. Infant death (up to 12 
months) 
Nelson and Broman 
1977
 
USA 
Prospective cohort (29551) 
Pregnant women enrolled 
at 12 academic medical 
centres  
Year of birth 1959-1965 
Mixed singleton and 
multiple births 
Exclusions:  children with 
gross CNS malformation, 
metabolic, chromosomal or 
other specific disorders or 
known neurological 
catastrophe e.g. meningitis 
post neonatal discharge 
Ethnicity: 52% white and 
48% black  
LMP Absolute birth weight ≤ 
2.5kg 
Severe mental or motor 
handicap (IQ < 50 and 
moderate or severe motor 
deficits due to cerebral palsy) 
(age 7 years) 
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Nobili et al 2007
 
Italy 
Case control study (180) 
Cases of children with non-
alcoholic fatty liver disease, 
consecutively observed in 
Liver Unit, and matched 
controls (age and sex) with 
normal liver scan and liver 
function 
Year of Birth:  1984-1998 
Exclusions unreported 
Unreported if 
singleton/multiple birth 
Ethnicity unreported 
Unreported Population chart ≤10
th
 
percentile (Gairdner- sex 
and age specific) 
Non-acute fatty liver disease 
(liver biopsy diagnosis) (mean 
age 11.3+/-3.8) 
North 1966
 
USA 
Retrospective 
cohort 
(2676) 
Deliveries at single 
maternity unit, infants 
weighing 1.0-2.5kg 
matched with infants 3.0-
3.5kg. 
Year of birth 1957-1964 
Mixed singleton/multiple 
birth 
No exclusions specified 
Ethnicity: 75% White, 25% 
Non-white 
Unreported Birth weight ≤2.5kg Neonatal death 
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O’Keefe et al 2003
 
Australia 
Prospective cohort (5023) 
Pregnant women recruited 
from single centre. Infants 
followed up. 
Year of birth: 1981-1984 
Singleton 
Exclusions: perinatal death 
and adoption 
Ethnicity: 97% White 
Unreported 1. Population chart <10
th
 
percentile (Roberts 
Australian norms, sex and 
gestation specific) 
2. Population chart <3rd 
percentile (Roberts 
Australian norms, sex and 
gestation specific) 
3.Ponderal index (kg/m3)< 
25
th
 percentile 
4.BHR (birth weight (g)/ 
head circumference (cm)) 
<25
th
 percentile 
 
1. Learning difficulties 
(questionnaire to mother) (age 
14 years) 
2. WRAT reading score <85 
(age 14 years) 
Ott 1995
 
USA 
Retrospective 
cohort 
(957) 
Infants of a series of high 
risk obstetric patients 
referred to single perinatal 
centre.  
Year of birth: 1990-1991 
Unclear if singleton/ 
multiple birth 
Congenital anomalies 
excluded 
Ethnicity unreported 
Unreported Population chart <10
th
 
percentile (Ott and 
Hadlock) 
Neonatal mortality 
Owen et al 2003
 
UK 
Retrospective 
cohort 
(1319) 
Random selection of 
children from 68 British 
secondary schools, birth 
records obtained from 
hospital of birth 
Year of birth:1982-1986 
Mixed singleton/ multiple 
birth 
No exclusions reported 
Ethnicity: 92% White, 6% 
South Asian, 2% Other 
Unreported Birth weight <2.5kg Total cholesterol <5mmol/L 
(fasting/non-fasting) (age 13-
16 years) 
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Padin-Rojas et al 1986
 
Puerto Rico 
Prospective cohort (48) 
Cohort of infants born at 
tertiary centre and recruited 
to trial of infant nutrition 
Year of birth: 1986 
Unclear if singleton/ 
multiple birth 
No exclusions specified 
Ethnicity unreported 
LMP Ponderal Index weight (g) 
x100/length (cm)
3
 (low, 
threshold unspecified) 
Bayley Mental Development 
Index <69 (age 1 year) 
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Pandolfi et al 2008
 
Italy 
Retrospective 
cohort 
(50) 
Women who had birth 
weight <2.5kg randomly 
recruited from neonatal unit 
registry of single hospital. 
Control subjects, next 
female in the registry with 
birth weight ≥ 3.0kg 
Year of birth: >1980 
Singleton 
Excluded if: Congenital 
malformations, 
chromosomal anomalies, 
major neonatal and 
maternal pregnancy 
complications including 
gestational diabetes and 
pre-eclampsia 
Ethnicity unreported 
Unreported Birth weight <2.5kg Polycystic ovarian syndrome 
(12 or more follicles < 10mm 
diameter or increased ovarian 
vol > 10cm3, associated with 
irregular menses, hirsutism) 
(age 
21.8 +/- 1.4 years) 
 
Pathai, Cumberland and 
Rahi 2010
 
UK 
Retrospective 
cohort 
(13613) 
Cohort of infants resident in 
UK, aged 9 months at time 
of recruitment. Details 
regarding birth weight and 
outcomes obtained through 
questionnaire to parents. 
Year of birth:2000 
Mixed singleton/ multiple 
birth 
No exclusions specified 
Ethnicity: 89% White, 6% 
South Asian, 2.5 % Black 
African/Caribbean  
Unreported Birth weight <2.5kg Strabismus (questionnaire to 
parents about strabismus and 
other eye conditions, common 
synonyms for strabismus 
considered positive response) 
(age 3 years) 
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Paz et al 1995
 
Israel  
Retrospective 
cohort 
(1707) 
All subjects born at 
University Medical center 
and subsequently drafted 
into the army. 
Year of birth:  1970 to 1971 
Singleton 
Congenital anomalies, 
chromosomal disorders or 
congenital infections 
excluded 
Ethnicity: 11% Israeli, 21% 
Asian, 42% Euro-
American, 26% African 
LMP Population chart <3
rd
 
percentile (based on study 
population) 
Low educational achievement 
(less than 12 years of 
schooling or attending 
vocational school) (age 18 
years) 
Pearce and O’Sullivan 
2003
 
UK 
Retrospective 
cohort 
(408) 
Children recruited from 26 
schools in Newcastle upon 
Tyne area, birth information 
obtained from parents, 
confirmed in >50% by 
hospital records 
Year of birth: unclear 
Unclear if singleton/ 
multiple birth 
Excluded pre-existing 
cardiac or renal disease 
Ethnicity: unreported 
Unreported Birth weight <2.5kg 1. Systolic BP >120mmHg 
(age 6-16years) 
2.Diastolic BP >80mmHg (age 
6-16 years) 
Peng et al 2005
 
China 
Retrospective 
cohort 
(147) 
Infants born at two Shangai 
hospitals.  
Year of birth 1983 
Mixed singleton/ multiple 
births 
Excluded if birth weight 
<1.2kg 
Ethnicity: Chinese 
LMP and newborn 
physical examination 
Population chart <10
th
 
percentile (chart 
unreported) 
1. Neurodevelopmental 
abnormalities (Gesell 
Developmental diagnosis DQ ≤ 
85)(1. Age 4 months 2. Age 36 
months) 
2. IQ (Weschler IQ ≤85) (Age 
16 years) 
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Plante 2004
 
USA 
Retrospective 
cohort 
(7802) 
All females born at term in 
Pennsylvania in 1974 who 
delivered full term singleton 
live born infants 1999-
2000, data regarding 
outcome obtained from 
check box on birth 
certificate 
Year of birth:1974 
Singleton 
Excluded racial origin other 
than black or white, or 
incomplete information 
Ethnicity: 79% White 21% 
Black 
clinical, LMP or 
ultrasound criteria 
Population <10
th
 centile 
(Brenner chart, gestation 
and race specific) 
1. Diabetes in pregnancy 
(gestational/ pre-existing) 
Pulver et al 2009
 
USA 
Retrospective 
cohort 
(316077) 
Population study of infants 
born in Utah, linked birth 
and death databases 
Year of birth: 1999-2005 
Unclear if singleton/ mixed 
Congenital anomalies not 
excluded 
Ethnicity unreported 
LMP, prenatal USS 
and/or newborn 
examination 
Population <10
th
 percentile 
(curves for the study 
population) 
1.Neonatal death (up to 28 
days) 
2.Infant death 
Rahaila et al 2002
 
Finland 
Retrospective 
cohort 
(100) 
All children with IUGR born 
at single university hospital, 
next AGA child of same 
gender and born at term 
selected as control. 
Year of birth: 1984 to 1986 
Singleton 
Congenital anomalies 
excluded 
Ethnicity unreported 
Unreported >2SD below mean weight 
for gestational age 
ABPM, mean systolic BP 
>120mmHg (age 12 years) 
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Rich-Edwards et al 1997
 
USA 
Retrospective 
cohort 
(66689) 
Nurses’ health study, 
postal questionnaires sent 
to registered nurses 
regarding their medical 
histories and lifestyle. Birth 
information self- reported. 
Outcome data from 
medical records 
Year of birth: 1921-1946 
Singleton 
Excluded if had 
cardiovascular disease at 
time of initial questionnaire, 
or birth weight unknown 
Ethnicity: unreported 
Self-report of 
prematurity, method of 
diagnosis unclear 
Birth weight ≤2495g 1. Non-fatal coronary heart 
disease (WHO criteria: 
symptoms and either 
diagnostic ECG or cardiac 
enzyme changes)(age 46-71 
years) 
2. Non-fatal stroke (typical 
neurological deficit of sudden 
onset for more than 24 hours. 
Ischaemic and haemorrhagic) 
(age 46-71 years) 
Salonen et al 2010
 
Finland 
Prospective cohort (70) 
All children with IUGR born 
at single university hospital, 
next AGA child of same 
gender and born at term 
selected as control. (AGA 
described as ≤ -2SD and ≤ 
+2SD scores of the 
respective mean for 
gestational age and sex) 
Year of birth: 1984 to 1986 
Singleton 
Congenital anomalies 
excluded 
Ethnicity unreported 
Unreported >2SD below mean weight 
for gestational age 
1. Systolic BP >140mmHg 
(age 20 years) 
2. Total cholesterol >5mmol/L 
(after overnight fast)(age 20 
years) 
3. BMI ≥ 30(age 20 years) 
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Sommerfelt et al 2001
 
Norway 
Prospective cohort (625) 
Multicenter study, parous 
mothers recruited before 
20 weeks gestation. Those 
with risk factors for SGA 
infant and 10% random 
sample of the rest followed 
up 
Year of birth 1986 to 1988 
Unclear if singleton/ 
multiple births 
Congenital anomalies 
excluded, and if unable to 
speak Scandinavian 
language 
Ethnicity unreported 
USS 17-18 wks, 
altered date from LMP 
if uncertain or >14 
days discrepancy  
Population chart <15
th
 
percentile (reference 
standards from Norwegian 
Birth Registry) 
Behavioural problems (total 
problem score (YCI and ERS), 
cut of > 95th percentile for 
scores from AGA group)(age 5 
years) 
Strauss 2000
 
UK 
Prospective cohort (3034) 
Infants born in the UK 
during a single week, 
followed up  with 
questionnaires and 
academic tests 
Year of birth: 1970 
Mixed singleton/ multiple 
birth 
Congenital anomalies 
excluded 
Ethnicity: 97% White 
British/European  
LMP Population chart <5
th
 
percentile (British reference 
standards (Cole/ Davie)) 
Impaired academic ability 
(teachers assessment bottom 
15
th
 percentile) 
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Thompson et al 2001
 
UK 
Retrospective 
cohort 
(810) 
Subsample of study of all 
births in Herefordshire, 
traced and still living in the 
county.  
Year of birth:1920-1930 
Singleton 
No exclusions specified 
Ethnicity unreported 
Unreported Birth weight <2.9kg Depression (5 or more 
Geriatric Depression Score, or 
3 or more Geriatric Mental 
State B version) (mean age 68 
years) 
Ullah et al 2009
 
Bangladesh 
Prospective cohort (770) 
Term newborns at a single 
hospital, stratified sampling 
from three birth weight 
strata (≤2, >2 to <2.5 and 
≥2.5kg)  
Year of birth: unreported 
Singleton 
Included infants defined as 
normal, therefore 
anomalies excluded 
Ethnicity: Bangladeshi 
LMP 1. Birth weight <2.5kg 
2. Birth weight ≤ 2kg 
1. Neonatal death (1
st
 7 days) 
2. Birth asphyxia (definition not 
described)(1
st
 7 days) 
3. Acute respiratory infection 
(definition not described) (1
st
 7 
days) 
Uvebrant and Hagberg 
1992
 
Sweden 
Case control study (613) Population based 
series of children with 
cerebral palsy and controls, 
term live born infant of the 
same sex and born in the 
same unit 
Year of birth: 1975-1982 
Mixed singleton/ multiple 
birth 
Excluded: missing data or 
postnatal (after first week 
of life) cause of cerebral 
palsy 
Ethnicity: unreported 
Unreported ≥-2SD below mean (Fryer 
Swedish growth chart) 
Cerebral palsy (non-
progressive disorder 
movement/ posture, Bax 
definition) (childhood, age not 
specified) 
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Vikse et al 2008
 
Norway 
Retrospective 
cohort 
(1937768) Birth data from 
Norwegian birth registry 
matched to data from 
Norwegian renal registry 
Year of birth: 1967 
onwards 
Mixed singleton/ multiple 
birth 
Congenital anomalies not 
excluded 
Ethnicity unreported 
Unreported Population chart <10
th
 
percentile 
End stage renal 
disease(definition not reported) 
(0.2-38 years) 
Walther and Ramaekers 
1982
 
The Netherlands 
Cohort, unclear if 
prospective/ 
retrospective 
(50) 25 consecutively born 
term infants showing 
intrauterine malnutrition 
prospectively compared to 
25 normally grown term 
infants 
Year of birth: not reported 
Singleton 
Congenital anomalies 
excluded 
Ethnicity: all Caucasian 
Dubowitz method Population chart <10
th
 
percentile (Kloosterman 
grid) 
Delayed language 
achievement  (Reynell 
Developmental Language 
scales ≥2 SD below standard 
mean) (age 31-42 months) 
Walther and Ramaekers 
1982
 
The Netherlands 
Cohort, unclear if 
prospective/ 
retrospective 
(500) consecutive live born 
infants admitted to the 
neonatal ward directly after 
birth at a single hospital.  
Year of birth: Unreported 
Singleton 
Congenital anomalies, 
chromosomal anomalies, 
fetal infections or 
haemolytic disease 
excluded. 
Ethnicity: all Caucasian 
Dubowitz method 1.Population chart <10th 
percentile (Kloosterman 
grid) 
2. Ponderal Index (kg/m
3
) 
<10
th
 percentile (Miller and 
Hassanein chart) 
1. Hypothermia (admission 
rectal temp < 35.5 C)(neonatal) 
2. Hypoglycaemia (≤ 
1.6mmol/L blood 
glucose)(neonatal) 
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Taiwan 
Case control study (810)All school children in 
Taiwan province screened 
for diabetes, all cases of 
type 1 1992-1997 and 
random selection of normal 
controls. Birth data 
obtained from Birth 
Registry 
Year of birth:1974 to 1991 
Unclear if singleton/multiple 
birth 
Excluded if missing data 
Ethnicity: unreported 
Unreported Birth weight ≤2.6kg 1.Type 1 Diabetes mellitus (≥ 
126mg/dl fasting blood 
glucose, received insulin within 
6 months, or diagnosis by 
referring physicians) (6-18 
years) 
2. BMI (≥95th percentile for 
sex and age specific 
anthropometrics of children in 
Taiwan) (6-18 years) 
Wennergren 1986
 
Sweden 
Prospective cohort (4415) Unselected 
population, all infants born 
in Goteburg  
Year of birth:1978 
Mixed singleton/ multiple 
births 
Exclusions: missing data 
Ethnicity: unreported 
Unreported Birth weight ≥-2SD below 
mean (standard 
unreported) 
Respiratory disorders 
(Respiratory rate ≥ 60/ min or 
<30/ min during first 3 hours; 
grunting/ chest wall recessions 
at 2hrs age or later; central 
cyanosis or apnoeic spells) 
(neonatal) 
Zhang et al 2007
 
Sweden 
Retrospective 
cohort 
(751281) Population 
based, data from Swedish 
birth registry 
Year of birth 1992-2001 
Singleton 
Exclusions: missing data 
Ethnicity: 87% Nordic 
USS 18 weeks 
gestation 
Population chart <10
th
 
percentile (centiles based 
on the study population) 
Early neonatal death (first 7 
days) 
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1. Apgar score 
2. apgar score.mp 
3. apgar.mp 
4. Resuscitation 
5. Neonatal resuscitation 
6. neonat*.mp. 
7. infant*.mp. 
8. newborn.mp. 
9. 1 or 2 or 3 or 4 or 5 
10. 6 or 7 or 8 
11. 9 and 10 
12. Diabetes Mellitus/ 
13. diabetes mellitus.mp. 
14. Hypertension/ or hypertension.mp. 
15. cardiovascular disease.mp. or Cardiovascular Diseases/ 
16. Metabolic Syndrome X/ or metabolic syndrome.mp. 
17. cerebral palsy.mp. or Cerebral Palsy/ 
18. Developmental Disabilities/ 
19. developmental delay.mp. 
20. learning difficulties.mp. 
21. Learning Disorders/ 
22. neonatal morbidity.mp. 
23. Infant Mortality/ 
24. neonatal mortality.mp. 
25. infant mortality.mp. 
26. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 
27. 11 and 26 
28. limit 27 to humans 
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Author, Year and 
Country 
Study design Population (total 
number) 
Gestational age and 
method of defining 
Apgar score timing 
and threshold 
Outcome Measure 
Abrams et al 2007 
USA 
Retrospective 
cohort 
(598) All infants with 
hydrops fetalis in 
neonatal network, any 
cause, born Jan 1996- 
March 2005 
Congenital anomalies 
not excluded 
unreported 1 min ≤ 3 
5 min ≤ 3 
Neonatal death (exact 
range unclear, death prior 
to discharge from hospital) 
Adamson et al 1995 
Australia 
Case control study (176) All singleton term 
infants in metropolitan 
area admitted to 2 study 
hospitals in 1992 (8 
month period) within 1st 
week of life with 
diagnosis of neonatal 
encephalopathy, plus 
one matched control on 
sex, hospital of delivery, 
time of birth, day of the 
week, maternal health 
insurance status. 
 
≥ 37 weeks 
Method unreported 
1 min ≤ 3 
1 min ≤ 7 
Neonatal encephalopathy 
(1
st
 7 days of life) (at least 
one of the following: 
seizures of any type/ 
duration, absent 
responsiveness to stimuli 
(stupor/ coma); altered 
responsiveness to stimuli 
for > 24 hrs, difficulty with 
control of respiration 
(presumed brain stem 
origin) inc cyanotic attacks 
after 2 days of age and 
recurrent apnoea any age, 
poor suck) 
 
Appendix 14. Characteristics of included studies in systematic review of Apgar score and adverse outcomes 
 
2
74
 
Aggarwal et al 2005 
India 
Case control study (50) Consecutive 
survivors at ≥ 34 weeks, 
5 min Apgar ≤ 6 or 
needed resuscitation for 
≥ 5 mins, and 25 
matched controls without 
asphyxia (Apgar ≥ 7) for 
gestation and weight, 
born at a single tertiary 
centre 
Congenital anomalies 
and neonates exposed 
to nephrotoxic drugs 
excluded 
≥ 34 weeks 
Method unreported 
5 min  ≤ 3 
5 min  ≤ 6 
 
 
Acute renal failure 
(neonatal) (serum 
creatinine >1.5mg/dl) 
 
Ajayi and Nzeh 2003 
Nigeria 
Prospective cohort (43) Babies with birth 
weight <1500g at 
delivery who survived at 
least 72 hours born at a 
secondary hospital 1992-
1994 
 
Unreported 1 min  ≤ 3 
5 min  ≤ 3 
 
Intraventricular 
haemorrhage/ 
periventricular 
leukomalacia (neonatal) 
(Papile Grade 1-4 on 
cranial USS) 
 
Ambalavanan and 
Carlo 2001 
USA 
Retrospective 
cohort 
(811) Neonates with birth 
weight <1000g 
neonates, excluding 
those who died in the 
delivery room, admitted 
to a tertiary care centre, 
1990-1996. 
Congenital anomalies 
excluded 
 
Unreported 5 min, all thresholds Neonatal death (before 
discharge, exact age 
unspecified) 
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Anyaegbunam et al 
1991 
USA 
Prospective cohort (270) Live births with 
umbilical cord pH taken 
and delivery on dates 
when investigator 
attending, all singletons 
with cephalic 
presentation 
 
 
>36 weeks gestation 
Method unreported 
5 min < 7 Neonatal sepsis (definition 
unreported) 
Apgar and James 
1962 
USA 
Cohort, unclear if 
prospective/ 
retrospective 
(27715) All live births > 
500g at a single centre, 
1952-1959 
 
Unreported 1 min, all thresholds Neonatal death (28 days) 
Atkinson 1983 
USA 
Retrospective 
cohort 
(239255) All live births in 
North Carolina region, 
1978-1980. 
Data presented 
separately for birth 
weight <1501g 
 
Unreported 5 min  ≤ 3 
5 min  ≤ 6 
 
Neonatal death (28 days) 
Baenziger et al 1999 
Switzerland 
 
Prospective cohort (12) High risk population, 
all had CTG 
abnormalities 
(bradycardia to <80bpm, 
reduced variability, late 
decelerations )or 
meconium or Apgar <6, 
born at single tertiary 
centre 1993-1995. 
Congenital anomalies 
excluded 
34+5-42+1 weeks 
gestation 
Method unreported 
 
1 min ≤ 3 Griffiths developmental 
quotient (≤ 80 abnormal) 
(9-15 months) 
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Bauder, von 
Siebenthal and Bucher 
2000 
Switzerland 
Case control study (72) 40 infants with PVL 
were registered to Swiss 
Pediatric surveillance 
unit, over 3 years. They 
were compared to a 
control group matched 
for gestational age. 35 
were preterm infants 
1995-1997 
Unreported 5 min <7 Periventricular 
leukomalacia 
(at least 2 cysts with 
diameter 2mm in the 
periventricular 
region)(neonatal) 
  
Beeby et al 1994 
Australia 
Retrospective 
cohort 
(623) Infants <32 weeks 
gestation born at a single 
centre. 
Year of birth 1985-1990 
Congenital anomalies 
excluded  
<32 weeks gestation 
Unreported 
1 min <4 1.Neonatal death (exact 
age unspecified) 
2.Intraventricular 
haemorrhage (Gd 3-4 
Papile, cranial USS or 
post-mortem)(neonatal, up 
to 14 days) 
3. Cerebral palsy 
(definition unreported)(age 
1 year) 
  
Behnke et al 1987 
USA 
Prospective cohort (748) live born infants 
with birth weight 500-
1800g, born at a single 
centre 1974-1980. 
 
 
Range unreported 
LMP/ Dubowitz 
method 
1 min ≤ 3 
1 min ≤ 3 
5min ≤ 6 
5 min ≤ 6 
Neonatal death (28 days) 
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Behnke et al 1989 
USA 
Prospective cohort (256) Same study 
population as above, 
20% sample selected for 
long term follow up 
Range unreported 
LMP/ Dubowitz 
method 
1 min ≤ 3 
1 min ≤ 3 
5min ≤ 6 
5 min ≤ 6 
1.Bayley mental 
development index 
(abnormal <85) (12 months 
of age) 
2.Bayley psychomotor 
development index 
(abnormal <85) (12 months 
of age) 
 
Bennett, Robinson and 
Sells 1983 
USA 
Retrospective 
cohort 
(8) All newborns of birth 
weight <800g admitted 
to tertiary neonatal care 
unit, 1977-1980, who 
survived to discharge 
home and were at least 
3 years of age at time of 
report 
No exclusions reported 
 
24-28 weeks gestation 
LMP/ Dubowitz 
method 
1 min ≤3 1.Bayley mental 
development index 
(abnormal <85) (6 months- 
2years of age) 
2.Stanford-Binet IQ score 
(abnormal <100) (age 3 
years) 
Berger et al 1997 
Germany 
Prospective cohort (5280) All live born 
infants at a single tertiary 
centre from 1984 to 
1988.  
No exclusions reported 
24-43 weeks gestation 
Method unreported 
1 min ≤ 4 
1 min ≤ 7 
5 min ≤ 4 
5 min ≤ 7 
10 min ≤ 4 
10 min ≤ 7 
 
Periventricular/ 
intraventricular 
haemorrhage (Grade 1-3 
Papile, cranial USS) 
(neonatal day5-8) 
Brandalise et al 1976 
Brazil 
Prospective cohort (93) newborns with 
different Apgar scores, 
unclear how selected. 
Birth weight >2500g.  
Year of birth unreported.  
No exclusions reported. 
≥ 37 weeks gestation 
Method unreported 
5 min < 7 Neonatal death (exact age 
unreported) 
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Buchmayer et al 2009 
Sweden 
Case control study (7160) Cases were 
infants with autistic 
disorders who had had 
hospital treatment, 5 
randomly selected 
controls matched to 
gender, birth year and 
birth hospital. Year of 
birth 1987-2002. 
Congenital 
malformations NOT 
excluded. 
Unreported 5 min ≤6 Autistic disorders (ICD-
9/10 classification) (up to 
age 10 years) 
Camp et al 1998 
USA 
Prospective cohort (33934) Collaborative 
Perinatal project, 
mothers enrolled 
antenatally in one of 12 
urban medical centres in 
the USA, 1959-1965. 
Infants had birth weight 
> 2000g 
Congenital anomalies, 
syndromes or infants 
who had neonatal 
seizures excluded 
Unreported 1 min <2  Weschler intelligence 
scale for children (IQ 
<70)(age 7 years) 
Casey, McIntire and 
Leveno 2001 
USA 
Prospective cohort (12899) Live born 
singleton infants at a 
single tertiary centre 
1988-1998,  excluded if 
no cord pH available, no 
other exclusions 
reported. 
>26 weeks gestation 
Method unreported 
5 min ≤3 
5 min ≤ 6 
Neonatal death (28 days) 
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Chandola et al 1992 
UK 
Retrospective 
cohort 
(24672) Index cases 
from referral register of 
children's clinic, who 
presented with 
hyperactivity, were free 
from mental handicap, 
psychoses and gross 
neurological  impairment, 
were not referred for any 
other problem. 129 could 
be linked on Cardiff 
Births Survey register, 
compared with other 
births in South 
Glamorgan region born 
1980-1984. 
No exclusions reported 
Unreported 1 min ≤6 
5 min ≤8 
Referral for hyperactivity 
symptoms (predominance 
of restless, inattentive and 
chaotic behaviour) (age 3-
6 years) 
Colburn and Salzman 
1960 
USA 
Cohort, unclear if 
prospective/ 
retrospective 
(1597) Consecutive 
deliveries of infants with 
birth weight >1000g at a 
single centre. Year of 
birth 1959 to 1960 
No exclusions reported  
Unreported 1 min ≤ 3 
1 min ≤ 6 
Neonatal death ( exact age 
unspecified) 
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Dalens et al 1981 
France 
Prospective cohort (57) neonates admitted 
to NICU at a single 
centre, without CSF 
infection, necessity for 
several examinations of 
CSF, precise knowledge 
of gestation and obstetric 
states, consenting  to 
long term follow up 
Year of birth unreported 
No exclusions reported 
37-42 weeks 
Method unreported 
1 min <3 
1 min ≤ 6 
Neurological sequelae 
(threshold unreported) 
(age 12 months) 
De Almeida et al 2008 
Brazil 
Prospective cohort (579) All live births of 
infants with birth weight 
400-1500g and gestation 
22-33 weeks, at 8 
tertiary hospitals. 
Year of birth 2004-2005 
Congenital anomalies 
excluded 
22-33 weeks 
Obstetric estimate/ 
physical examination 
of infant 
5 min <7 Neonatal death (first 7 
days) 
Den Ouden et al 1990 
Netherlands 
Prospective cohort (1192) All live born 
infants in Netherlands 
with gestational age < 32 
weeks and/ or 
birthweight <1500g. 
Year of birth 1983 
Congenital anomalies 
excluded 
<32 weeks 5 min ≤ 6 Neurological dysfunction 
(increased/ decreased 
excitablility, increased/ 
decreased mobility, 
hyper/hypotonia, 
asymmetry)(neonatal) 
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Deorari, Paul and 
Singh 1989 
India 
Prospective cohort (103) 36 infants with 
Apgar ≤ 3, 32 infants 
with Apgar 4-6, and 35 
matched for weight and 
gestation who had 1 min 
apgar >6. Born at single 
centre, year of birth 
unreported. 
No exclusions reported 
Unreported 1 min ≤ 3 1. Seizures (threshold 
unreported) (up to 72 
hours of age) 
2.Developmental delay 
(DQ <70) (age 12 months) 
Dijxhoorn et al 1986 
Netherlands 
Prospective cohort (803) Infants part of 
Groningen Perinatal 
project, delivered 
vaginally 1975-1978, 
average weight for 
gestational age, at term 
gestation. 
Year of birth 1975-1978 
No exclusions reported 
≥ 37 weeks 
Method unreported 
1 min ≤ 3  
1 min ≤ 6 
Neurological abnormality 
(hyper/hypokinesia, 
hyper/hypotonia, 
hemisyndrome, apathy, 
hyperexcitability) (neonatal 
day 4-5) 
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Drage et al 1966 
USA 
Prospective cohort (18038) Collaborative 
Study of Cerebral Palsy, 
Mental Retardation and 
other Neurological and 
Sensory Disorders of 
Infancy and Childhood. 
13 collaborating 
institutions, year of birth 
unreported. 
Exclusions: 
malformations of CNS, 
Down's syndrome, 
hypothyroidism, other 
syndromes associated 
with mental retardation  
Unreported 5 min ≤ 6 1.Abnormal gross motor 
skills (walking along a 
straight line, hopping, ball 
catching)(age 4 years) 
2. Abnormal behaviour 
profile( 5 point scale: 
emotional reactivity, 
degree of irritability, degree 
of cooperation, degree of 
dependence, duration of 
attention span, goal 
orientation, response to 
direction, level of activity, 
nature of activity, nature of 
communication) (age 4 
years) 
Drage et al 1964 
USA 
 As above Unreported 1 min ≤ 3  
1 min ≤ 6 
Neonatal death (28 days) 
Drage et al 1966 
USA 
 As above Unreported 5 min ≤ 3  
5 min ≤ 6 
Neurological abnormality 
(definition unreported) (age 
12 months) 
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Echandia and Ruiz 
2006 
Colombia 
Retrospective 
cohort 
(287) Low 
socioeconomic stratum 
Infants with one of the 
following risk factors: 
respiratory problems 
requiring mechanical 
ventilation, Apgar <7 at 5 
minutes, 3 apnoeic 
episodes, neurological 
abnormalities such as 
convulsions, paralysis, 
hyper/ hypotonia, altered 
consciousness, bacterial 
meningitis. Single level 1 
hospital, year of birth 
1989 to 1997. 
Exclusions: congenital 
anomalies, intrauterine 
infection, prenatal 
neurological compromise 
27-43 weeks gestation 
Method unreported 
1 min ≤ 3  
1 min ≤ 6 
5 min ≤ 3  
5 min ≤ 6 
1.Seizures (definition 
unreported) (neonatal) 
2. Neuromotor 
abnormalities (definition 
unreported) (age 12 
months) 
Ehrenstein et al 2006 
Denmark 
Retrospective 
cohort 
(131696) All singleton 
live births in 1978-2001 
in North Jutland County, 
Denmark. 
Congenital anomalies 
excluded 
No gestational age 
restrictions 
Method unreported 
5 min <7 Hospitalisation with 
epilepsy (Hospital 
discharge database ICD-
10 codes) (childhood, 
median age 12 years) 
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Ekure, Iroha and Egri-
Okwaji 2011 
Nigeria 
Prospective cohort (560)Consecutive 
deliveries at a single 
university teaching 
hospital (stillbirth 
reported in paper but 
only live births in 
analysis). 86.1% term, 
13.6% preterm. Year of 
birth 2002 (6 month 
period) 
No exclusions reported 
No gestational age 
restrictions 
Method unreported 
1 min ≤ 3  
1 min ≤ 6 
5 min ≤ 3  
5 min ≤ 6 
Neonatal death (7days) 
 Evans et al 2007 
Australia               
Retrospective 
cohort 
(5713) All infants of 24-
32 weeks gestation, data 
collected through 
Australia and New 
Zealand neonatal 
network prospective 
audit. 
Year of birth 1998-2001 
Congenital anomalies 
and hydrops fetalis 
excluded 
24-32 weeks gestation 
Early obstetric USS/ 
LMP 
1 min <4 Neonatal death (before 
discharge from hospital) 
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Graham, Holcroft and 
Blakemore 2002 
USA 
Case control study (36) All cases of 
neonatal seizures 
according to hospital 
records, matched 2:1 by 
birth weight, gestational 
age and route of delivery 
to neonates born during 
the same period at a 
single tertiary centre.  
Year of birth 1988-1999 
Congenital anomalies 
excluded 
24-40 weeks gestation 
Method unreported 
1 min <7 
5min <7 
Seizures (definition 
unreported) (neonatal) 
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Grether et al 1996 
USA 
Case control study (114) Cases were 
singleton births during 
study period in one of 
four San Francisco bay 
counties, birth weight 
<1500g at birth, survival 
to age 3 years, and 
moderate or severe CP. 
Controls randomly 
selected, without 
matching, from infants 
with birth weight <1500g 
born in same counties 
and survived to age 3 
years 
Year of birth 1983-1985 
Excluded if CP from 
cause after 28 days, or 
transient abnormalities. 
Congenital anomalies/ 
infections not excluded 
from analysis 
Gestation unreported 
LMP/ USS before 19 
weeks gestation 
5 min ≤ 5 Cerebral palsy (chronic 
disability of CNS origin 
characterised by aberrant 
control of movement or 
posture, appearing early in 
life and not the result of 
progressive disease)(age 3 
years) 
Heller et al 2003 
Germany 
Retrospective 
cohort 
(512496) Data obtained 
from the perinatal birth 
register of Hesse, all live 
births within study 
period. 
Year of birth 1990-1999 
Congenital anomalies 
excluded 
No restrictions on 
gestational age 
Method unreported 
1 min ≤ 3 
1 min ≤ 7 
5 min ≤ 3 
5 min ≤ 7 
10 min ≤3 
10 min ≤ 7 
Neonatal death (7 days) 
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Heuchan et al 2002 
Australia 
Retrospective 
cohort 
(5637) Data from 
Australia and New 
Zealand neonatal 
network, live births 
during study period 24-
30 weeks gestation with 
USS or post-mortem 
data available 
Year of birth 1995-1997 
Excluded if data 
unavailable 
24-30 weeks gestation 
Method unreported 
1 min <4 Intraventricular 
haemorrhage (cranial USS/ 
post-mortem Papile grade 
3-4)(neonatal) 
Holst et al 1989 
Denmark 
Retrospective 
cohort 
(4038) All surviving 
singletons born in 
Frederiksborg county 
during 1978, records 
from birth and routine 
check-up at 4 years old. 
Congenital anomalies 
not excluded 
Unreported 1 min ≤6 
10 min <10 
Handicap (cerebral palsy, 
mental retardation 
(mild/severe), epilepsy, 
severe defects of vision 
and hearing. GP records, 
exact definitions 
unreported) (age 4 years) 
Iijima et al 2009 
Japan 
Retrospective 
cohort 
(113) Live born infants 
22-24 weeks gestation 
who survived delivery 
room resuscitation and 
were treated with 
expectation of survival at 
a single tertiary centre. 
Year of birth 1991-2006 
Congenital anomalies 
and lethal chromosomal 
anomalies excluded 
Early USS (95%) and 
LMP 
5 min ≤ 3 1.Neonatal death (before 
discharge from hospital) 
2. Neurological disability 
(cerebral palsy, 
developmental delay, 
deafness and blindness. 
Exact definitions 
unreported, from hospital 
records) (age 2 years) 
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Ikonen 1967 
Finland 
Retrospective 
cohort 
(11855) Live born infants 
in single centre during 
study period.  
Year of birth 1963-1965 
No exclusions reported 
Unreported 1 min ≤3 
1 min ≤ 6 
Neonatal death (exact age 
unreported) 
Ikonen 1973 
Finland 
Retrospective 
cohort 
(1006)Series selected 
from among infants with 
birth weight >2500g: all 
infants with apgar 0-3, all 
infants with apgar 4-6, 
and a random selection 
of infants with scores 7-
10 born at a single 
centre. 
Year of birth 1964-1968 
No exclusions reported 
Unreported 1 min ≤3 
1 min ≤ 6 
1.Cerebral disturbances 
(intracranial haemorrhage 
(clinical/autopsy), cerebral 
lesion or clinical suspicion, 
cerebral irritation, cerebral 
depression, symptomatic 
hypoglycaemia, 
hypocalcaemia. Exact 
thresholds unreported) 
(neonatal) 
2. Respiratory 
disturbances (including 
aspiration syndrome (resp 
sx with radiological findings 
of streaky infiltration in 
perihilar region), hyaline 
membrane disease 
(Silverman's score ≥ 4/ 
radiographic findings), 
pneumonia, respiratory 
distress (resp rate >70/min 
for at least 6 hrs with 
Silverman's score <4)) 
(neonatal) 
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Ikonen 1974 
Finland 
 
Retrospective 
cohort 
(218) Series selected 
from among live born 
infants BW 1000-1990g 
all infants with 1 min 
Apgar 0-3, all infants 
with apgar 4-6, random 
sample of infants with 
score 7-10. 
Year of birth 1964-1968. 
No exclusions reported 
Unreported 1 min ≤3 
1 min ≤ 6 
As above 
Indredavik et al 2010 
Norway 
Prospective cohort (192) 3 groups: preterm, 
birth weight ≤ 1500g, 
term small for gestational 
age(birth weight <10
th
 
centile), and term normal 
weight controls. All 
VLBW admitted to NICU 
at Trondheim university 
hospital 1986- 1988, 
term SGA and control 
infants born to mothers 
living in city of 
Trondheim, enrolled into 
study 10% random 
sample controls, and all 
SGA children included 
Congenital anomalies 
excluded 
Preterm 24-41 weeks 
Term ≥ 37 weeks 
gestation 
Method unreported 
1 min ≤3 
1 min ≤ 6 
5 min ≤3 
5 min ≤ 6 
 
Psychiatric diagnoses 
(Schedule for affective 
disorders and 
schizophrenia for school 
age children (KSADS), 
DSM-IV criteria) (age 14 
years) 
Appendix 14. Characteristics of included studies in systematic review of Apgar score and adverse outcomes 
 
2
90
 
Ishikawa et al 1995 
Japan 
Prospective cohort (164) Cohort of infants 
with birth weight 490-
1500g born at a single 
tertiary centre. 
Year of birth 1977-1982 
No exclusions reported. 
Unreported 5 min <4 Epilepsy (chronic condition 
characterised by the 
repeated occurrence of 
seizures such as those 
with EEG epileptic seizure 
discharges) (age 6 years) 
Issel et al 1976 
Germany 
Retrospective 
cohort 
(6483) Regional cohort 
of infants, birth weight 
1010-4500g. Year of 
birth unreported, no 
exclusions reported 
Unreported 1 min ≤ 3 
1 min ≤ 7 
Neonatal death (exact 
timing unreported) 
Jacobsson et al 2002 
Sweden 
Case control study (435) All preterm 
children with spastic CP 
if born and lived in study 
region(western Sweden) 
for 4 years and lacked 
obvious postnatal cause 
of CP. Matched with 2 
controls, closest births 
before and after case 
birth matched for 
gestational age, gender, 
multiple gestation and 
delivery ward. 
Year of birth 1983-1990 
No exclusions reported 
<37 weeks gestation 
97% USS performed 
16-19 weeks gestation 
1 min <7 
5 min <7 
10 min <7 
Cerebral palsy (group of 
non- progressive motor 
impairment syndromes, 
secondary to lesions or 
abnormalities of the brain 
arising in the early stages 
of development)(age 4 
years and older) 
Jennett et al 1981 
USA 
Retrospective 
cohort 
(10124) All live births at 
single hospital during 
study period. 
Year of birth 1977-1980 
No exclusions reported 
Unreported 
Obstetric estimate/ 
Ballard examination of 
the newborn 
1 min and 5 min, all 
thresholds 
Neonatal death (exact age 
unreported) 
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Johnson et al 1999 
USA 
Prospective cohort (28127) Infants with birth 
weight ≥ 2500g and 
jaundice, not treated with 
exchange transfusion or 
phototherapy. 
Year of birth 1959-1966. 
No exclusions reported 
Unreported 5 min ≤3 
5 min ≤ 6 
Neurological disability 
(suspected/ confirmed, 
exact definition unreported) 
(age 7 years) 
Kato et al 1996 
Japan 
Retrospective 
cohort 
(228) Cohort of singleton 
infants with birth weight 
<1500g born at 2 centres 
1984-1993. 
Major anomalies 
excluded 
Unreported 1 min ≤ 4 
5 min ≤ 4 
1.Neonatal mortality (7 
days) 
2. Cerebral palsy/ mental 
retardation (definition 
unspecified) (>12 months 
old, exact age unspecified) 
Krebs, Langhoff-Roos 
and Thorngren-
Jerneck 2001 
Denmark 
 
Case control study (274) All singleton 
breech presentation at 
term, identified from 
national registry data. 
115 infants with Apgar 
score ≤6 at 5 min and 
controls (subsequent 2 
deliveries from same 
hospital with Apgar >6 at 
5 min) selected 
Year of birth 1982-1992 
Congenital anomalies 
excluded 
>37 weeks gestation 
Method unreported 
5 min ≤ 6 1.Cerebral palsy 
2. Speech and language 
problems 
(definitions unreported, 
questionnaire to parents) 
(age 4-15 years) 
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Lee, Subeh and Gould 
2010 
USA 
Retrospective 
cohort 
(690933) All singleton 
live births of preterm 
infants from US birth 
cohort dataset (National 
Center for health 
statistics). 
Year of birth: 2001-2002 
 Exclusions: congenital 
anomalies, multiple 
pregnancy, extremes of 
birth weight (<1st or 
>99th percentile)  
24-36 weeks gestation 
LMP 
5 min ≤3 
5 min ≤ 6 
Neonatal death (28 days) 
Lie, Groholt and Eskild 
2010 
Norway 
Retrospective 
cohort 
(543064) All singletons, 
born during study period, 
who survived the first 
year of life. Norwegian 
birth registry data. 
Year of birth 1986-1995 
Congenital anomalies 
excluded 
Unreported 5 min ≤4 
5 min ≤6 
Cerebral palsy (ICD-9 
classification) (up to age 5 
years) 
Luthy et al 1987 
Canada 
Prospective cohort (246) Singleton infants, 
cephalic presentation, 
with birth weight 600-
1750g born at single 
tertiary centre during 
study period. 
Year of birth 1981-1985 
Exclusions: congenital 
anomalies, antenatal 
haemorrhage, infants 
delivered before the 
onset of labour. 
26-32 weeks 
Method unreported 
1 min ≤3 1.Neonatal mortality (exact 
age unreported) 
2.Intracranial haemorrhage 
(cranial USS, Papile grade 
3-4) (neonatal, 76-92 
hours) 
3. Cerebral palsy 
(definition unreported) (18 
months of age) 
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Mahon et al 2007 
Denmark 
Retrospective 
cohort 
(335268) All singleton 
live births in North 
Jutland, Aarhus and 
Viborg counties of 
Denmark, obtained from 
national registry data.  
Year of birth 1980-2001 
Congenital anomalies 
NOT excluded. Excluded 
implausible gestational 
age/ birth weight 
combination i.e. <28 
weeks and >2500g 
25-45 weeks gestation 
Method unreported 
5 min ≤ 6 Hospital admission with 
pneumococcal disease 
(ICD 8/10 codes 
pneumoccocal meningitis, 
septicaemia, 
pneumococcal pneumonia) 
(age 0-144 months) 
Minchom et al 1987 
UK 
Retrospective 
cohort 
(41144) Cases with 
seizures within 48 hours 
of birth, and other infants 
born during the study 
period who had not had 
seizures.  Infants 
identified by data from 
the Cardiff Births survey. 
Year of birth: 1970-1979 
Congenital anomalies 
NOT excluded 
≥ 37 weeks 
Method unreported 
1 min ≤ 3 Seizures (convulsions, fits, 
seizures, clonic 
movements or jerky 
movements recorded in 
case notes by experienced 
observers) (neonatal, first 
48 hours) 
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Misra et al 1994 
India 
Retrospective 
cohort 
(154) Cases were term 
infants with Apgar score 
≤ 6, controls had Apgar ≥ 
7, born at a single 
centre. 
Year of birth unreported 
Exclusions: history of 
maternal narcotic intake, 
respiratory distress, 
central cyanosis, 
jaundice, abdominal 
distension and 
congenital malformations  
37 -41 weeks 
Method unreported 
5 min ≤3 
5 min <7 
1.Neonatal death (exact 
age unreported) 
2. Denver developmental 
screening test (abnormal, 
threshold unreported) (age 
3 months and age 11 
months) 
Moro et al 2007 
Spain 
Retrospective 
cohort 
(8741) Infants with birth 
weight <1500g from 
Spanish Society of 
Neonatology (SEN) 1500 
database 
Year of birth: 2002-2005 
No exclusions reported 
Gestation range 
unreported 
LMP 
1 min <4 
1 min ≤ 6 
5 min <4 
5 min ≤ 6 
1.Mortality (prior to 
discharge, up to 60 days) 
Moster, Lie and 
Markestad 2001 
Norway 
Retrospective 
cohort 
(235165) All infants born 
during study period with 
birth weight > 2500g, or 
if birth weight data 
missing gestational age 
>37 weeks from 
Norwegian birth registry. 
Year of birth: 1983-1987 
Congenital anomalies 
excluded except 
congenital dislocation of 
the hip 
Unreported 5 min ≤ 3 
5 min ≤ 6 
1.Neonatal death (exact 
age unreported) 
2. Infant death (first year of 
life) 
3. Cerebral palsy 
(definition unreported) (8-
12 years old) 
Appendix 14. Characteristics of included studies in systematic review of Apgar score and adverse outcomes 
 
2
95
 
Moster et al 2002 
Norway 
Retrospective 
cohort 
(727) All survivors with 
children with birth weight 
>2500g and Apgar 0-3, a 
random sample of 400 
with score 4-6 and 404 
score 7-10, identified 
from Norwegian birth 
registry 
Year of birth: 1983-1987 
Congenital anomalies 
excluded except 
congenital dislocation of 
the hip, major 
neurological impairment 
also excluded. 
Unreported 5 min ≤ 3 
5 min ≤ 6 
1.Seizures (definition 
unreported, questionnaire 
to parent when child 8-13 
years old)(neonatal) 
2. Minor motor impairment 
(definition unreported, 
questionnaire to 
parents)(8-13 years old) 
3. Epilepsy (definition 
unreported, questionnaire 
to parents) (8-13 years old) 
Moura et al 2010 
Brazil 
Prospective cohort (3845) Live births in 
Pelotas birth cohort, born 
in 2004. 
No exclusions reported 
Gestation range 
unreported 
Dubowitz method 
5 min <7 Suspected developmental 
delay (Battelle Screening 
developmental inventory 
(BSDI), cut off -1SD in 
score table for reference 
population) (age 12 
months) 
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Murphy et al 1995 
UK 
Case control study (293) Cases all singleton 
children with cerebral 
palsy identified from 
regional register of early 
childhood impairments, 
controls surviving 
singleton preterm infants 
randomly selected from 
hospital admission 
registers and Oxford 
record linkage study. 
Year of birth: 1984-1990 
No other exclusions 
reported 
<32 weeks 
LMP and USS prior to 
20 weeks gestation 
5 min ≤ 3 Cerebral palsy (permanent 
disorder of movement and 
posture) (age 3-5 years) 
Myers, Paton and 
Fisher 1987 
USA 
Retrospective 
cohort 
(226) All live born infants 
22-32 weeks gestation or 
500-1499g included, 
born at a single centre. 
Year of birth 1983-1984 
Congenital anomalies 
incompatible with life 
excluded 
22-32 weeks gestation 
LMP, size at first 
obstetric examination, 
quickening 
1 min ≤ 3 Death 
(neonatal/postneonatal) 
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Nelson and Ellenberg 
1981 
USA 
Prospective cohort (47869) Infants born to 
women participating in 
the National 
Collaborative Perinatal 
project, received 
antenatal care and 
delivered at one of 12 
teaching hospitals, 
singleton children with 
known Apgar scores 
included. 
Year of birth: 1959-1966 
Exclusions: cerebral 
palsy resulting from 
trauma, infection or 
vascular accident after 
1st month of life or gross 
CNS malformations 
Unreported 1 min ≤ 3 
1 min ≤ 6 
5 min ≤ 3 
5 min ≤ 6 
10 min ≤ 3 
10 min ≤ 6 
1. Cerebral palsy (chronic 
disability characterised by 
aberrant control of 
movement or posture 
appearing early in life, not 
the result of recognised 
progressive disease. 
Significant handicap in 
independent functioning) 
(age 1-7 years) 
2. Infant mortality (first year 
of life) 
Oain et al 1988 
Norway 
Retrospective 
cohort 
(580) All singleton 
breech deliveries, birth 
weight >500g, at a single 
tertiary centre. 
Year of birth 1972-1979 
Congenital anomalies 
NOT excluded 
Unreported 1 min ≤ 3 
1 min ≤ 6 
5 min ≤ 6 
 
Neonatal death (exact age 
unreported) 
Obwegeser, Bohm and 
Gruber 1993 
Germany 
Retrospective 
cohort 
(7848) All live births 
within study period, at 
single university hospital, 
with Apgar score and 
cord pH available.  
Year of birth: 1981-1990. 
No exclusions reported 
Unreported 5 min ≤7 Neonatal death (exact age 
unreported) 
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Paludetto et al 1981 
Italy 
Prospective cohort (50) Neonates admitted 
to NICU at a single 
tertiary centre for a 
variety of reasons, 50 of 
138 admitted during the 
study period followed up.  
Year of birth 1975-1976 
No exclusions reported 
≥ 37 weeks gestation 
Method unreported 
1 min ≤ 3 
5 min ≤ 7 
Neurodevelopmental delay 
(any including tetraplegia, 
psychomotor delay, 
hemiparesis, West's 
syndrome.  Vojta's 
diagnostic scheme, Brunet 
Lezine's scale; threshold 
unreported) (age 9-24 
months) 
Patterson et al 1994 
UK 
Case control study (1626) Cases with IDDM 
born in Scotland during 
the study period 
identified from 
computerised hospital 
discharge records, with 
an additional 21 cases 
from a database 
maintained by Scottish 
clinicians. Record 
linkage to match to 
maternal discharge 
records to obtain 
perinatal data. 5 control 
subjects randomly 
selected from deliveries 
of same sex on same 
date at hospitals in the 
same health board. All 
singletons. 
Year of birth: 1975-1976 
No other exclusions 
reported 
no restrictions, 8 % of 
cases/ controls <38 
weeks gestation 
Method unreported 
5 min ≤ 7 Insulin dependent diabetes 
mellitus (diagnostic criteria 
unreported) (age <15 
years) 
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Paul, Koh and 
Monfared 1979 
USA 
Retrospective 
cohort 
(201) All live births 1001-
1500g at single centre. 
Year of birth 1975-1977 
Excluded congenital 
anomalies incompatible 
with life, congenital 
infections 
Unreported 5 min <7 Neonatal death (exact age 
unspecified) 
Perlman and Risser 
1996 
USA 
Prospective cohort (96) Neonates born at a 
single centre and 
admitted to NICU who 
were at high risk for 
asphyxia: meconium, 
CTG abnormalities, 
abruption or 5 min Apgar 
5 or less, pH <7.0 or BE 
>14, requiring ventilation 
or chest compressions. 
Year of birth: 1993 
No exclusions reported 
>37 weeks gestation 
Method unreported 
5 min ≤5 Seizures (definition 
unreported) (day 1 of life) 
Robertson and Harrild 
2010 
UK 
Case control study (1442) Cases of type 1 
diabetes under 15 years 
old from the SSG for the 
care of Diabetes in the 
young database, linked 
to data on the Aberdeen 
maternity neonatal 
databank, matched to 3 
controls according to 
year of birth. All 
singletons 
Year of birth: 1972-2002 
No other exclusions 
reported 
Unreported 1 min ≤ 7 
5 min ≤ 7 
Insulin dependent diabetes 
mellitus (diagnostic criteria 
unreported) (age 0-15 
years) 
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Ruth and Raivio 1988 
Finland 
Prospective cohort (925) All live born infants 
at a single centre over a 
2 month period. 
Year of birth: 1984 
Congenital anomalies 
not excluded initially, but 
abnormal outcome 
related to cause other 
than asphyxia excluded 
from the analysis 
Unreported 5 min ≤ 7 Death or abnormal 
development (definite 
abnormality including 
cerebral palsy or 
noticeable delay in 
development, slight 
abnormality if transient 
delay in muscle tone, 
slightly abnormal 
development or abnormal 
pattern of motor function 
development) (12 months 
of age) 
Sanders and Slade 
2010 
Australia 
Retrospective 
cohort 
(882) A sample of 5 year 
old children completed 
questionnaire and 
transcribed information 
from birth records, 
sampling frame 
electronic database of 
School dental service in 
South Australia. All 
singletons 
Year of birth: 1998 
No other exclusions 
reported 
37-41 weeks 
LMP/USS 
5 min ≤ 8 Dental caries (one or more 
decayed, missing or filled 
teeth) (age 5 years) 
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Schmidt, Schuz and 
Lahteenmaki 2010 
Denmark, Finland, 
Sweden and Norway 
Case control study (14518) Cases children 
diagnosed with a primary 
CNS tumour. Identified 
from national cancer 
registries.  Matched by 
DOB, sex, country to 5 
control children aged 0-
14 years. 
Year of birth: 1971-2006. 
No exclusions reported 
Gestation range 
unreported 
LMP/ early scan after 
period in study where 
introduced into 
general practice 
5 min ≤ 7 CNS tumour (International 
Classfication of Childhood 
cancer version 3) (age 0-
14 years) 
Seidman et al 1991 
Israel 
Retrospective 
cohort 
(1942) All subjects born 
at single tertiary centre 
between 1970 and 1971 
and subsequently 
drafted into the army 17 
years later. 
All singletons 
No other exclusions 
reported 
Unreported 1 min ≤ 7 
5 min ≤ 7 
Intelligence test (equivalent 
of Weschler scale, 
threshold <85) (age 17 
years) 
Serenius et al 2004 
Sweden 
Retrospective 
cohort 
(218) All live born infants 
of 23-25 weeks gestation 
in study period, born at 2 
tertiary centres.  
Year of birth 1992-1998 
Congenital anomalies 
NOT excluded 
23-25 weeks gestation 
<18 week scan 94%, 
LMP 6% 
1 min ≤ 3 
5 min ≤ 3 
Death (prior to discharge 
from neonatal unit, exact 
age unspecified) 
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Shankaran et al 2002 
USA 
Retrospective 
cohort 
(5986) National institute 
of child health and 
development (NICHD) 
research network 
registry (12 centres). All 
live births 501-1000g. 
Year of birth: 1993-1997 
No exclusions reported 
Gestation range 
unreported 
LMP, obstetric 
examination and USS 
1 min ≤ 3 
5 min ≤ 3 
Death (up to 120 days of 
age) 
Soleimani et al 2010 
Iran 
Case control study (3577) Cases were 
children with 
documented cerebral 
palsy, referred to 
rehabilitation centre, 
controls 3465 children 
without CP who had 
attended centre for well-
being check-up. 
Year of birth: 2001-2007 
Exclusions:  no overt 
congenital anomalies, 
chromosomal, metabolic 
and neurodegenerative 
disorders, congenital 
infections 
Gestation range 
unreported 
LMP 
5 min <5 Cerebral palsy (non-
progressive motor 
dysfunction, examination 
findings of increased tone 
(spasticity, rigidity, 
dystonia, or 
choreoathetosis) (age1-6 
years) 
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Stelmach, Pisarev and 
Talvik 2005 
Estonia 
Case control study (421) Cases children 
with cerebral palsy of 
any severity, ascertained 
from population based 
prevalence study 
(children aged 1-15) and 
controls selected from 
general population 
register. Matched by sex, 
year and month of birth 
and place of residence at 
the time of birth.  
Year of birth: 1985-1999 
Exclusions: postnatal 
aetiology of CP, 
syndromes and CNS 
malformations 
27-42 weeks gestation 
Method unreported 
1 min ≤ 4 
1 min ≤ 7 
5 min ≤ 7 
Cerebral palsy (permanent 
disorder, movement and 
posture, non-progressive 
lesion, presence of lesion 
in developing/ immature 
brain) (age 1-15 years 
Tejani and Verma 
1989 
USA 
Retrospective 
cohort 
(392) All infants with 
birth weight <2000g and 
umbilical cord pH 
available during study 
period. 
Year of birth: 1981-1986 
Congenital anomalies 
excluded 
Gestation range 
unreported 
Obstetric estimate and 
Dubowitz method 
1 min ≤ 6 
5 min ≤ 6 
1.Neonatal death (exact 
age unreported) 
2. Peri/intraventricular 
haemorrhage (Papile 
grade 1-4 on cranial USS) 
(1
st
 24 hours of life) 
3. Respiratory distress 
syndrome (radiologic 
evidence of 
reticulogranular pattern/ air 
bronchograms) (neonatal) 
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Thorngren-Jerneck 
and Herbst 2001 
Sweden 
Retrospective 
cohort 
(1028705) Infants born 
at term during study 
period, data from 
Swedish Medical Birth 
registry 
Year of birth: 1988-1997 
Congenital anomalies 
excluded 
≥ 37 weeks gestation 
USS/ LMP 
5 min <7 1.Infant mortality (up to 12 
months of age) 
2. Seizures (definition 
unreported) (neonatal) 
3. Intracranial 
haemorrhage (definition 
unreported) (neonatal) 
Topp, Langhoff-Roos 
and Uldall 1997 
Denmark 
Case control study (862) Data from Danish 
cerebral palsy register, 
175 singleton CP infants 
evaluated, controls 
selected from all preterm 
singleton live born 
infants in Eastern 
Denmark during the 
same period, matched 
by gestational age and 
year of birth 
Year of birth: 1982-1986 
Congenital anomalies 
NOT excluded 
< 37 weeks gestation 
LMP/ USS in some 
cases 
1 min <7 
5 min <7 
Cerebral palsy (definition 
unreported) (age 4-6 
years) 
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Tran, Gray and 
O’Callaghan 2005 
Australia 
Case control study (149) Cohort of infants 
born at <28 weeks 
gestation, at single 
tertiary centre, enrolled 
in neonatal follow up 
program. 
Year of birth:  1989-1996 
Exclusions: congenital/ 
chromosomal anomalies 
excluded. Multiple 
pregnancy of triplets or 
higher. 
≥ 24 weeks, <28 
weeks gestation 
LMP/ USS < 20 weeks 
 
 
1 min <6 
5 min <6 
Cerebral palsy (persistent 
abnormality of movement 
and posture resulting in 
impairment of function due 
to non-progressive lesion 
in immature brain) (age 2 
years) 
Valentin et al 1993 
Sweden 
Retrospective 
cohort 
(200) All babies with 1 
min Apgar ≤ 8 born at a 
single centre and 52 
randomly selected 
babies with 1 min Apgar 
score ≥9. 
Year of birth 1982 
No exclusions reported 
Unreported 1 min <7 
5 min <7 
Neonatal morbidity 
(neonatal unit admission 
requiring specific 
treatment, e.g. Assisted 
ventilation, IV fluids, death 
or survival with sequelae) 
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Walstab et al 2004 
Australia 
Case control study (439) Cases included 
148 children with 
moderate or severe CP 
from Victorian cerebral 
palsy register born at of 
10 hospitals.. Cases 
matched with 1-2 
controls  for year of birth, 
plurality, sex, birth 
weight, gestation and 
hospital of birth 
Year of birth: 1983-1992 
Post neonatal cases 
excluded 
Congenital anomalies 
NOT excluded 
Unreported 1 min ≤ 3 
1 min ≤ 6 
5 min ≤ 6 
Cerebral palsy (definition 
and age unreported) 
Weinberger et al 2000 
USA 
Prospective cohort (852)Neonates with birth 
weight 500-2000g at 3 
hospitals enrolled for 
follow up 
Year of birth: 1984-1987 
No exclusions reported 
23-34 weeks 
USS <20 weeks 
5 min <6 1.Neonatal death (exact 
age unreported) 
2. Respiratory distress 
syndrome (definition 
unreported) (neonatal) 
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Zanini et al 2011 
Brazil 
Retrospective 
cohort 
(134933) All live births to 
women living in the State 
of Rio Grande do Sul, 
with birth certificates. 
Data from live birth and 
death database 
Year of birth: 2003 
Exclusions: missing 
data, presumed errors of 
incompatible gestation 
and birth weight. 
Congenital anomalies 
not excluded 
>22 weeks gestation 
Method unreported 
1 min <7 
5 min <7 
Neonatal death (<28 days) 
Min= Minutes, mg/dl= miligrams per decilitre, g=grams, USS= ultrasound scan, PVL= periventricular leukomalacia, LMP= last menstrual period, ICD= 
International Center for disease classification, CSF= cerebrospinal fluid, NICU= neonatal intensive care unit, IQ= intelligence quotient, DQ= 
Development quotient, CNS= central nervous system, CP= cerebral palsy, SGA= small for gestational age, DSM= diagnostic and statistical manual of 
mental disorders, SD= standard deviation 
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The formula is as follows:178 
 Pretest odds = (Pretest probability / (1 - Pretest probability) 
 Posttest odds = Pretest odds * Likelihood ratio 
In equation above, positive post-test probability is calculated using the 
likelihood ratio positive, and the negative post-test probability is calculated 
using the likelihood ratio negative. 
 Posttest probability = Posttest odds / (Posttest odds + 1)  
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1. cost effectiveness.mp. or Cost-Benefit Analysis/ 
2. Hypothermia, Induced/ or neonatal cooling.mp. 
3. cerebral palsy.mp. or Cerebral Palsy/ 
4. neurodevelopmental delay.mp. 
5. 1 and 2 and 3 and 4 
6. 1 and 2 and 3 
7. 1 and 2 
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Cost of test 
Cost of umbilical cord pH test on point of care analyser= £2.42 (University 
of Nottingham) 
Cost of midwife x 1hr patient contact (including qualifications)= £97174 
Assume it takes 10 minutes for midwife to perform test 
Cost of performing umbilical cord pH test= (97/6)+  2.42= £18.59 
 
Community costs to age 18 months of a non-encephalopathic baby 
Average number of GP consultations per person per year= 6.5 in 0-4 year 
age group (2008/2009)173  
6.5 x1.5= 9.75 consultations in 18 month period 
Cost of 10 minute GP consultation= £36174 
£36 x 9.75 = £351 
Four visits to practice nurse for routine immunisations (15 mins per visit, 1 
hour total) 
Cost of 1 hour practice nurse time= £39174 
Child health surveillance, cost for first three visits (to 18 months)= £10.74 
+ £6.82 + £9.44 = £27.00 (1997 costs) Inflated to 2011 costs= £50 
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£351 +£39 +£50 = £440 total community costs of a non-
encephalopathic baby to 18 months of age 
Inpatient costs at time of delivery for a non-encephalopathic baby 
0.1% of obstetric patients would have a neonate with multiple minor 
diagnoses, and 0.7% would have a neonate with one minor diagnosis of 
all obstetric unit admissions.171 When restricted to delivery events only 
(51.2%), this translated to 0.2% and 1.4% respectively. 
Mean cost of neonate with multiple minor diagnoses= £716 
(2005/2006)171 
Mean cost of neonate with one minor diagnosis= £1,091(2005/2006)171 
0.002 x 1,091= £2.18 
0.014 x 763= £ 10.68 
Inpatient cost at time of delivery= £2.18 +£10.68= £12.86, inflated to 
2010/11 costs = £14.74 
 
Hospital costs of a non-encephalopathic baby to age 18 months 
Hospital admission rate (2007/2008) 0-5 year age group =128.9 per 1000 
population172 
=0.13% x1.5 (18 months) = 0.20 
Cost of hospital readmission (2006/2007)= £480163 
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Assume stay one day 
0.20 x £480= £96, inflated to 2010/2011 = £106.08 hospital costs to age 
18 months 
Total hospital costs: £14.74 + £106.08 = £120.82 
In all cases, cost inflations were performed according to the following 
formula: 
((Current price index/ original price index) – 1) x original cost = added cost 
in 2010/2011 
E.g. 2006/2007 index = 249.8174 
2010/2011= 276174 
276/249.8-1= 0.105 
0.105 x£96= £10.08 
Therefore 2010/2011 cost =£96 +£10.08=£106.08 
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Table 1. Distributions 
NAME DESCRIPTION TYPE PARAMETERS Estimated 
Value 
speccordpH_7 Specificity cord 
pH threshold 
<7.00 
Beta subtype: 2, alpha: 137.8, beta: 62.2 0.689 
senscordpH_7 Sensitivity cord 
pH threshold 
<7.00 
Beta subtype: 2, alpha: 3.75, beta: 2.25 0.625 
speccordpH_710 Specificity cord 
pH threshold 
<7.10 
Beta subtype: 2, alpha: 310.08, beta: 29.92 0.912 
senscordpH_710 Sensitivity cord 
pH threshold 
<7.10 
Beta subtype: 2, alpha: 6.042, beta: 31.958 0.159 
RRCPcooling_7 Relative risk of 
neonatal cooling 
for cerebral 
palsy in a 
population with 
pH <7.00 
LogNormal umeanoflogs: -0.371, sigmastddevoflogs: 
0.127 
0.69563 
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RRcoolingthresh_710 Relative risk of 
neonatal cooling 
for cerebral 
palsy in a 
population with 
pH <7.10 
LogNormal umeanoflogs: 0.981, sigmastddevoflogs: 
1.041 
4.58523 
CP_prevalence Prevalence of 
cerebral palsy 
Beta subtype: 2, alpha: 2, beta: 998 0.002 
cost_cooling Cost of neonatal 
cooling including 
equipment 
Gamma alpha: 3.2, lambda: 0.000489 6543.967 
cost_hosp_cool Hospital costs 
for initial 
inpatient stay 
per cooled infant 
Gamma alpha: 122, lambda: 0.00875 13942.86 
cost_hospread_cooled Hospital 
readmission 
costs in the first 
year of life per 
cooled infant 
Gamma alpha: 16.9, lambda: 0.0141 1198.582 
cost_transfer_cool Neonatal 
transfer costs 
per cooled infant 
Gamma alpha: 127, lambda: 0.7840 161.9898 
cost_comm6_cool Community care 
costs per cooled 
infant until 6 
months of age 
Gamma alpha: 106, lambda: 0.14077 753.0014 
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cost_comm612_cool Community care 
costs per cooled 
infant from 6-12 
months of age 
Gamma alpha: 33.5, lambda: 0.06893 486.0003 
cost_inpatient_noncool Hospital costs 
for initial 
inpatient stay 
per non-cooled 
infant (with 
encephalopathy) 
Gamma alpha: 118, lambda: 0.00839 14064.36 
cost_hospread_noncool Hospital 
readmission 
costs in the first 
year of life per 
non-cooled 
infant (with 
encephalopathy) 
Gamma alpha: 10, lambda: .003775 2649.007 
cost_trans_noncool Neonatal 
transfer costs 
per non-cooled 
infant (with 
encephalopathy) 
Gamma alpha: 110, lambda: .6918 159.0055 
cost_comm6_noncool Community care 
costs per non-
cooled infant 
until 6 months of 
age (with 
encephalopathy) 
Gamma alpha: 66, lambda: .08365 789.0018 
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cost_comm612_noncool Community care 
costs per non-
cooled infant 
from 6-12 
months of age 
(with 
encephalopathy) 
Gamma alpha: 23.5, lambda: .031085 755.9916 
Cost_CP_comm_cool Cost of 
community care 
per cooled 
infant, who is 
diagnosed with 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 12.6, lambda: .03378 373.0018 
cost_CP_cool_hosp Inpatient costs 
care per cooled 
infant, who is 
diagnosed with 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 6.54, lambda: .00375 1744 
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cost_CPcomm_noncool Cost of 
community care 
per non-cooled 
infant, who is 
diagnosed with 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 16, lambda: .031558 507.003 
cost_CPhosp_noncool Inpatient costs of 
care per non-
cooled infant, 
who is 
diagnosed with 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 5.24, lambda: .004292 1220.876 
cost_noCPinpt_cool Inpatient costs of 
care per cooled 
infant, who does 
not develop 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 3.2, lambda: .022378 142.9976 
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cost_comm_noCPcool Costs of 
community care 
per cooled 
infant, who does 
not develop 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 12.5, lambda: .052966 236.0005 
cost_hospnoCP_noncool Inpatient costs of 
care per cooled 
infant, who does 
not develop 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 3.2, lambda: .022378 142.9976 
Cost_commnoCP_noncool Costs of 
community care 
per cooled 
infant, who does 
not develop 
cerebral palsy, 
from 12-18 
months 
Gamma alpha: 12.7, lambda: .053814 235.9981 
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Table 2. Variables 
NAME DESCRIPTI
ON 
DEFINE
D AT 
FORMULA VALUE 
cordph7 Probability 
of a positive 
cord pH 
(<7.00) test 
Node1: 
Neonate
s 
(senscordpH_7*CP_prevalence)+((1-speccordpH_7)*(1-
CP_prevalence)) 
0.311627999999999
9 
Pcordph71 Probability 
of a positive 
cord pH 
(<7.10) test 
Node1: 
Neonate
s 
(senscordpH_710*CP_prevalence)+((1-speccordpH_710)*(1-
CP_prevalence)) 
0.088142000000000
08 
PPVCordP
h7 
Positive 
predictive 
value of 
cord pH 
<7.00 
Node1: 
Neonate
s 
(senscordpH_7*CP_prevalence)/((senscordpH_7*CP_prevalen
ce)+((1-speccordpH_7)*(1-CP_prevalence))) 
0.004011192832479
753 
npvcordph
7 
Negative 
predictive 
value of 
cord pH 
<7.00 
Node1: 
Neonate
s 
(speccordpH_7*(1-CP_prevalence))/(((1-
senscordpH_7)*CP_prevalence)+((speccordpH_7)*(1-
CP_prevalence))) 
0.998910472825739
5 
ppVcordpH
71 
Positive 
predictive 
value of 
cord pH 
<7.10 
Node1: 
Neonate
s 
(senscordpH_710*CP_prevalence)/((senscordpH_710*CP_pre
valence)+((1-speccordpH_710)*(1-CP_prevalence))) 
0.003607814662703
3622 
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NPVcordpH71 Negative 
predictive 
value of cord 
pH <7.10 
Node1: 
Neonates 
(speccordpH_710*(1-CP_prevalence))/(((1-
senscordpH_710)*CP_prevalence)+((speccordpH_710)*
(1-CP_prevalence))) 
0.99815541454919
52 
cost_comm_w
ell 
Community 
costs of a non-
encephalopathi
c infant, who 
does not 
develop 
cerebral palsy, 
until 18 months 
of age 
Node1: 
Neonates 
440.00 440.0 
cost_hosp_well Hospital costs 
of a non-
encephalopathi
c infant, who 
does not 
develop 
cerebral palsy, 
until 18 months 
of age, 
including 
neonatal 
period 
Node1: 
Neonates 
120.82 120.82 
cost_cordpH Cost of 
performing 
cord pH test 
Node1: 
Neonates 
18.59 18.59 
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